<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_arh5usZ">Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</title>
				<funder>
					<orgName type="full">National Heart, Lung, and Blood Institute</orgName>
					<orgName type="abbreviated">NHLBI</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100000050</idno>
				</funder>
				<funder>
					<orgName type="full">American College of Cardiology Clinical Policy Science Operations</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD, FACC, FAHA, Chair;</roleName><forename type="first">Glenn</forename><forename type="middle">N</forename><surname>Levine</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, FAHA, MACC, Chair-Elect;</roleName><forename type="first">Patrick</forename><forename type="middle">T</forename><surname>O'gara</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, FACC, FAHA, Immediate Past Chair;</roleName><forename type="first">Jonathan</forename><forename type="middle">L</forename><surname>Halperin</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MHS, FACC, FAHA</roleName><forename type="first">Sana</forename><forename type="middle">M</forename><surname>Al-Khatib</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MS, FAHA</roleName><forename type="first">Joshua</forename><forename type="middle">A</forename><surname>Beckman</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MS</roleName><forename type="first">Kim</forename><forename type="middle">K</forename><surname>Birtcher</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Biykem</forename><surname>Bozkurt</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MPH, MACC</roleName><forename type="first">Ralph</forename><forename type="middle">G</forename><surname>Brindis</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, FACC</roleName><forename type="first">Joaquin</forename><forename type="middle">E</forename><surname>Cigarroa</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD, FAHA</roleName><forename type="first">Lesley</forename><forename type="middle">H</forename><surname>Curtis</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MPH, FACC, FAHA</roleName><forename type="first">Anita</forename><surname>Deswal</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, FACC, FAHA</roleName><forename type="first">Lee</forename><forename type="middle">A</forename><surname>Fleisher</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, FACC</roleName><forename type="first">Federico</forename><surname>Gentile</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, FAHA</roleName><forename type="first">Samuel</forename><surname>Gidding</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MS, FACC, FAHA</roleName><forename type="first">Zachary</forename><forename type="middle">D</forename><surname>Goldberger</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, FACC, FAHA;</roleName><forename type="first">Mark</forename><forename type="middle">A</forename><surname>Hlatky</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">John</forename><surname>Ikonomidis</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD, FAHA</roleName><forename type="first">José</forename><forename type="middle">A</forename><surname>Joglar</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, FACC, FAHA</roleName><forename type="first">Laura</forename><surname>Mauri</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MSc, FAHA</roleName><forename type="first">Susan</forename><forename type="middle">J</forename><surname>Pressler</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD, RN, FAHA</roleName><forename type="first">Barbara</forename><surname>Riegel</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Duminda</forename><forename type="middle">N</forename><surname>Wijeysundera</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MB, MD, MSc, FAHA</roleName><forename type="first">Paul</forename><forename type="middle">K</forename><surname>Whelton</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Chair;</roleName><forename type="first">Robert</forename><forename type="middle">M</forename><surname>Carey</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, FAHA, Vice Chair;</roleName><forename type="first">Wilbert</forename><forename type="middle">S</forename><surname>Aronow</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MPH, MBA, FAHA †;</roleName><forename type="first">Donald</forename><forename type="middle">E</forename><surname>Casey</surname><genName>Jr</genName></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MBA</roleName><forename type="first">Karen</forename><forename type="middle">J</forename><surname>Collins</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>RN, ANP</roleName><forename type="first">Cheryl</forename><surname>Dennison Himmelfarb</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD, FAHA §;</roleName><forename type="first">Sondra</forename><forename type="middle">M</forename><surname>Depalma</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Kenneth</forename><forename type="middle">A</forename><surname>Jamerson</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, FAHA †;</roleName><forename type="first">Daniel</forename><forename type="middle">W</forename><surname>Jones</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PharmD</roleName><forename type="first">Eric</forename><forename type="middle">J</forename><surname>Maclaughlin</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD, FAHA †;</roleName><forename type="first">Paul</forename><surname>Muntner</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MSc, MAS, MBA, FAHA †;</roleName><forename type="first">Bruce</forename><surname>Ovbiagele</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MACC, FAHA † †</roleName><forename type="first">Sidney</forename><forename type="middle">C</forename><surname>Smith</surname><genName>Jr</genName></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>JD</roleName><forename type="first">Crystal</forename><forename type="middle">C</forename><surname>Spencer</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, PhD ‡ ‡</roleName><forename type="first">Randall</forename><forename type="middle">S</forename><surname>Stafford</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, FAHA § §</roleName><forename type="first">Sandra</forename><forename type="middle">J</forename><surname>Taler</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MS, FACC</roleName><forename type="first">Randal</forename><forename type="middle">J</forename><surname>Thomas</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Sr, MD, MACC, FAHA †;</roleName><forename type="first">Kim</forename><forename type="middle">A</forename><surname>Williams</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MHS ¶ ¶;</roleName><forename type="first">Jeff</forename><forename type="middle">D</forename><surname>Williamson</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Jackson</forename><forename type="middle">T</forename><surname>Wright</surname><genName>Jr</genName></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> American Society for Preventive Cardiology Representative.</note>
								<orgName type="department">American Society for Preventive Cardiology Representative</orgName>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_h9bYUDu">Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">53A41DCCF4AAB762DCD07DEFFC12C6C2</idno>
					<idno type="DOI">10.1161/HYP.0000000000000066/-/</idno>
					<note type="submission">Approval Committee and the American Heart Association Science Advisory and Coordinating Committee in September 2017 and by the American Heart Association Executive Committee in October 2017.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T07:59+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="14" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="15" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="16" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="17" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="18" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="19" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="20" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="21" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="22" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="23" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="24" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="25" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="26" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="27" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="28" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="29" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="30" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="31" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="32" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="33" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="34" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="35" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="36" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="37" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="38" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="39" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="40" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="41" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="42" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="43" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="44" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="45" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="46" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="47" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="48" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="49" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="50" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="51" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="52" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="53" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="54" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="55" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="56" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_N7bhqQT">Intended Use</head><p xml:id="_Ecmar2G"><s xml:id="_XKBczcj">Practice guidelines provide recommendations applicable to patients with or at risk of developing CVD.</s><s xml:id="_jdRXBNJ">The focus is on medical practice in the United States, but guidelines developed in collaboration with other organizations can have a global impact.</s><s xml:id="_WPBZNw2">Although guidelines may be used to inform regulatory or payer decisions, they are intended to improve patients' quality of care and align with patients' interests.</s><s xml:id="_b8jsSAE">Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances and should not replace clinical judgment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_yAH4nsh">Clinical Implementation</head><p xml:id="_mkhv7vA"><s xml:id="_ex9w3Qq">Management in accordance with guideline recommendations is effective only when followed by both practitioners and patients.</s><s xml:id="_mN7ZsNU">Adherence to recommendations can be enhanced by shared decision making between clinicians and patients, with patient engagement in selecting interventions on the basis of individual values, preferences, and associated conditions and comorbidities.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_fCX2SmJ">Methodology and Modernization</head><p xml:id="_e3f5zhC"><s xml:id="_F7qK7wU">The ACC/AHA Task Force on Clinical Practice Guidelines (Task Force) continuously reviews, updates, and modifies guideline methodology on the basis of published standards from organizations, including the Institute of Medicine, <ref type="bibr">P-3,P-4</ref> and on the basis of internal reevaluation.</s><s xml:id="_e6hCyyq">Similarly, the presentation and delivery of guidelines are reevaluated and modified on the basis of evolving technologies and other factors to facilitate optimal dissemination of information to healthcare professionals at the point of care.</s></p><p xml:id="_A4zRXYV"><s xml:id="_VAJJMGg">Toward this goal, this guideline continues the introduction of an evolved format of presenting guideline recommendations and associated text called the "modular knowledge chunk format."</s><s xml:id="_xdBkWMT">Each modular "chunk" includes a table of related recommendations, a brief synopsis, recommendation-specific supportive text, and when appropriate, flow diagrams or additional tables.</s><s xml:id="_4aMcq5z">References are provided within the modular chunk itself to facilitate quick review.</s><s xml:id="_DZ8GeHF">Additionally, this format will facilitate seamless updating of guidelines with focused updates as new evidence is published, as well as content tagging for rapid electronic retrieval of related recommendations on a topic of interest.</s><s xml:id="_HVseFHE">This evolved approach format was instituted when this guideline was near completion; therefore, the present document represents a transitional format that best suits the text as written.</s><s xml:id="_uTsrAKM">Future guidelines will fully implement this format, including provisions for limiting the amount of text in a guideline.</s></p><p xml:id="_TJJANVR"><s xml:id="_JCHQ8PX">Recognizing the importance of cost-value considerations in certain guidelines, when appropriate and feasible, an analysis of the value of a drug, device, or intervention may be performed in accordance with the ACC/AHA methodology.</s><s xml:id="_A4jKZRm"><ref type="bibr">P-5</ref> To ensure that guideline recommendations remain current, new data are reviewed on an ongoing basis, with full guideline revisions commissioned in approximately 6-year cycles.</s><s xml:id="_WuWNGfR">Publication of new, potentially practice-changing study results that are relevant to an existing or new drug, device, or management strategy will prompt evaluation by the Task Force, in consultation with the relevant guideline writing committee, to determine whether a focused update should be commissioned.</s><s xml:id="_hRjpE3a">For additional information and policies regarding guideline development, we encourage readers to consult the ACC/AHA guideline methodology manual <ref type="bibr">P-6</ref> and other methodology articles.</s><s xml:id="_3S7AQ8m"><ref type="bibr">P-7-P-10</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_afBSBHN">Selection of Writing Committee Members</head><p xml:id="_QCNqTjP"><s xml:id="_tpmpuH8">The Task Force strives to avoid bias by selecting experts from a broad array of backgrounds.</s><s xml:id="_h4yjutu">Writing committee members represent different geographic regions, sexes, ethnicities, races, intellectual perspectives/biases, and scopes of clinical practice.</s><s xml:id="_fHakXkW">The Task Force may also invite organizations and professional societies with related interests and expertise to participate as partners, collaborators, or endorsers.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_jfmrkDw">Relationships With Industry and Other Entities</head><p xml:id="_r2wM6Kx"><s xml:id="_KxKqxnu">The ACC and AHA have rigorous policies and methods to ensure that guidelines are developed without bias or improper influence.</s><s xml:id="_BPcQB6g">The complete relationships with industry and other entities (RWI) policy can be found online.</s><s xml:id="_FZHMqgJ">Appendix 1 of the present document lists writing committee members' relevant RWI.</s><s xml:id="_fMJdbUS">For the purposes of full transparency, writing committee members' comprehensive disclosure information is available online.</s><s xml:id="_SPJrV77">Comprehensive disclosure information for the Task Force is available online.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_hnWcYCz">Evidence Review and Evidence Review Committees</head><p xml:id="_q6z8RXu"><s xml:id="_8hWsCDd">In developing recommendations, the writing committee uses evidence-based methodologies that are based on all available data.</s><s xml:id="_TDvYDQq"><ref type="bibr">P-6-P-9</ref> Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion.</s><s xml:id="_5HahJD6">Only key references are cited.</s></p><p xml:id="_NrCkju5"><s xml:id="_YeFpM9S">An independent evidence review committee (ERC) is commissioned when there are 1 or more questions deemed of utmost clinical importance that merit formal systematic review.</s><s xml:id="_MKM7Gbn">The systematic review will determine which patients are most likely to benefit from a drug, device, or treatment strategy and to what degree.</s><s xml:id="_nBjhxu4">Criteria for commissioning an ERC and formal systematic review include: a) the absence of a current authoritative systematic review, b) the feasibility of defining the benefit and risk in a time frame consistent with the writing of a guideline, c) the relevance to a substantial number of patients, and d) the likelihood that the findings can be translated into actionable recommendations.</s><s xml:id="_fgauJAe">ERC members may include methodologists, epidemiologists, healthcare providers, and biostatisticians.</s><s xml:id="_SMKYAwg">The recommendations developed by the writing committee on the basis of the systematic review are marked with "SR."</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vBRfnBT">Guideline-Directed Management and Therapy</head><p xml:id="_PdvT6VD"><s xml:id="_4fFJMsA">The term guideline-directed management and therapy (GDMT) encompasses clinical evaluation, diagnostic testing, and pharmacological and procedural treatments.</s><s xml:id="_HDmRvSd">For these and all recommended drug treatment regimens, the reader should confirm the dosage by reviewing product insert material and evaluate the treatment regimen for contraindications and interactions.</s><s xml:id="_qBrCBHw">The recommendations are limited to drugs, devices, and treatments approved for clinical use in the United States.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_XRVuXFN">Class of Recommendation and Level of Evidence</head><p xml:id="_vWYTTkD"><s xml:id="_EWTr7rY">The Class of Recommendation (COR) indicates the strength of the recommendation, encompassing the estimated magnitude and certainty of benefit in proportion to risk.</s><s xml:id="_2dz5SAz">The Level of Evidence (LOE) rates the quality of scientific evidence that supports the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources (Table <ref type="table">1</ref>).</s><s xml:id="_2yqj5EY"><ref type="bibr">P-6-P-8</ref> The reader is encouraged to consult the full-text guideline <ref type="bibr">P-11</ref> for additional guidance and details about hypertension, since the executive summary contains mainly the recommendations.</s></p><p xml:id="_XPh5t6G"><s xml:id="_XkFdD6K">Glenn N. Levine, MD, FACC, FAHA Chair, ACC/AHA Task Force on Clinical Practice Guidelines</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1." xml:id="_xncj7YB">Introduction</head><p xml:id="_jq9JpvQ"><s xml:id="_CHRgsPQ">In 2013, the National Heart, Lung, and Blood Institute (NHLBI) Advisory Council recommended that the NHLBI focus specifically on reviewing the highest-quality evidence and partner with other organizations to develop recommendations.</s><s xml:id="_XFpB65H">S1-1,S1-2 Accordingly, the ACC and AHA collaborated with the NHLBI and stakeholder and professional organizations to complete and publish 4 guidelines (on assessment of cardiovascular risk, lifestyle modifications to reduce cardiovascular risk, management of blood cholesterol in adults, and management of overweight and obesity in adults) to make them available to the widest possible constituency.</s><s xml:id="_aRmDM4h">In 2014, the ACC and AHA in partnership with several other professional societies initiated a guideline on the prevention, detection, evaluation and management of high blood pressure in adults.</s><s xml:id="_RPJmsvf">Under the management of the ACC/AHA Task Force, a Prevention Subcommittee was appointed to help guide development of the suite of guidelines on prevention of cardiovascular disease.</s></p><p xml:id="_9D7pcwk"><s xml:id="_dFwukqc">As early as the 1920s, and subsequently in the 1959 Build and Blood Pressure Study <ref type="bibr">S1-3</ref> of almost 5 million adults insured between 1934 and 1954, a strong direct relationship was noted between level of BP and risk of clinical complications and death.</s><s xml:id="_taspHgy">In the 1960s, these findings were confirmed in a series of reports from the Framingham Heart Study.</s><s xml:id="_4RD4EcZ"><ref type="bibr">S1-4</ref> The 1967 and 1970 Veterans Administration Cooperative Study Group reports ushered in the era of effective treatment for high BP.</s><s xml:id="_EyTAWXG"><ref type="bibr">S1-5,S1-6</ref> The first comprehensive guideline for detection, evaluation, and management of high BP was published in 1977, under the sponsorship of the NHLBI.</s><s xml:id="_UECehVh"><ref type="bibr">S1-7</ref> In subsequent years, a series of Joint National Committee (JNC) BP guidelines were published to assist the practice community and improve prevention, awareness, treatment, and control of high BP.</s><s xml:id="_tGNEjq8"><ref type="bibr">S1-7-S1-9</ref> The present guideline updates prior JNC reports.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.1." xml:id="_cCH5SMB">Methodology and Evidence Review</head><p xml:id="_fNxGGJq"><s xml:id="_MFFbdua">An extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline, was conducted between February and August 2015.</s><s xml:id="_CAhc9Q8">Key search words included but were not limited to the following: adherence; aerobic; alcohol intake; ambulatory care; antihypertensive : agents, drug, medication, therapy;  beta adrenergic blockers; blood pressure: arterial, control,  determination, devices, goal, high, improve, measurement,  monitoring, ambulatory; calcium channel blockers; diet;  diuretic agent; drug therapy; heart failure: diastolic, systolic; hypertension: white coat, masked, ambulatory, isolated  ambulatory, isolated clinic, diagnosis, reverse white coat, prevention, therapy, treatment, control; intervention; lifestyle:  measures, modification; office visits; patient outcome; performance measures; physical activity; potassium intake; protein  intake; renin inhibitor; risk reduction: behavior, counseling;  screening; sphygmomanometers; spironolactone; therapy;  treatment: adherence, compliance, efficacy, outcome, protocol,  regimen; weight.</s><s xml:id="_NUWM2RF">Additional relevant studies published through June 2016, during the guideline writing process, were also considered by the writing committee and added to the evidence tables when appropriate.</s><s xml:id="_qzBrgqJ">The final evidence tables included in the Online Data Supplement summarize the evidence used by the writing committee to formulate recommendations.</s></p><p xml:id="_GEVHZku"><s xml:id="_RsyCYan">As noted in the preamble, an independent ERC was commissioned to perform a formal systematic review of 4 critical clinical questions related to hypertension (Table <ref type="table">2</ref>), the results of which were considered by the writing committee for incorporation into this guideline.</s><s xml:id="_C7TNpa5">Concurrent with this process, writing committee members evaluated other published data relevant to the guideline.</s><s xml:id="_AhTreQD">The findings of the ERC and the writing committee members were formally presented and discussed, and then guideline recommendations were developed.</s><s xml:id="_Ubdz5wX">The systematic review report, "Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults," is published in conjunction with this guideline, S1-10 and its respective data supplements are available online.</s><s xml:id="_gmqHxEh">No writing committee member reported a RWI.</s><s xml:id="_rTwybeQ">Drs.</s><s xml:id="_y4xUwNe">Whelton, Wright and Williamson had leadership roles in SPRINT (Systolic Blood Pressure Intervention Trial).</s><s xml:id="_qJGWcrk">Dr. Carey chaired committee discussions in which the SPRINT results were considered.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.2." xml:id="_Sw5A7RY">Organization of the Writing Committee</head><p xml:id="_HXmAhWF"><s xml:id="_76JVapg">The writing committee consisted of clinicians, cardiologists, epidemiologists, internists, an endocrinologist, a geriatrician, a nephrologist, a neurologist, a nurse, a pharmacist, a physician assistant, and 2 lay/patient representatives.</s><s xml:id="_MqPE5zM">It included representatives from the ACC, AHA, American Academy of Physician Assistants (AAPA), Association of Black Cardiologists (ABC), American College of Preventive Medicine (ACPM), American Geriatrics Society (AGS), American Pharmacists Association (APhA), American Society of Hypertension (ASH), American Society for Preventive Cardiology (ASPC), National Medical Association (NMA), and Preventive Cardiovascular Nurses Association (PCNA).</s></p><p xml:id="_5FqkcTd"><s xml:id="_Kev9hHM">Table 1.</s><s xml:id="_AyBRwkx">Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.3." xml:id="_c8jf8zx">Document Review and Approval</head><p xml:id="_qvua4ns"><s xml:id="_3r5ZpGz">This document was reviewed by 2 official reviewers nominated by the ACC and AHA; 1 reviewer each from the AAPA, ABC, ACPM, AGS, APhA, ASH, ASPC NMA, and PCNA; and 38 individual content reviewers.</s><s xml:id="_Q4WUGP4">Reviewers' RWI information was distributed to the writing committee and is published in this document (Appendix 2).</s></p><p xml:id="_cuepXPF"><s xml:id="_Exbf5mj">This document was approved for publication by the governing bodies of the ACC, AHA, AAPA, ABC, ACPM, AGS, APhA, ASH, ASPC, NMA, and PCNA.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.4." xml:id="_vpCDwhA">Scope of the Guideline</head><p xml:id="_vybwNhZ"><s xml:id="_Ujw82qU">The present guideline is intended to be a resource for the clinical and public health practice communities.</s><s xml:id="_zCav2NT">It is designed to be comprehensive but succinct and practical in providing guidance for prevention, detection, evaluation, and management of high BP.</s><s xml:id="_jWr9K2c">It is an update of the NHLBI publication, "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure" (JNC 7).</s><s xml:id="_VwcKHp8"><ref type="bibr">S1-9</ref> It incorporates new information from studies of office-based BP-related risk of CVD, ambulatory blood pressure monitoring (ABPM), home blood pressure monitoring (HBPM), telemedicine, and various other areas.</s><s xml:id="_YRTaKWb">This guideline does not address the use of BP-lowering medications for the purposes of prevention of recurrent CVD events in patients with stable ischemic heart disease (SIHD) or chronic heart failure (HF) in the absence of hypertension; these topics are the focus of other ACC/AHA guidelines.</s><s xml:id="_FKWyBfg"><ref type="bibr">S1-11,S1-12</ref> In developing the present guideline, the writing committee reviewed prior published guidelines, evidence reviews, and related statements.</s><s xml:id="_rtvA8xz">Table <ref type="table">3</ref> contains a list of publications and statements deemed pertinent to this writing effort and is intended for use as a resource, thus obviating the need to repeat existing guideline recommendations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.5." xml:id="_FkYU4wc">Abbreviations and Acronyms</head><p xml:id="_wHEeerb"><s xml:id="_Hmtq94A">Abbreviation/ Acronym Meaning/Phrase ABPM ambulatory blood pressure monitoring ACE angiotensin-converting enzyme AF atrial fibrillation ARB angiotensin receptor blocker BP blood pressure CCB calcium channel blocker CHD coronary heart disease CKD chronic kidney disease CPAP continuous positive airway pressure CVD cardiovascular disease DBP diastolic blood pressure DM diabetes mellitus ECG electrocardiogram ESRD end-stage renal disease GDMT guideline-directed management and therapy GFR glomerular filtration rate HBPM home blood pressure monitoring EHR electronic health record HF heart failure HFpEF heart failure with preserved ejection fraction HFrEF heart failure with reduced ejection fraction ICH intracerebral hemorrhage JNC Joint National Commission LV left ventricular LVH left ventricular hypertrophy MI myocardial infarction MRI magnetic resonance imaging PAD peripheral artery disease RAS renin-angiotensin system RCT randomized controlled trial SBP systolic blood pressure SIHD stable ischemic heart disease TIA transient ischemic attack</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2." xml:id="_m8CAeap">BP and CVD Risk</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1." xml:id="_zT6eQGS">Observational Relationship</head><p xml:id="_UHBPB7k"><s xml:id="_a8ZUuhX">Observational studies have demonstrated graded associations between higher systolic blood pressure (SBP) and diastolic blood pressure (DBP) and increased CVD risk.</s><s xml:id="_4uuh8q7"><ref type="bibr">S2.1-1,S2.1-2</ref></s><s xml:id="_aDy2bfU">In a meta-analysis of 61 prospective studies, the risk of CVD increased in a log-linear fashion from SBP levels &lt;115 mm Hg to &gt;180 mm Hg and from DBP levels &lt;75 mm Hg to &gt;105 mm Hg.</s><s xml:id="_MYwbS8p"><ref type="bibr">S2.1-1</ref></s><s xml:id="_rEg7p9X">In that analysis, 20 mm Hg higher SBP and 10 mm Hg higher DBP were each associated with a doubling in the risk of death from stroke, heart disease, or other vascular disease.</s><s xml:id="_sNYb4db">In a separate observational study including &gt;1 million adult patients ≥30 years of age,</s></p><p xml:id="_N4NVb7G"><s xml:id="_N4svQPr">Table 2. Systematic Review Questions on High BP in Adults Question Number Question Section Number 1 Is there evidence that self-directed monitoring of BP and/or ambulatory BP monitoring are superior to office-based measurement of BP by a healthcare worker for 1) preventing adverse outcomes for which high BP is a risk factor and 2) achieving better BP control?</s><s xml:id="_2QMmgN5">4.2 2 What is the optimal target for BP lowering during antihypertensive therapy in adults?</s><s xml:id="_yAvzM9W">8.1.5</s><s xml:id="_c7F6dfH">9.3 9.6 3 In adults with hypertension, do various antihypertensive drug classes differ in their comparative benefits and harms?</s><s xml:id="_vgSqfSj">8.1.6</s><s xml:id="_vt5nyaD">8.2 4 In adults with hypertension, does initiating treatment with antihypertensive pharmacological monotherapy versus initiating treatment with 2 drugs (including fixed-dose combination therapy), either of which may be followed by the addition of sequential drugs, differ in comparative benefits and/or harms on specific health outcomes?</s><s xml:id="_BQAJ9bR">8.1.6.1 BP indicates blood pressure.</s><s xml:id="_yjbVTM4">Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025 higher SBP and DBP were associated with increased risk of CVD incidence and angina, myocardial infarction (MI), HF, stroke, peripheral artery disease (PAD), and abdominal aortic aneurysm, each evaluated separately.</s><s xml:id="_zQW7NKd">S2.1-2</s><s xml:id="_YJY7c6N">An increased risk of CVD associated with higher SBP and DBP has been reported across a broad age spectrum, from 30 years to &gt;80 years of age.</s><s xml:id="_p5ZpN8r">Although the relative risk of incident CVD associated with higher SBP and DBP is smaller at older ages,</s></p><p xml:id="_s3CeWBV"><s xml:id="_dXK3cYh">Table 3. Associated Guidelines and Statements the corresponding high BP-related increase in absolute risk is larger in older persons (≥65 years) given the higher absolute risk of CVD at an older age.</s><s xml:id="_Jkb3b2h">S2.1-1</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2." xml:id="_AsjPfc6">BP Components</head><p xml:id="_cPV8JMs"><s xml:id="_TSuhYKN">Epidemiological studies have evaluated associations of SBP and DBP, as well as derived components of BP measurements (including pulse pressure, mean BP, and mid-BP), with CVD outcomes (Table <ref type="table">4</ref>).</s><s xml:id="_Zu7yymX">When considered separately, higher levels of both SBP and DBP have been associated with increased CVD risk.</s><s xml:id="_dxBUSx9">S2.2-1,S2.2-2</s><s xml:id="_6wpsgMz">Higher SBP has consistently been associated with increased CVD risk after adjustment for, or within strata of, DBP.</s><s xml:id="_9jN3WVw"><ref type="bibr">S2.2-3-S2.2-5</ref></s><s xml:id="_wvaMY9t">In contrast, after consideration of SBP through adjustment or stratification, DBP has not been consistently associated with CVD risk.</s><s xml:id="_xNWqmjD"><ref type="bibr">S2.2-6,S2.2-7</ref></s><s xml:id="_hAE9VE6">Although pulse pressure and mid-BP have been associated with increased CVD risk independent of SBP and DBP in some studies, SBP (especially) and DBP are prioritized in the present document because of the robust evidence base for these measures in both observational studies and clinical trials and because of their ease of measurement in practice settings.</s><s xml:id="_g5Ve2fZ"><ref type="bibr">S2.2-8-S2.2-11</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3." xml:id="_Rj48rrC">Population Risk</head><p xml:id="_R6PCUfV"><s xml:id="_8MHFGVF">In 2010, high BP was the leading cause of death and disabilityadjusted life years worldwide.</s><s xml:id="_XFfMKM4"><ref type="bibr">S2.3-1,S2.3-2</ref></s><s xml:id="_bXa92FR">In the United States, hypertension (see Section 3.1 for definition) accounted for more CVD deaths than any other modifiable CVD risk factor and was second only to cigarette smoking as a preventable cause of death for any reason.</s><s xml:id="_SfhDHPw"><ref type="bibr">S2.3-3</ref></s><s xml:id="_Y8xtP5a">In a follow-up study of 23 272 US NHANES (National Health and Nutrition Examination Survey) participants, &gt;50% of deaths from coronary heart disease (CHD) and stroke occurred among individuals with hypertension.</s><s xml:id="_NCatWm6"><ref type="bibr">S2.3-4</ref></s><s xml:id="_x7MUH2V">Because of the high prevalence of hypertension and its associated increased risk of CHD, stroke, and end-stage renal disease (ESRD), the population-attributable risk of these outcomes associated with hypertension is high.</s><s xml:id="_E5jZPFc"><ref type="bibr">S2.3-4,S2.3-5</ref></s><s xml:id="_RzCMBrN">In the populationbased ARIC (Atherosclerosis Risk in Communities) study, 25% of the cardiovascular events (CHD, coronary revascularization, stroke, or HF) were attributable to hypertension.</s><s xml:id="_tNeYD74">In the Northern Manhattan study, the percentage of events attributable to hypertension was higher in women (32%) than in men (19%) and higher in blacks (36%) than in whites (21%).</s><s xml:id="_kejf8kg"><ref type="bibr">S2.3-6</ref></s><s xml:id="_nZMRVR7">In 2012, hypertension was the second leading assigned cause of ESRD, behind diabetes mellitus (DM), and accounted for 34% of incident ESRD cases in the US population.</s></p><p xml:id="_eXX3c6f"><s xml:id="_vVMkaxA">S2.3-7 2.4.</s><s xml:id="_ndeHfYV">Coexistence of Hypertension and Related Chronic Conditions Recommendation for Coexistence of Hypertension and Related Chronic Conditions References that support the recommendation are summarized in Online Data Supplement 1. COR LOE Recommendation I B-NR 1. Screening for and management of other modifiable CVD risk factors are recommended in adults with hypertension.</s><s xml:id="_SkuH66H">S2.4-1,S2.4-2 3. Classification of BP 3.1.</s><s xml:id="_7F9HwXA">Definition of High BP Recommendation for Definition of High BP References that support the recommendation are summarized in Online Data Supplement 2. COR LOE Recommendation I B-NR 1. BP should be categorized as normal, elevated, or stage 1 or 2 hypertension to prevent and treat high BP (Table <ref type="table">6</ref>).</s><s xml:id="_2AXd3tV">S3.1-1-S3.1-20</s></p><p xml:id="_KEY8CCg"><s xml:id="_vdBqVjk">Table 6.</s><s xml:id="_4XzEdus">Categories of BP in Adults* BP Category SBP DBP Normal &lt;120 mm Hg and &lt;80 mm Hg Elevated 120-129 mm Hg and &lt;80 mm Hg Hypertension Stage 1 130-139 mm Hg or 80-89 mm Hg Stage 2 ≥140 mm Hg or ≥90 mm Hg *Individuals with SBP and DBP in 2 categories should be designated to the higher BP category.</s><s xml:id="_t9DFmCY">BP indicates blood pressure (based on an average of ≥2 careful readings obtained on ≥2 occasions, as detailed in Section 4); DBP, diastolic blood pressure; and SBP systolic blood pressure.</s></p><p xml:id="_T54yV2Y"><s xml:id="_MNMmcFu">Table 5. CVD Risk Factors Common in Patients With Hypertension Modifiable Risk Factors* Relatively Fixed Risk Factors † Current cigarette smoking, secondhand smoking CKD Family history Diabetes mellitus Increased age Dyslipidemia/hypercholesterolemia Low socioeconomic/educational status Overweight/obesity Male sex Physical inactivity/low fitness Obstructive sleep apnea Unhealthy diet Psychosocial stress *Factors that can be changed and, if changed, may reduce CVD risk.</s><s xml:id="_A7TBXWK">†Factors that are difficult to change (CKD, low socioeconomic/educational status, obstructive sleep apnea S2.4-3 ), cannot be changed (family history, increased age, male sex), or, if changed through the use of current intervention techniques, may not reduce CVD risk (psychosocial stress).</s><s xml:id="_DaaK5Ky">CKD indicates chronic kidney disease; and CVD, cardiovascular disease.</s></p><p xml:id="_wtzhcyR"><s xml:id="_Z8UXMfd">Table 4. BP Measurement Definitions BP Measurement Definition SBP First Korotkoff sound* DBP Fifth Korotkoff sound* Pulse pressure SBP minus DBP Mean arterial pressure DBP plus one third pulse pressure † Mid-BP Sum of SBP and DBP, divided by 2 *See Section 4 for a description of Korotkoff sounds.</s><s xml:id="_rpZG2dq">†Calculation assumes normal heart rate.</s><s xml:id="_yc7gbgA">BP indicates blood pressure; DBP, diastolic blood pressure; and SBP, systolic blood pressure.</s><s xml:id="_UmX7jhS">Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2." xml:id="_H3dhHRW">Lifetime Risk of Hypertension</head><p xml:id="_5ePxs3B"><s xml:id="_aAzAs4W">Observational studies have documented a relatively high incidence of hypertension over periods of 5 to 10 years of followup.</s><s xml:id="_2At9BAK">S3.2-1,S3.2-2</s><s xml:id="_SYvbJty">Thus, there is a much higher long-term population burden of hypertension as BP progressively increases with age.</s><s xml:id="_DxqCeSv">Several studies have estimated the long-term cumulative incidence of developing hypertension.</s><s xml:id="_CTdRugS"><ref type="bibr">S3.2-3,S3.2-4</ref></s><s xml:id="_s4BhVS7">In an analysis of 1132 white male medical students (mean age: approximately 23 years at baseline) in the Johns Hopkins Precursors study, 0.3%, 6.5%, and 37% developed hypertension at age 25, 45, and 65 years, respectively.</s><s xml:id="_FTvDdRE"><ref type="bibr">S3.2-5</ref></s><s xml:id="_vaEgSmA">In MESA (Multi-Ethnic Study of Atherosclerosis), the percentage of the population developing hypertension over their lifetimes was higher for African Americans and Hispanics than for whites and Asians.</s><s xml:id="_UDReSVR"><ref type="bibr">S3.2-3</ref></s><s xml:id="_nhmADfJ">For adults 45 years of age without hypertension, the 40-year risk of developing hypertension was 93% for African-American, 92% for Hispanic, 86% for white, and 84% for Chinese adults.</s><s xml:id="_zu5UC3Q"><ref type="bibr">S3.2-3</ref></s><s xml:id="_aY6SHrQ">In the Framingham Heart Study, approximately 90% of adults free of hypertension at age 55 or 65 years developed hypertension during their lifetimes.</s><s xml:id="_Cwvk9hQ"><ref type="bibr">S3.2-4</ref></s><s xml:id="_XHfzbbn">All of these estimates were based on use of the 140/90-mm Hg cutpoint for recognition of hypertension and would have been higher had the 130/80-mm Hg cutpoint been used.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3." xml:id="_fGguPGx">Prevalence of High BP</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4." xml:id="_kngCNsJ">Measurement of BP</head><p xml:id="_XrNFgdb"><s xml:id="_Jj8Gxgu">4.1.</s><s xml:id="_x83WXty">Accurate Measurement of BP in the Office Recommendation for Accurate Measurement of BP in the Office COR LOE Recommendation I C-EO 1.</s><s xml:id="_QVJWtep">For diagnosis and management of high BP, proper methods are recommended for accurate measurement and documentation of BP (Table 8).</s></p><p xml:id="_CsFV5sE"><s xml:id="_m45VkVK">Table 7. Prevalence of Hypertension Based on 2 SBP/DBP Thresholds* † SBP/DBP ≥130/80 mm Hg or Self-Reported Antihypertensive Medication † SBP/DBP ≥140/90 mm Hg or Self-Reported Antihypertensive Medication ‡ Overall, crude 46% 32% Men (n=4717) Women (n=4906) Men (n=4717) Women (n=4906) Overall, age-sex adjusted 48% 43% 31% 32% Age group, y 20-44 30% 19% 11% 10% 45-54 50% 44% 33% 27% 55-64 70% 63% 53% 52% 65-74 77% 75% 64% 63% 75+ 79% 85% 71% 78% Race-ethnicity § Non-Hispanic white 47% 41% 31% 30% Non-Hispanic black 59% 56% 42% 46% Non-Hispanic Asian 45% 36% 29% 27% Hispanic 44% 42% 27% 32% The prevalence estimates have been rounded to the nearest full percentage.</s><s xml:id="_GkFhPrv">*130/80 and 140/90 mm Hg in 9623 participants (≥20 years of age) in NHANES 2011-2014.</s><s xml:id="_qFnz33p">†BP cutpoints for definition of hypertension in the present guideline.</s><s xml:id="_VQgQvcN">‡BP cutpoints for definition of hypertension in JNC 7. §Adjusted to the 2010 age-sex distribution of the US adult population.</s><s xml:id="_2uXSms8">BP indicates blood pressure; DBP, diastolic blood pressure; NHANES, National Health and Nutrition Examination Survey; and SBP, systolic blood pressure.</s></p><p xml:id="_KHCRnK2"><s xml:id="_MR5TaRd">Table 8.</s><s xml:id="_dxuUvhq">Checklist for Accurate Measurement of BP S4.1-1,S4.1-2</s><s xml:id="_jzEwpqM">Key Steps for Proper BP Measurements Specific Instructions Step 1: Properly prepare the patient 1. Have the patient relax, sitting in a chair (feet on floor, back supported) for &gt;5 min.</s></p><p xml:id="_JRVKxv2"><s xml:id="_y3SvhXg">2. The patient should avoid caffeine, exercise, and smoking for at least 30 min before measurement.</s></p><p xml:id="_8BHN25R"><s xml:id="_YBuZ98S">3. Ensure patient has emptied his/her bladder.</s></p><p xml:id="_ZfE924B"><s xml:id="_jzvbnrc">4. Neither the patient nor the observer should talk during the rest period or during the measurement.</s></p><p xml:id="_vSMSfcE"><s xml:id="_mPATQbP">5. Remove all clothing covering the location of cuff placement.</s></p><p xml:id="_TUQHnev"><s xml:id="_anYm8cN">6. Measurements made while the patient is sitting or lying on an examining table do not fulfill these criteria.</s></p><p xml:id="_wSsSzWE"><s xml:id="_kaAzsrw">Step 2: Use proper technique for BP measurements 1. Use a BP measurement device that has been validated, and ensure that the device is calibrated periodically.*</s><s xml:id="_S65UTDw">2. Support the patient's arm (eg, resting on a desk).</s></p><p xml:id="_YfaKybK"><s xml:id="_pCtWVky">3. Position the middle of the cuff on the patient's upper arm at the level of the right atrium (the midpoint of the sternum).</s></p><p xml:id="_TZWUB5P"><s xml:id="_BuYBDze">4. Use the correct cuff size, such that the bladder encircles 80% of the arm, and note if a larger-or smaller-than-normal cuff size is used (Table <ref type="table">9</ref>).</s></p><p xml:id="_cr5y63c"><s xml:id="_f7DPAk2">5. Either the stethoscope diaphragm or bell may be used for auscultatory readings.</s><s xml:id="_HeM2yGb"><ref type="bibr">S4.1-3,S4.1-4</ref></s><s xml:id="_MEVbTGy">Step 3: Take the proper measurements needed for diagnosis and treatment of elevated BP/hypertension 1.</s><s xml:id="_kSaY2J2">At the first visit, record BP in both arms.</s><s xml:id="_pPkPWN6">Use the arm that gives the higher reading for subsequent readings.</s></p><p xml:id="_jJPKcxE"><s xml:id="_Z3v56Ka">2. Separate repeated measurements by 1-2 min.</s></p><p xml:id="_3SaSUTA"><s xml:id="_Qsz87zk">3. For auscultatory determinations, use a palpated estimate of radial pulse obliteration pressure to estimate SBP.</s><s xml:id="_uJS9emV">Inflate the cuff 20-30 mm Hg above this level for an auscultatory determination of the BP level.</s><s xml:id="_P6SvEyE">June 2018 4.2.</s><s xml:id="_rdjDh4n">Out-of-Office and Self-Monitoring of BP</s></p><p xml:id="_PcZSgep"><s xml:id="_2SvDg8C">Recommendation for Out-of-Office and Self-Monitoring of BP References that support the recommendation are summarized in Online Data Supplement 3 and Systematic Review Report.</s><s xml:id="_YuVmTxv">COR LOE Recommendation I A SR 1. Out-of-office BP measurements are recommended to confirm the diagnosis of hypertension (Table 11) and for titration of BP-lowering medication, in conjunction with telehealth counseling or clinical interventions.</s><s xml:id="_zxbgM5z">S4.2-1-S4.2-4</s><s xml:id="_Uf9ckfP">SR indicates systematic review.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3." xml:id="_Z25r5kf">Masked and White Coat Hypertension</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_mwyZMCn">Recommendations for Masked and White Coat Hypertension</head><p xml:id="_WEw32Ub"><s xml:id="_TMs53BB">References that support recommendations are summarized in Online Data Supplements 4, 5, and 6.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_zqdc4mH">COR LOE Recommendations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_QhsJgRB">IIa B-NR</head><p xml:id="_ZaeUqsg"><s xml:id="_GaGQMbr">1.</s><s xml:id="_AeUZNH5">In adults with an untreated SBP greater than 130 mm Hg but less than 160 mm Hg or DBP greater than 80 mm Hg but less than 100 mm Hg, it is reasonable to screen for the presence of white coat hypertension by using either daytime ABPM or HBPM before diagnosis of hypertension.</s><s xml:id="_Jh3WqXY">S4.</s></p><p xml:id="_S8m77FY"><s xml:id="_quS6nCg">3-1-S4.3-8</s><s xml:id="_PTex5NT">IIa C-LD 2. In adults with white coat hypertension, periodic monitoring with either ABPM or HBPM is reasonable to detect transition to sustained hypertension.</s><s xml:id="_xVAS2Gr">S4.3-2,S4.3-5,S4.3-7</s><s xml:id="_EEHXVTe">Table 9. Selection Criteria for BP Cuff Size for Measurement of BP in Adults Arm Circumference Usual Cuff Size 22-26 cm Small adult 27-34 cm Adult 35-44 cm Large adult 45-52 cm Adult thigh Adapted with permission from Pickering et al S4.1-5 (American Heart Association, Inc.).</s></p><p xml:id="_SuAMQfd"><s xml:id="_hW5r9YK">BP indicates blood pressure.</s></p><p xml:id="_vfFX9jz"><s xml:id="_TRtY5fK">Step 4: Properly document accurate BP readings 1. Record SBP and DBP.</s><s xml:id="_APb9Q8v">If using the auscultatory technique, record SBP and DBP as onset of the first Korotkoff sound and disappearance of all Korotkoff sounds, respectively, using the nearest even number.</s></p><p xml:id="_WYRCBdf"><s xml:id="_X5zh7tz">2. Note the time of most recent BP medication taken before measurements.</s></p><p xml:id="_KpTMWys"><s xml:id="_JbYw4xe">Step 5: Average the readings Use an average of ≥2 readings obtained on ≥2 occasions to estimate the individual's level of BP.</s></p><p xml:id="_j9kdEuB"><s xml:id="_jQuFYFt">Step 6: Provide BP readings to patient Provide patients the SBP/DBP readings both verbally and in writing.</s></p><p xml:id="_yu5bXyq"><s xml:id="_BZupa5m">*See Section 4.2 for additional guidance.</s><s xml:id="_fNqS68D">Adapted with permission from Mancia et al S4.1-1 (Oxford University Press), Pickering et al S4.1-5 (American Heart Association, Inc.), and Weir et al S4.1-2 (American College of Physicians, Inc.).</s></p><p xml:id="_VFug6Jd"><s xml:id="_RU5CFhz">BP indicates blood pressure; DBP, diastolic blood pressure; and SBP, systolic blood pressure.</s><s xml:id="_yVe64b5">Monitors with provision for storage of readings in memory are preferred.</s></p><p xml:id="_nVnhU66"><s xml:id="_vab5jf3">Verify use of appropriate cuff size to fit the arm (Table <ref type="table">9</ref>).</s></p><p xml:id="_pwZhMzs"><s xml:id="_YATdhWT">Verify that left/right inter-arm differences are insignificant.</s><s xml:id="_EjKTnVP">If differences are significant, instruct patient to measure BPs in the arm with higher readings.</s></p><p xml:id="_263X5P5"><s xml:id="_8gDG5pB">Instructions on HBPM procedures:</s></p><p xml:id="_ckjYvfP"><s xml:id="_KmhVT7q">Remain still:</s></p><p xml:id="_w5BEhBK"><s xml:id="_E5YK7tW">Avoid smoking, caffeinated beverages, or exercise within 30 min before BP measurements.</s></p><p xml:id="_dxEtJZT"><s xml:id="_7jjcm3v">Ensure ≥5 min of quiet rest before BP measurements.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_EE93XmK">Sit correctly:</head><p xml:id="_p8caSBJ"><s xml:id="_jhGus36">Sit with back straight and supported (on a straight-backed dining chair, for example, rather than a sofa).</s></p><p xml:id="_c7e5G9z"><s xml:id="_rfr2Tjx">Sit with feet flat on the floor and legs uncrossed.</s></p><p xml:id="_dCfB3XY"><s xml:id="_UpFxucu">Keep arm supported on a flat surface (such as a table), with the upper arm at heart level.</s></p><p xml:id="_e9kpQWk"><s xml:id="_KcWcHuh">Bottom of the cuff should be placed directly above the antecubital fossa (bend of the elbow).</s></p><p xml:id="_yStjSNJ"><s xml:id="_t7sPskh">Take multiple readings:</s></p><p xml:id="_7ecZCDA"><s xml:id="_D5Uzq6e">Take at least 2 readings 1 min apart in morning before taking medications and in evening before supper.</s><s xml:id="_tzQd8UC">Optimally, measure and record BP daily.</s></p><p xml:id="_NmKPY67"><s xml:id="_VrSvrVq">Ideally, obtain weekly BP readings beginning 2 weeks after a change in the treatment regimen and during the week before a clinic visit.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RGmSquU">Record all readings accurately:</head><p xml:id="_KfQfdWW"><s xml:id="_xJMZPGc">Monitors with built-in memory should be brought to all clinic appointments.</s></p><p xml:id="_c2xGH9d"><s xml:id="_73g782E">BP should be based on an average of readings on ≥2 occasions for clinical decision making.</s></p><p xml:id="_BbDpR37"><s xml:id="_vtmW8Zt">The information above may be reinforced with videos available online.</s></p><p xml:id="_7QDGycD"><s xml:id="_KUGWMrk">See Table <ref type="table">11</ref> for HBPM targets.</s><s xml:id="_JaKypPw">BP indicates blood pressure; and HBPM, home blood pressure monitoring.</s></p><p xml:id="_mrV8wZt"><s xml:id="_HBcwYjF">Table 10.</s><s xml:id="_Tu68XU6">Continued Table 10.</s><s xml:id="_c3tUs6M">Procedures for Use of HBPM S4.2-5-S4.2-7</s><s xml:id="_DjfNsbK">Patient training should occur under medical supervision, including: Information about hypertension Selection of equipment Acknowledgment that individual BP readings may vary substantially Interpretation of results (Continued ) Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025 Figure 1.</s><s xml:id="_eswyHGJ">Detection of white coat hypertension or masked hypertension in patients not on drug therapy.</s><s xml:id="_pPQF97N">Colors correspond to Class of Recommendation in Table 1.</s><s xml:id="_YJjtZcf">ABPM indicates ambulatory blood pressure monitoring; BP, blood pressure; and HBPM, home blood pressure monitoring.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_gX9snzh">IIa C-LD</head><p xml:id="_FHBJzTG"><s xml:id="_5FXk2Pv">3. In adults being treated for hypertension with office BP readings not at goal and HBPM readings suggestive of a significant white coat effect, confirmation by ABPM can be useful.</s><s xml:id="_ZMmutrb"><ref type="bibr">S4.3-9,S4.3-10</ref></s><s xml:id="_ghztJMp">IIa B-NR 4. In adults with untreated office BPs that are consistently between 120 mm Hg and 129 mm Hg for SBP or between 75 mm Hg and 79 mm Hg for DBP, screening for masked hypertension with HBPM (or ABPM) is reasonable.</s><s xml:id="_WEKHPF8"><ref type="bibr">S4.3-3,S4.3-4,S4.3-6,S4.3-8,S4.3-11</ref></s><s xml:id="_YCZUUQv">IIb C-LD</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_8JeEHFk">5.</head><p xml:id="_gS3X8H7"><s xml:id="_vvTCgzn">In adults on multiple-drug therapies for hypertension and office BPs within 10 mm Hg above goal, it may be reasonable to screen for white coat effect with HBPM (or ABPM).</s><s xml:id="_MkX3tXZ"><ref type="bibr">S4.3-3,S4.3-7,S4.3-12</ref></s><s xml:id="_6RgfKj8">IIb C-EO 6.</s><s xml:id="_5avjsMJ">It may be reasonable to screen for masked uncontrolled hypertension with HBPM in adults being treated for hypertension and office readings at goal, in the presence of target organ damage or increased overall CVD risk.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Q2sTHkK">IIb C-EO</head><p xml:id="_6GmGhGE"><s xml:id="_bwj2xG5">7. In adults being treated for hypertension with elevated HBPM readings suggestive of masked uncontrolled hypertension, confirmation of the diagnosis by ABPM might be reasonable before intensification of antihypertensive drug treatment.</s></p><p xml:id="_22p8hcE"><s xml:id="_YMPx88y">Table 11.</s><s xml:id="_T47MUkb">Corresponding Values of SBP/DBP for Clinic, HBPM, Daytime, Nighttime, and 24-Hour ABPM Measurements Clinic HBPM Daytime ABPM Nighttime ABPM 24-Hour ABPM 120/80 120/80 120/80 100/65 115/75 130/80 130/80 130/80 110/65 125/75 140/90 135/85 135/85 120/70 130/80 160/100 145/90 145/90 140/85 145/90 ABPM indicates ambulatory blood pressure monitoring; BP, blood pressure; DBP, diastolic blood pressure; HBPM, home blood pressure monitoring; and SBP, systolic blood pressure.</s><s xml:id="_wdHb2RJ">Recommendations for Masked and White Coat Hypertension (Continued) COR LOE Recommendations Table 12.</s><s xml:id="_NWgm4wM">BP Patterns Based on Office and Out-of-Office Measurements Office/Clinic/ Healthcare Setting Home/Nonhealthcare/ ABPM Setting Normotensive No hypertension No hypertension Sustained hypertension Hypertension Hypertension Masked hypertension No hypertension Hypertension White coat hypertension Hypertension No hypertension ABPM indicates ambulatory blood pressure monitoring; and BP, blood pressure.</s><s xml:id="_kdW4nY9">Figure 2. Detection of white coat effect or masked uncontrolled hypertension in patients on drug therapy.</s><s xml:id="_S9T5Bj2">Colors correspond to Class of Recommendation in Table 1.</s><s xml:id="_cHzWAeZ">See Section 8 for treatment options.</s><s xml:id="_RQPfMZp">ABPM indicates ambulatory blood pressure monitoring; BP, blood pressure; CVD, cardiovascular disease; and HBPM, home blood pressure monitoring.</s><s xml:id="_BrKQMg8">Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025  <ref type="table">13</ref> are present or in adults with resistant hypertension.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5." xml:id="_9Jj9Tz8">Causes of Hypertension</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.1." xml:id="_JhUm9n8">Secondary Forms of Hypertension</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_XPDdzjS">Recommendations for Secondary Forms of Hypertension</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_mSbpE3C">IIb C-EO</head><p xml:id="_ekF94jM"><s xml:id="_ZRX4nP7">2. If an adult with sustained hypertension screens positive for a form of secondary hypertension, referral to a physician with expertise in that form of hypertension may be reasonable for diagnostic confirmation and treatment.</s><s xml:id="_QK4je7G">Table 1.</s><s xml:id="_uHzhWU7">TOD indicates target organ damage (eg, cerebrovascular disease, hypertensive retinopathy, left ventricular hypertrophy, left ventricular dysfunction, heart failure, coronary artery disease, chronic kidney disease, albuminuria, peripheral artery disease).</s></p><p xml:id="_YUtfWas"><s xml:id="_dwgDu42">Table 13.</s><s xml:id="_3RBP2Dc">Causes of Secondary Hypertension With Clinical Indications and Diagnostic Screening Tests Prevalence Clinical Indications Physical Examination Screening Tests Additional/Confirmatory Tests Common causes Renal parenchymal disease S5.1-1,S5.1-2</s><s xml:id="_zHzpcpe">1%-2% Urinary tract infections; obstruction, hematuria; urinary frequency and nocturia; analgesic abuse; family history of polycystic kidney disease; elevated serum creatinine; abnormal urinalysis Abdominal mass (polycystic kidney disease); skin pallor Renal ultrasound Tests to evaluate cause of renal disease Renovascular disease S5.1-3 5%-34%* Resistant hypertension; hypertension of abrupt onset or worsening or increasingly difficult to control; flash pulmonary edema (atherosclerotic); early-onset hypertension, especially in women (fibromuscular hyperplasia) Abdominal systolicdiastolic bruit; bruits over other arteries (carotid -atherosclerotic or fibromuscular dysplasia), femoral Renal Duplex Doppler ultrasound; MRA; abdominal CT Bilateral selective renal intra-arterial angiography (Continued ) Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025 June 2018 Common causes (Continued) Primary aldosteronism S5.1-4,S5.1-5</s><s xml:id="_7HnnAxA">8%-20% † Resistant hypertension; hypertension with hypokalemia (spontaneous or diuretic induced); hypertension and muscle cramps or weakness; hypertension and incidentally discovered adrenal mass; hypertension and obstructive sleep apnea; hypertension and family history of early-onset hypertension or stroke Arrhythmias (with hypokalemia); especially atrial fibrillation Plasma aldosterone/ renin ratio under standardized conditions (correction of hypokalemia and withdrawal of aldosterone antagonists for 4-6 wk) Oral sodium loading test (with 24-h urine aldosterone) or IV saline infusion test with plasma aldosterone at 4 h of infusion Adrenal CT scan, adrenal vein sampling.</s><s xml:id="_WHYcWYv">Obstructive sleep apnea S5.1-6 ‡ 25%-50% Resistant hypertension; snoring; fitful sleep; breathing pauses during sleep; daytime sleepiness Obesity, Mallampati class III-IV; loss of normal nocturnal BP fall Berlin Questionnaire; S5.1-7 Epworth Sleepiness Score; S5.1-8 overnight oximetry Polysomnography Drug or alcohol induced S5.1-9 § 2%-4% Sodium-containing antacids; caffeine; nicotine (smoking); alcohol; NSAIDs; oral contraceptives; cyclosporine or tacrolimus; sympathomimetics (decongestants, anorectics); cocaine, amphetamines and other illicit drugs; neuropsychiatric agents; erythropoiesis-stimulating agents; clonidine withdrawal; herbal agents (Ma Huang, ephedra) Fine tremor, tachycardia, sweating (cocaine, ephedrine, MAO inhibitors); acute abdominal pain (cocaine) Urinary drug screen (illicit drugs) Response to withdrawal of suspected agent Uncommon causes Pheochromocytoma/ paraganglioma S5.1-10 0.1%-0.6%</s><s xml:id="_uFf8HUN">Resistant hypertension; paroxysmal hypertension or crisis superimposed on sustained hypertension; "spells," BP lability, headache, sweating, palpitations, pallor; positive family history of pheochromocytoma/ paraganglioma; adrenal incidentaloma Skin stigmata of neurofibromatosis (café-au-lait spots; neurofibromas); Orthostatic hypotension 24-h urinary fractionated metanephrines or plasma metanephrines under standard conditions (supine position with indwelling IV cannula) CT or MRI scan of abdomen/pelvis Cushing's syndrome S5.1-11 &lt;0.1% Rapid weight gain, especially with central distribution; proximal muscle weakness; depression; hyperglycemia Central obesity, "moon" face, dorsal and supraclavicular fat pads, wide (1-cm) violaceous striae, hirsutism Overnight 1-mg dexamethasone suppression test 24-h urinary free cortisol excretion (preferably multiple); midnight salivary cortisol Hypothyroidism S5.1-9 &lt;1% Dry skin; cold intolerance; constipation; hoarseness; weight gain Delayed ankle reflex; periorbital puffiness; coarse skin; cold skin; slow movement; goiter Thyroid-stimulating hormone; free thyroxine None Hyperthyroidism S5.1-9 &lt;1% Warm, moist skin; heat intolerance; nervousness; tremulousness; insomnia; weight loss; diarrhea; proximal muscle weakness Lid lag; fine tremor of the outstretched hands; warm, moist skin Thyroid-stimulating hormone; free thyroxine Radioactive iodine uptake and scan Aortic coarctation (undiagnosed or repaired) S5.1-12 0.1% Young patient with hypertension (&lt;30 y of age) BP higher in upper extremities than in lower extremities; absent femoral pulses; continuous murmur over patient's back, chest, or abdominal bruit; left thoracotomy scar (postoperative) Echocardiogram Thoracic and abdominal CT angiogram or MRA (Continued )</s></p><p xml:id="_ZYhFaeT"><s xml:id="_yurCYFy">Table 13.</s><s xml:id="_aw9MNWA">Continued Prevalence Clinical Indications Physical Examination Screening Tests Additional/Confirmatory Tests Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025 5.1.1.</s><s xml:id="_Dm95xWe">Drugs and Other Substances With Potential to Impair BP Control 5.1.2.</s><s xml:id="_grdxWrs">Primary Aldosteronism Recommendations for Primary Aldosteronism COR LOE Recommendations I C-EO 1.</s><s xml:id="_DASWsBK">In adults with hypertension, screening for primary aldosteronism is recommended in the presence of any of the following concurrent conditions: resistant hypertension, hypokalemia (spontaneous or substantial, if diuretic induced), incidentally discovered adrenal mass, family history of early-onset hypertension, or stroke at a young age (&lt;40 years).</s><s xml:id="_9RcU635">I C-LD 2. Use of the plasma aldosterone: renin activity ratio is recommended when adults are screened for primary aldosteronism.</s><s xml:id="_xSNRmz5">S5.1.2-1</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_KkBe7eA">I C-EO</head><p xml:id="_5VkVdG5"><s xml:id="_2msxTpS">3. In adults with hypertension and a positive screening test for primary aldosteronism, referral to a hypertension specialist or endocrinologist is recommended for further evaluation and treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.1.3." xml:id="_3bd6Kug">Renal Artery Stenosis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dA8S2E9">Recommendations for Renal Artery Stenosis</head><p xml:id="_PKvS85b"><s xml:id="_p6Yxpup">References that support recommendations are summarized in Online Data Supplements 7 and 24.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_WuFJ3Ch">COR LOE Recommendations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_yj93Fet">I A</head><p xml:id="_KRKHuJz"><s xml:id="_XJzvDMw">1. Medical therapy is recommended for adults with atherosclerotic renal artery stenosis.</s><s xml:id="_HaNcngj">S5.1.3-1,S5.1.</s></p><p xml:id="_CxqYGN8"><s xml:id="_xTTKS9p">3-2 IIb C-EO 2. In adults with renal artery stenosis for whom medical management has failed (refractory hypertension, worsening renal function, and/or intractable HF) and those with nonatherosclerotic disease, including fibromuscular dysplasia, it may be reasonable to refer the patient for consideration of revascularization (percutaneous renal artery angioplasty and/or stent placement).</s><s xml:id="_WyD8tSU">Uncommon Causes (Continued) Primary hyperparathyroidism S5.1-13 Rare Hypercalcemia Usually none Serum calcium Serum parathyroid hormone Congenital adrenal hyperplasia S5.1-14 Rare Hypertension and hypokalemia; virilization (11-beta-hydroxylase deficiency [11-beta-OH]); incomplete masculinization in males and primary amenorrhea in females (17-alpha-hydroxylase deficiency [17-alpha-OH]) Signs of virilization (11-beta-OH) or incomplete masculinization (17-alpha-OH) Hypertension and hypokalemia with low or normal aldosterone and renin 11-beta-OH: elevated deoxycorticosterone (DOC), 11-deoxycortisol, and androgens17alpha-OH; decreased androgens and estrogen; elevated deoxycorticosterone and corticosterone Mineralocorticoid excess syndromes other than primary aldosteronism S5.1-14 Rare Early-onset hypertension; resistant hypertension; hypokalemia or hyperkalemia Arrhythmias (with hypokalemia) Low aldosterone and renin Urinary cortisol metabolites; genetic testing Acromegaly S5.1-15 Rare Acral features, enlarging shoe, glove, or hat size; headache, visual disturbances; diabetes mellitus Acral features; large hands and feet; frontal bossing Serum growth hormone ≥1 ng/mL during oral glucose load Elevated age-and sex-matched IGF-1 level; MRI scan of the pituitary *Depending on the clinical situation (hypertension alone, 5%; hypertension starting dialysis, 22%; hypertension and peripheral vascular disease, 28%; hypertension in the elderly with congestive heart failure, 34%).</s><s xml:id="_z35gsmr">†8% in general population with hypertension; up to 20% in patients with resistant hypertension.</s><s xml:id="_C7GzkFV">‡Although obstructive sleep apnea is listed as a cause of secondary hypertension, RCTs on the effects of continuous positive airway pressure on lowering BP in patients with hypertension have produced mixed results (see Section 5.4.4 for details).</s><s xml:id="_8Jpgn3S">§For a list of frequently used drugs causing hypertension and accompanying evidence, see Table 14.</s><s xml:id="_MdDBksA">BP indicates blood pressure; CT, computed tomography; DOC, 11-deoxycorticosterone; IGF-1, insulin-like growth factor-1; IV, intravenous; MAO, monamine oxidase; MRI, magnetic resonance imaging; MRA, magnetic resonance arteriography; NSAIDs, nonsteroidal anti-inflammatory drugs; OH, hydroxylase; and RCT, randomized clinical trial.</s></p><p xml:id="_WuSmXfs"><s xml:id="_2UR69HX">Table 13.</s><s xml:id="_DZQ6nWq">Continued Prevalence Clinical Indications Physical Examination Screening Tests Additional/Confirmatory Tests 1.</s><s xml:id="_bSpEEKH">In adults with hypertension and obstructive sleep apnea, the effectiveness of continuous positive airway pressure (CPAP) to reduce BP is not well established.</s><s xml:id="_Cqmkncf">S5.1.4-1-S5.1.4-5</s><s xml:id="_FGRrp9c">6. Nonpharmacological Interventions Recommendations for Nonpharmacological Interventions References that support recommendations are summarized in Online Data Supplements 9-21.</s><s xml:id="_QYMvYdF">COR LOE Recommendations I A 1. Weight loss is recommended to reduce BP in adults with elevated BP or hypertension who are overweight or obese.</s><s xml:id="_K77jW2j">S6-1-S6-4 I A 2. A heart-healthy diet, such as the DASH (Dietary Approaches to Stop Hypertension) diet, that facilitates achieving a desirable weight is recommended for adults with elevated BP or hypertension.</s><s xml:id="_9JYzzJX">S6-5-S6-7 I A 3. Sodium reduction is recommended for adults with elevated BP or hypertension.</s><s xml:id="_DZy5jJW">S6-8-S6-12</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_cDMA3VD">I A</head><p xml:id="_sRFhHyW"><s xml:id="_gBYsU7E">5. Increased physical activity with a structured exercise program is recommended for adults with elevated BP or hypertension.</s><s xml:id="_AR7Sssp">S6-3,S6-4,S6-12,S6-18-S6-22 I A</s></p><p xml:id="_dkJENmz"><s xml:id="_n9aj3nN">6. Adult men and women with elevated BP or hypertension who currently consume alcohol should be advised to drink no more than 2 and 1 standard drinks* per day, respectively.</s><s xml:id="_39YTm5p">S6-23-S6-28 *In the United States, 1 "standard" drink contains roughly 14 g of pure alcohol, which is typically found in 12 oz of regular beer (usually about 5% alcohol), 5 oz of wine (usually about 12% alcohol), and 1.5 oz of distilled spirits (usually about 40% alcohol).</s><s xml:id="_WH4HvRr"><ref type="bibr">S6-29</ref> Table 15.</s><s xml:id="_8ykM7AV">Best Proven Nonpharmacological Interventions for Prevention and Treatment of Hypertension* Nonpharmacological Intervention Dose Approximate Impact on SBP Hypertension Normotension Reference Weight loss Weight/body fat Best goal is ideal body weight, but aim for at least a 1-kg reduction in body weight for most adults who are overweight.</s><s xml:id="_x7E7Rs2">Expect about 1 mm Hg for every 1-kg reduction in body weight.</s><s xml:id="_MHxn477">-5 mm Hg -2/3 mm Hg S6-1 Healthy diet DASH dietary pattern Consume a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with reduced content of saturated and total fat.</s><s xml:id="_3hRjWuK">-11 mm Hg -3 mm Hg S6-6,S6-7 Reduced intake of dietary sodium Dietary sodium Optimal goal is &lt;1500 mg/d, but aim for at least a 1000-mg/d reduction in most adults.</s><s xml:id="_c6C9TQW">-5/6 mm Hg -2/3 mm Hg S6-9,S6-10 Enhanced intake of dietary potassium Dietary potassium Aim for 3500-5000 mg/d, preferably by consumption of a diet rich in potassium.</s><s xml:id="_xX3Rv9y">-4/5 mm Hg -2 mm Hg S6-13 Physical activity Aerobic 90-150 min/wk 65%-75% heart rate reserve -5/8 mm Hg -2/4 mm Hg S6-18,S6-22 Dynamic resistance 90-150 min/wk 50%-80% 1 rep maximum 6 exercises, 3 sets/exercise, 10 repetitions/set -4 mm Hg -2 mm Hg S6-18 Isometric resistance 4 × 2 min (hand grip), 1 min rest between exercises, 30%-40% maximum voluntary contraction, 3 sessions/wk 8-10 wk -5 mm Hg -4 mm Hg S6-19,S6-30 Moderation in alcohol intake Alcohol consumption In individuals who drink alcohol, reduce alcohol † to: Men: ≤2 drinks daily Women: ≤1 drink daily -4 mm Hg -3 mm Hg S6-22-S6-24</s></p><p xml:id="_sY6qcck"><s xml:id="_PrtdN2T">Resources: Your Guide to Lowering Your Blood Pressure With DASH-How Do I Make the DASH?</s><s xml:id="_kdPGcJu">Available at: <ref type="url" target="https://www.nhlbi.nih.gov/health/resources/heart/">https://www.nhlbi.nih.gov/health/resources/heart/</ref></s><s xml:id="_eTBG9tU">hbp-dash-how-to.</s><s xml:id="_KvZW3xb">Accessed September 15, 2017.</s><s xml:id="_m585D6k"><ref type="bibr">S6-31</ref> Top 10 Dash Diet Tips.</s><s xml:id="_uF2rka5">Available at: <ref type="url" target="http://dashdiet.org/dash_diet_tips.asp">http://dashdiet.org/dash_diet_tips.asp</ref>.</s><s xml:id="_WVeTjXH">Accessed September 15, 2017.</s><s xml:id="_JxNzGw7">S6-32 *Type, dose, and expected impact on BP in adults with a normal BP and with hypertension.</s><s xml:id="_2m4k6Y4">†In the United States, one "standard" drink contains roughly 14 g of pure alcohol, which is typically found in 12 oz of regular beer (usually about 5% alcohol), 5 oz of wine (usually about 12% alcohol), and 1.5 oz of distilled spirits (usually about 40% alcohol).</s><s xml:id="_TSMVVH5"><ref type="bibr">S6-29</ref> DASH indicates Dietary Approaches to Stop Hypertension; and SBP, systolic blood pressure.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_MJvFNQ6">Recommendations for</head><p xml:id="_rbq5w2U"><s xml:id="_8AGRZHe">Nonpharmacological Interventions (Continued) 7. Patient Evaluation 7.1.</s><s xml:id="_NPff4cj">Laboratory Tests and Other Diagnostic Procedures 8. Treatment of High BP 8.1.</s><s xml:id="_DMEEqfE">Pharmacological Treatment</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.1.1." xml:id="_UxYpGd2">Initiation of Pharmacological BP Treatment in the Context of Overall CVD Risk</head><p xml:id="_fpypPrQ"><s xml:id="_NWc6xpq">For any specific difference in BP, the relative risk of CVD is constant across groups that differ in absolute risk of atherosclerotic CVD, S8.1.1-1-S8.1.1-4</s><s xml:id="_8gt9xmT">albeit with some evidence of lesser relative risk but greater excess risk in older than in younger adults.</s><s xml:id="_GFUGKEU">S8.1.1-5-S8.1.1-8</s><s xml:id="_nnA6EMA">Thus, there are more potentially preventable CVD events attributable to elevated BP in individuals with higher than with lower risk of CVD and in older than in younger adults.</s><s xml:id="_2WQwdbz">The relative risk reduction for CVD prevention with use of BP-lowering medications is fairly constant for groups that differ in CVD risk across a wide range of estimated absolute risk S8.1.1-9,S8.1.1-10</s><s xml:id="_BxyKVen">and across groups defined by sex, age, body mass index, and the presence or absence of DM, AF, and CKD.</s><s xml:id="_Pxgjp87">S8.1.1-5,S8.1.1-11-S8.1.1-21</s><s xml:id="_fzJrnva">As a consequence, the absolute CVD risk reduction attributable to BP lowering is greater at greater absolute levels of CVD risk.</s><s xml:id="_BkXzfAb">S8.1.1-9,S8.1.1-10,S8.1.1-12,S8.1.1-15-S8.1.1-19,S8.1.1-22,S8.1.1-23</s><s xml:id="_YJCPdhJ">Put another way, for a given magnitude of BP reduction due to antihypertensive medications, fewer individuals at high CVD risk would need to be treated to prevent a CVD event (ie, lower number needed to treat) than those at low CVD risk.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.1.2." xml:id="_TRhmynq">BP Treatment Threshold and the Use of CVD Risk Estimation to Guide Drug Treatment of Hypertension</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_yP2KGgP">Recommendations for BP Treatment Threshold and Use of Risk Estimation* to Guide Drug Treatment of Hypertension</head><p xml:id="_zAKnPfz"><s xml:id="_6hdXDdU">References that support recommendations are summarized in Online Data Supplement 23.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_VjZ8Z8p">COR LOE Recommendations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Du9hrDy">I SBP: A</head><p xml:id="_AcKg4Rr"><s xml:id="_ewwyqjs">1. Use of BP-lowering medications is recommended for secondary prevention of recurrent CVD events in patients with clinical CVD and an average SBP of 130 mm Hg or higher or an average DBP of 80 mm Hg or higher, and for primary prevention in adults with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 10% or higher and an average SBP 130 mm Hg or higher or an average DBP 80 mm Hg or higher.</s><s xml:id="_nWm88HG">S8.1.2-1-S8.1.2-9</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_8uvmbVM">DBP: C-EO I C-LD</head><p xml:id="_pDvFKFv"><s xml:id="_gyz49tH">2. Use of BP-lowering medication is recommended for primary prevention of CVD in adults with no history of CVD and with an estimated 10-year ASCVD risk &lt;10% and an SBP of 140 mm Hg or higher or a DBP of 90 mm Hg or higher.</s><s xml:id="_QcaV6WE">S8.1.2-3,S8.1.2-10-S8.1. <ref type="bibr">[2]</ref><ref type="bibr" target="#b97">[3]</ref></s><s xml:id="_9yduWc6">4]<ref type="bibr" target="#b129">[5]</ref><ref type="bibr" target="#b147">[6]</ref><ref type="bibr">[7]</ref><ref type="bibr">[8]</ref><ref type="bibr">[9]</ref><ref type="bibr" target="#b6">[10]</ref><ref type="bibr">[11]</ref><ref type="bibr">[12]</ref><ref type="bibr">[13]</ref> *ACC/AHA Pooled Cohort Equations (<ref type="url" target="http://tools.acc.org/ASCVD-Risk-">http://tools.acc.org/ASCVD-Risk-</ref>Estimator/)</s><s xml:id="_qNNFFwp"><ref type="bibr">S8.1.2-13a</ref></s><s xml:id="_QAyzj6d">to estimate 10-year risk of atherosclerotic CVD.</s><s xml:id="_m2nHZbm">ASCVD was defined as a first CHD death, non-fatal MI or fatal or non-fatal stroke.</s></p><p xml:id="_YmBgsFp"><s xml:id="_aG6BnzP">Table 16.</s><s xml:id="_bumYpB3">Historical Features Favoring Hypertension Cause Primary Hypertension Secondary Hypertension Gradual increase in BP, with slow rate of rise in BP BP lability, episodic pallor and dizziness (pheochromocytoma) Lifestyle factors that favor higher BP (eg, weight gain, high-sodium diet, decreased physical activity, job change entailing increased travel, excessive consumption of alcohol) Snoring, hypersomnolence (obstructive sleep apnea) Prostatism (chronic kidney disease due to post-renal urinary tract obstruction) Family history of hypertension Muscle cramps, weakness (hypokalemia from primary aldosteronism or secondary aldosteronism due to renovascular disease) Weight loss, palpitations, heat intolerance (hyperthyroidism) Edema, fatigue, frequent urination (kidney disease or failure) History of coarctation repair (residual hypertension associated with coarctation) Central obesity, facial rounding, easy bruisability (Cushing's syndrome) Medication or substance use (eg, alcohol, NSAIDS, cocaine, amphetamines) Absence of family history of hypertension BP indicates blood pressure; and NSAIDs, nonsteroidal anti-inflammatory drugs.</s></p><p xml:id="_DaJBhyS"><s xml:id="_HqeC4zz">Table 17.</s><s xml:id="_3cjeduq">Basic and Optional Laboratory Tests for Primary Hypertension Basic testing Fasting blood glucose* Complete blood count Lipid profile Serum creatinine with eGFR* Serum sodium, potassium, calcium* Thyroid-stimulating hormone Urinalysis Electrocardiogram Optional testing Echocardiogram Uric acid Urinary albumin to creatinine ratio *May be included in a comprehensive metabolic panel.</s><s xml:id="_4z4Wxpr">eGFR indicates estimated glomerular filtration rate.</s><s xml:id="_XfZHeXV">8.1.3.</s><s xml:id="_vVjeP5z">Follow-Up After Initial BP Evaluation Recommendations for Follow-Up After Initial BP Evaluation References that support recommendations are summarized in Online Data Supplement 24.</s><s xml:id="_fR89u8q">COR LOE Recommendations I B-R 1. Adults with an elevated BP or stage 1 hypertension who have an estimated 10year ASCVD risk less than 10% should be managed with nonpharmacological therapy and have a repeat BP evaluation within 3 to 6 months.</s><s xml:id="_cAS8z49">S8.1.3-1,S8.1.3-2</s><s xml:id="_N6TP3RA">I B-R 2. Adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of 10% or higher should be managed initially with a combination of nonpharmacological and antihypertensive drug therapy and have a repeat BP evaluation in 1 month.</s><s xml:id="_Q24C7JD">S8.1.3-1,S8.1.3-2</s><s xml:id="_3QZMCCN">I B-R 3. Adults with stage 2 hypertension should be evaluated by or referred to a primary care provider within 1 month of the initial diagnosis, have a combination of nonpharmacological and antihypertensive drug therapy (with 2 agents of different classes) initiated, and have a repeat BP evaluation in 1 month.</s><s xml:id="_uRk6VPD">S8.1.3-1,S8.1.3-2</s><s xml:id="_kEs6K7R">I B-R 4. For adults with a very high average BP (eg, SBP ≥180 mm Hg or DBP ≥110 mm Hg), evaluation followed by prompt antihypertensive drug treatment is recommended.</s><s xml:id="_MbcHnJX">S8.1.3-1,S8.1.3-2</s><s xml:id="_Qjf3fe3">IIa C-EO 5.</s><s xml:id="_ufY4qJW">For adults with a normal BP, repeat evaluation every year is reasonable.</s><s xml:id="_JWbQ5sP">Recommendations for Follow-Up After Initial BP Evaluation (Continued) COR LOE Recommendations Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.1.4." xml:id="_5vDp6P7">General Principles of Drug Therapy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_9sV7amU">Recommendation for General Principle of Drug Therapy</head><p xml:id="_JJ7ntRr"><s xml:id="_W3dbXbP">References that support recommendations are summarized in Online Data Supplement 25.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_65UX5BT">COR LOE Recommendation</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_FFnEWcf">III: Harm A</head><p xml:id="_zTKntS8"><s xml:id="_vV2gHDU">1. Simultaneous use of an ACE inhibitor, ARB, and/or renin inhibitor is potentially harmful and is not recommended to treat adults with hypertension.</s><s xml:id="_t6WJknS">S8.1.4-1-S8.1.4-3</s></p><p xml:id="_QJjwFvt"><s xml:id="_JegjeYe">Table 18.</s><s xml:id="_6CPjngv">Oral Antihypertensive Drugs Class Drug Usual Dose, Range (mg/d)* Daily Frequency Comments Primary agents Thiazide or thiazidetype diuretics Chlorthalidone 12.5-25 1 Chlorthalidone is preferred on the basis of prolonged half-life and proven trial reduction of CVD.</s><s xml:id="_Q3xHxUc">Monitor for hyponatremia and hypokalemia, uric acid and calcium levels.</s><s xml:id="_avbNggY">Use with caution in patients with history of acute gout unless patient is on uric acid-lowering therapy.</s><s xml:id="_ynmDxQv">Hydrochlorothiazide 25-50 1 Indapamide 1.25-2.5 1 Metolazone 2.5-5 1 ACE inhibitors Benazepril 10-40 1 or 2 Do not use in combination with ARBs or direct renin inhibitor.</s></p><p xml:id="_y3ntBcU"><s xml:id="_bWPv9KM">There is an increased risk of hyperkalemia, especially in patients with CKD or in those on K + supplements or K + -sparing drugs.</s></p><p xml:id="_eMsmcqV"><s xml:id="_cZ4TQu8">There is a risk of acute renal failure in patients with severe bilateral renal artery stenosis.</s></p><p xml:id="_UQvJ5Cc"><s xml:id="_Cb5pJfy">Do not use if patient has history of angioedema with ACE inhibitors.</s></p><p xml:id="_xgmWHyB"><s xml:id="_ENXEbTH">Avoid in pregnancy.</s><s xml:id="_Sau8TnX">There is an increased risk of hyperkalemia in CKD or in those on K + supplements or K + -sparing drugs.</s></p><p xml:id="_Ph5y57C"><s xml:id="_Mpncj2Q">There is a risk of acute renal failure in patients with severe bilateral renal artery stenosis.</s></p><p xml:id="_ZxdAwM7"><s xml:id="_vt5uv3n">Do not use if patient has history of angioedema with ARBs.</s><s xml:id="_TycCHGE">Patients with a history of angioedema with an ACE inhibitor can receive an ARB beginning 6 weeks after ACE inhibitor is discontinued.</s><s xml:id="_E3ymVyP">Avoid in pregnancy.</s><s xml:id="_hASF9V7">Candesartan 8-32 1 Eprosartan 600-800 1 or 2 Irbesartan 150-300 1 Losartan 50-100 1 or 2 Olmesartan 20-40 1 Telmisartan 20-80 1 Valsartan 80-320 1 CCBdihydropyridines Amlodipine 2.5-10 1 Avoid use in patients with HFrEF; amlodipine or felodipine may be used if required.</s><s xml:id="_gDdhqTF">They are associated with dose-related pedal edema, which is more common in women than men.</s><s xml:id="_4Zw7VcH">Felodipine 2.5-10 1 Isradipine 5-10 2 Nicardipine SR 60-120 2 Nifedipine LA 30-90 1 Nisoldipine 17-34 1 CCBnondihydropyridines Diltiazem ER 120-360 1 Avoid routine use with beta blockers because of increased risk of bradycardia and heart block.</s><s xml:id="_H3QTqgv">Do not use in patients with HFrEF.</s><s xml:id="_dFrY9ER">There are drug interactions with diltiazem and verapamil (CYP3A4 major substrate and moderate inhibitor).</s><s xml:id="_VyrB8Kt">Verapamil IR 120-360 3 Verapamil SR 120-360 1 or 2 Verapamil-delayed onset ER 100-300 1 (in the evening) (Continued ) Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025 Secondary agents Diuretics-loop Bumetanide 0.5-2 2 These are preferred diuretics in patients with symptomatic HF.</s><s xml:id="_PbqzUjC">They are preferred over thiazides in patients with moderate-to-severe CKD (eg, GFR &lt;30 mL/min).</s><s xml:id="_n7Z2vEh">Furosemide 20-80 2 Torsemide 5-10 1 Diureticspotassium sparing Amiloride 5-10 1 or 2 These are monotherapy agents and minimally effective antihypertensive agents.</s><s xml:id="_YtqyTZs">Combination therapy of potassium-sparing diuretic with a thiazide can be considered in patients with hypokalemia on thiazide monotherapy.</s><s xml:id="_hpKZcVh">Avoid in patients with significant CKD (eg, GFR &lt;45 mL/min).</s><s xml:id="_DcHc888">Triamterene 50-100 1 or 2 Diureticsaldosterone antagonists Eplerenone 50-100 1 or 2 These are preferred agents in primary aldosteronism and resistant hypertension.</s><s xml:id="_5njpy6W">Spironolactone is associated with greater risk of gynecomastia and impotence as compared with eplerenone.</s><s xml:id="_2dCNnjD">This is common add-on therapy in resistant hypertension.</s><s xml:id="_zN4bZE2">Avoid use with K + supplements, other K + -sparing diuretics, or significant renal dysfunction.</s><s xml:id="_ZCcAmaR">Eplerenone often requires twice-daily dosing for adequate BP lowering.</s><s xml:id="_krNDZcB">Spironolactone 25-100 1 Beta blockerscardioselective Atenolol 25-100 2 Beta blockers are not recommended as first-line agents unless the patient has IHD or HF.</s><s xml:id="_7JD4TS9">These are preferred in patients with bronchospastic airway disease requiring a beta blocker.</s><s xml:id="_AT2DSza">Bisoprolol and metoprolol succinate are preferred in patients with HFrEF.</s><s xml:id="_FpA8Z9x">Avoid abrupt cessation.</s><s xml:id="_mGmq3ad">Betaxolol 5-20 1 Bisoprolol 2.5-10 1 Metoprolol tartrate 100-200 2 Metoprolol succinate 50-200 1 Beta blockerscardioselective and vasodilatory Nebivolol 5-40 1 Nebivolol induces nitric oxide-induced vasodilation.</s><s xml:id="_mGnHvXz">Avoid abrupt cessation.</s><s xml:id="_mCc6Gjk">Beta blockersnoncardioselective Nadolol 40-120 1 Avoid in patients with reactive airways disease.</s><s xml:id="_eHh4UdP">Avoid abrupt cessation.</s><s xml:id="_ZtErsxA">Propranolol IR 80-160 2 Propranolol LA 80-160 1 Beta blockersintrinsic sympathomimetic activity Acebutolol 200-800 2 Generally avoid, especially in patients with IHD or HF.</s><s xml:id="_dHBP856">Avoid abrupt cessation.</s><s xml:id="_pdumqxR">Penbutolol 10-40 1 Pindolol 10-60 2 Beta blockerscombined alphaand beta-receptor Carvedilol 12.5-50 2 Carvedilol is preferred in patients with HFrEF.</s><s xml:id="_FYmzASc">Avoid abrupt cessation.</s><s xml:id="_HqPfSEz">Carvedilol phosphate 20-80 1 Labetalol 200-800 2 Direct renin inhibitor Aliskiren 150-300 1 Do not use in combination with ACE inhibitors or ARBs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_m6pChJm">Aliskiren is very long acting.</head><p xml:id="_yFByfxT"><s xml:id="_cwTTr3v">There is an increased risk of hyperkalemia in CKD or in those on K + supplements or K + -sparing drugs.</s></p><p xml:id="_a9HPM84"><s xml:id="_RXQSSp9">Aliskiren may cause acute renal failure in patients with severe bilateral renal artery stenosis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_X3DBEZe">Avoid in pregnancy.</head><p xml:id="_CV2sYz7"><s xml:id="_aRK5gjh">Alpha-1 blockers Doxazosin 1-16 1 These are associated with orthostatic hypotension, especially in older adults.</s><s xml:id="_cnkD3fV">They may be considered as second-line agent in patients with concomitant BPH.</s><s xml:id="_dnR93tx">Prazosin 2-20 2 or 3 Terazosin 1-20 1 or 2 Central alpha 2agonist and other centrally acting drugs Clonidine oral 0.1-0.8 2 These are generally reserved as last-line because of significant CNS adverse effects, especially in older adults.</s><s xml:id="_dHsfeWe">Avoid abrupt discontinuation of clonidine, which may induce hypertensive crisis; clonidine must be tapered to avoid rebound hypertension.</s><s xml:id="_w8JTNm8">Clonidine patch 0.1-0.3 1 weekly Methyldopa 250-1000 2 Guanfacine 0.5-2 1 Table 18.</s><s xml:id="_QgVfAHh">Continued Class Drug Usual Dose, Range (mg/d) * Daily Frequency Comments (Continued ) Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025 June 2018 8.1.5.</s><s xml:id="_8URuT4m">BP Goal for Patients With Hypertension Recommendations for BP Goal for Patients With Hypertension References that support recommendations are summarized in Online Data Supplement 26 and Systematic Review Report COR LOE Recommendations I SBP: B-R SR 1.</s><s xml:id="_bE2Yf22">For adults with confirmed hypertension and known CVD or 10-year ASCVD event risk of 10% or higher (see Section 8.1.2),</s><s xml:id="_hwYeYvk">a BP target of less than 130/80 mm Hg is recommended.</s><s xml:id="_gP7U9s4">S8.1.5-1-S8.1.5-5</s><s xml:id="_tNt4aQc">DBP: C-EO IIb SBP: B-NR 2. For adults with confirmed hypertension, without additional markers of increased CVD risk, a BP target of less than 130/80 mm Hg may be reasonable.</s><s xml:id="_5sp2YhN">S8.1.5-6-S8.1.5-9</s><s xml:id="_RzmuARX">DBP: C-EO SR indicates systematic review.</s><s xml:id="_28TaKhz">8.1.6.</s><s xml:id="_7hCT8mH">Choice of Initial Medication Recommendation for Choice of Initial Medication References that support the recommendation are summarized in Online Data Supplement 27 and Systematic Review Report COR LOE Recommendation I A SR 1.</s><s xml:id="_eCwPGc8">For initiation of antihypertensive drug therapy, first-line agents include thiazide diuretics, CCBs, and ACE inhibitors or ARBs.</s><s xml:id="_FDd9PDT">S8.1.6-1,S8.1.6-2</s><s xml:id="_NmDaW4M">SR indicates systematic review.</s><s xml:id="_3fNRxcp">8.1.6.1.</s><s xml:id="_qt3kwNq">Choice of Initial Monotherapy Versus Initial Combination Drug Therapy Recommendations for Choice of Initial Monotherapy Versus Initial Combination Drug Therapy* COR LOE Recommendations I C-EO 1. Initiation of antihypertensive drug therapy with 2 first-line agents of different classes, either as separate agents or in a fixed-dose combination, is recommended in adults with stage 2 hypertension and an average BP more than 20/10 mm Hg above their BP target.</s><s xml:id="_HTDv8Nx">IIa C-EO 2. Initiation of antihypertensive drug therapy with a single antihypertensive drug is reasonable in adults with stage 1 hypertension and BP goal &lt;130/80 mm Hg with dosage titration and sequential addition of other agents to achieve the BP target.</s><s xml:id="_zjR9xdf">*Fixed-dose combination antihypertensive medications are listed in Online Data Supplement D.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.2." xml:id="_eMnfcMn">Follow-Up of BP During Antihypertensive Drug Therapy</head><p xml:id="_RQvtKKV"><s xml:id="_BQYtjTj">Appropriate follow-up and monitoring enable assessment of adherence (see Section 12.1) and response to therapy, help identify adverse responses to therapy and target organ damage, and allow assessment of progress toward treatment goals.</s><s xml:id="_qUXP6Ry">High-quality RCTs have successfully and safely developed strategies for follow-up, monitoring, and reassessment from which recommendations can be made (Figure <ref type="figure" target="#fig_3">4</ref>).</s><s xml:id="_eFkB8CE">S8.2-1,S8.2-2</s><s xml:id="_ZrAyR2d">A systematic approach to out-of-office BP assessment is an essential part of follow-up and monitoring of BP, to assess response to therapy; check for evidence of white coat hypertension, white coat effect, masked hypertension, or masked uncontrolled hypertension; and help achieve BP targets (see Sections 4 and 12).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.2.1." xml:id="_vhcvhgw">Follow-Up After Initiating Antihypertensive Drug Therapy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_xRYNcPD">Recommendation for Follow-Up After Initiating Antihypertensive Drug Therapy</head><p xml:id="_s56vsN6"><s xml:id="_XNnrNWu">References that support the recommendation are summarized in Online Data Supplement 28.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_NE4PtpD">COR LOE Recommendation</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_4PynEYn">I B-R</head><p xml:id="_QFVrXSk"><s xml:id="_NCtZmXP">1. Adults initiating a new or adjusted drug regimen for hypertension should have a follow-up evaluation of adherence and response to treatment at monthly intervals until control is achieved.</s><s xml:id="_QtykT9a">S8.2.1-1-S8.</s></p><p xml:id="_qWcXHmA"><s xml:id="_aD4sZRm">2.1-3 Secondary agents (Continued) Direct vasodilators Hydralazine 100-200 2 or 3 These are associated with sodium and water retention and reflex tachycardia; use with a diuretic and beta blocker.</s><s xml:id="_38Fp8X6">Hydralazine is associated with drug-induced lupus-like syndrome at higher doses.</s><s xml:id="_u3WMTQF">Minoxidil is associated with hirsutism and requires a loop diuretic.</s><s xml:id="_CYW3JtH">Minoxidil can induce pericardial effusion.</s><s xml:id="_3sHQfvE">Minoxidil 5-100 1-3 *Dosages may vary from those listed in the FDA-approved labeling (available at <ref type="url" target="https://dailymed.nlm.nih.gov/dailymed/">https://dailymed.nlm.nih.gov/dailymed/</ref>).</s><s xml:id="_gT4yaKQ">From Chobanian et al JNC 7. S8.1.4-4</s><s xml:id="_UhcpTgS">ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; BPH, benign prostatic hyperplasia; CCB, calcium channel blocker; CKD, chronic kidney disease; CNS, central nervous system; CVD, cardiovascular disease; ER, extended release; GFR, glomerular filtration rate; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; IHD, ischemic heart disease; IR, immediate release; LA, long-acting; and SR, sustained release.</s></p><p xml:id="_Az6QWBk"><s xml:id="_NsPJPwq">Table 18.</s><s xml:id="_9t4EuDY">Continued Class Drug Usual Dose, Range (mg/d) * Daily Frequency Comments Recommendations for Choice of Initial Monotherapy Versus Initial Combination Drug Therapy* COR LOE Recommendations Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025 8.2.2.</s><s xml:id="_NPBD353">Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP Recommendation for Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP References that support the recommendation are summarized in Online Data Supplement 29.</s><s xml:id="_f6CND4J">COR LOE Recommendation I A 1. Follow-up and monitoring after initiation of drug therapy for hypertension control should include systematic strategies to help improve BP, including use of HBPM, team-based care, and telehealth strategies.</s><s xml:id="_RTM8gGS">S8.3.2-1-S8.3.2-6</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9." xml:id="_h7jjnGG">Hypertension in Patients With Comorbidities</head><p xml:id="_gkMFRh5"><s xml:id="_JVzYCqM">Certain comorbidities may affect clinical decision-making in hypertension.</s><s xml:id="_yaHYBUT">These include ischemic heart disease, HF with reduced ejection fraction (HFrEF), HFpEF, CKD (including renal transplantation), cerebrovascular disease, AF, PAD, DM, and metabolic syndrome.</s><s xml:id="_jbKrXed"><ref type="bibr">S9-1</ref> As noted in Section 8.1.2,</s><s xml:id="_bn4VjQJ">this guideline generally recommends use of BP-lowering medications for secondary prevention of CVD in patients with clinical CVD (CHD, HF, and stroke) and an average BP ≥130/80 mm Hg and for primary prevention of CVD in adults with an estimated 10-year ASCVD risk of ≥10% and an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg.</s><s xml:id="_QEPHBSU">Although we recommend use of the ACC/AHA Pooled Cohort Equations (<ref type="url" target="http://tools.acc.org/ASCVD-">http://tools.acc.org/ASCVD-</ref>Risk-Estimator/) to estimate 10-year risk of ASCVD to establish the BP threshold for treatment, the vast majority of adults with a co-morbidity are likely to have a 10-year risk of ASCVD that exceeds 10%.</s><s xml:id="_T9PVArF">In some instances, clinical trial confirmation of treatment in patients with comorbidities is limited to a target BP of 140/90 mm Hg.</s><s xml:id="_y8NKRDX">In addition, the selection of medications for use in treating high BP in patients with CVD is guided by their use for other compelling indications (eg, beta blockers after MI, ACE inhibitors for HFrEF), as discussed in specific guidelines for the clinical condition.</s><s xml:id="_gecPVpA"><ref type="bibr">S9-2-S9-4</ref> The present guideline does not address the recommendations for treatment of hypertension occurring with acute coronary syndromes.</s><s xml:id="_VNuveSc">Table 1.</s><s xml:id="_TxVFNMr">*GDMT beta blockers for BP control or relief of angina include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol, propranolol, and timolol.</s><s xml:id="_yxJsqTJ">Avoid beta blockers with intrinsic sympathomimetic activity.</s><s xml:id="_wUYUcrm">The beta blocker atenolol should not be used because it is less effective than placebo in reducing cardiovascular events.</s><s xml:id="_4zrq3Rr">†If needed for BP control.</s><s xml:id="_hhgjyEn">ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; GDMT, guideline-directed management and therapy; and SIHD, stable ischemic heart disease.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.1." xml:id="_aYDHYCX">Stable Ischemic Heart Disease</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_XBH67Vk">Recommendations for Treatment of Hypertension in Patients With Stable Ischemic Heart Disease (SIHD) (Continued)</head><p xml:id="_VTUCx5u"><s xml:id="_KB8423U">June 2018</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.2." xml:id="_zT5azWg">Heart Failure</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ghHduGn">Recommendation for Prevention of HF in Adults With Hypertension</head><p xml:id="_mznF8kT"><s xml:id="_j8ZPSND">References that support the recommendation are summarized in Online Data Supplement 33.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_JBQnFrR">COR LOE Recommendation</head><p xml:id="_XwbfEJw"><s xml:id="_dFgE5WG">I SBP: B-R 1.</s><s xml:id="_kr2V5cA">In adults at increased risk of HF, the optimal BP in those with hypertension should be less than 130/80 mm Hg.</s><s xml:id="_R3KsWac">S9.2-1-S9.2-3</s><s xml:id="_h8qC4Tt">DBP: C-EO  In adults with hypertension and CKD (stage 3 or higher or stage 1 or 2 with albuminuria [≥300 mg/d, or ≥300 mg/g albumin-tocreatinine ratio or the equivalent in the first morning void]), treatment with an ACE inhibitor is reasonable to slow kidney disease progression.</s><s xml:id="_nJrcdj3">S9.3-3,S9.3-7-S9. <ref type="bibr" target="#b97">[3]</ref><ref type="bibr">[4]</ref></s><s xml:id="_CfvTJHV">5]<ref type="bibr" target="#b147">[6]</ref><ref type="bibr">[7]</ref><ref type="bibr">[8]</ref><ref type="bibr">[9]</ref><ref type="bibr" target="#b6">[10]</ref><ref type="bibr">[11]</ref><ref type="bibr">[12]</ref> IIb C-EO 3. In adults with hypertension and CKD (stage 3 or higher or stage 1 or 2 with albuminuria [≥300 mg/d, or ≥300 mg/g albuminto-creatinine ratio in the first morning void]), <ref type="bibr">S9.3-7,S9.3-8</ref></s><s xml:id="_Zj7WYvv">treatment with an ARB may be reasonable if an ACE inhibitor is not tolerated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.2.1." xml:id="_NGKXbxv">Heart Failure With Reduced Ejection Fraction</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_gZC7jrX">Recommendations for Treatment of Hypertension in</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.2.2." xml:id="_HSsMPBV">Heart Failure With Preserved Ejection Fraction</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_yQKMsfS">Recommendations for Treatment of Hypertension in</head><p xml:id="_9jrMz5E"><s xml:id="_5B2Pjxq">SR indicates systematic review.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.3.1." xml:id="_aAEQwJg">Hypertension After Renal Transplantation</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_AFDKErK">Recommendations for Treatment of Hypertension After Renal Transplantation</head><p xml:id="_FsXuF5m"><s xml:id="_rYYhBFA">References that support recommendations are summarized in Online Data Supplements 39 and 40.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Q65N7z6">COR LOE Recommendations</head><p xml:id="_CwufmJn"><s xml:id="_NkJZGbH">IIa SBP: B-NR 1.</s><s xml:id="_F4hcPZA">After kidney transplantation, it is reasonable to treat patients with hypertension to a BP goal of less than 130/80 mm Hg.</s><s xml:id="_mKa8FGK">S9.</s></p><p xml:id="_d4uhyxG"><s xml:id="_GvqrNhY">3.1-1 DBP: C-EO Recommendations for Treatment of Hypertension in Patients With CKD (Continued) COR LOE Recommendations Figure 6.</s><s xml:id="_Vjz2Bzg">Management of hypertension in patients with CKD.</s><s xml:id="_ZSHM5jW">Colors correspond to Class of Recommendation in Table 1.</s><s xml:id="_HeVXFvw">*CKD stage 3 or higher or stage 1 or 2 with albuminuria ≥300 mg/d or ≥300 mg/g creatinine.</s><s xml:id="_323ymbm">ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; and CKD, chronic kidney disease.</s><s xml:id="_XRsHcMd">Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025 IIa B-R 2. After kidney transplantation, it is reasonable to treat patients with hypertension with a calcium antagonist on the basis of improved GFR and kidney survival.</s><s xml:id="_dRhdm9G">S9.3.1-2</s><s xml:id="_UUGSzu9">9.4.</s><s xml:id="_FPR9mNZ">Cerebrovascular Disease 9.4.1.</s><s xml:id="_spNqDNT">Acute Intracerebral Hemorrhage Recommendations for Management of Hypertension in Patients With Acute Intracerebral Hemorrhage (ICH) References that support recommendations are summarized in Online Data Supplement 41.</s><s xml:id="_HSxkm5Z">COR LOE Recommendations IIa C-EO 1.</s><s xml:id="_UcpTPsc">In adults with ICH who present with SBP greater than 220 mm Hg, it is reasonable to use continuous intravenous drug infusion (Table 19) and close BP monitoring to lower SBP.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Hun2cUh">III: Harm A</head><p xml:id="_WYVFkWd"><s xml:id="_vRkP4bD">2. Immediate lowering of SBP (Table <ref type="table">19</ref>) to less than 140 mm Hg in adults with spontaneous ICH who present within 6 hours of the acute event and have an SBP between 150 mm Hg and 220 mm Hg is not of benefit to reduce death or severe disability and can be potentially harmful.</s><s xml:id="_Rj5RsS8">S9.4.1-1,S9.4.1-2</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.4.2." xml:id="_Z8a75kP">Acute Ischemic Stroke</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_WfxVzG4">Recommendations for Management of Hypertension in Patients With Acute Ischemic Stroke</head><p xml:id="_44ZJnRV"><s xml:id="_wuc6uaE">References that support recommendations are summarized in Online Data Supplement 42. 4.2-9 Recommendations for Treatment of Hypertension After Renal Transplantation (Continued) COR LOE Recommendations Figure 7. Management of hypertension in patients with acute ICH.</s><s xml:id="_UfKyMqt">Colors correspond to Class of Recommendation in Table 1.</s><s xml:id="_3yrNhxt">BP indicates blood pressure; ICH, intracerebral hemorrhage; IV, intravenous; and SBP, systolic blood pressure.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ZKhdBv6">COR</head><p xml:id="_8Ke6njZ"><s xml:id="_MadAARE">June 2018</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.4.3." xml:id="_dgAAZTe">Secondary Stroke Prevention</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_9EZhtsM">Recommendations for Treatment of Hypertension for Secondary Stroke Prevention</head><p xml:id="_PsGcY5Y"><s xml:id="_TYezEVP">References that support recommendations are summarized in Online Data Supplements 43 and 44.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_rNJJzjA">COR LOE Recommendations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_7ZPpUXG">I A</head><p xml:id="_AcXYpur"><s xml:id="_eCSkmwA">1. Adults with previously treated hypertension who experience a stroke or transient ischemic attack (TIA) should be restarted on antihypertensive treatment after the first few days of the index event to reduce the risk of recurrent stroke and other vascular events.</s><s xml:id="_FfkKQcS">S9.4.3-1-S9.4.3-3</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_qNhpHrE">I A</head><p xml:id="_uuWPBkc"><s xml:id="_CDkXKAw">2. For adults who experience a stroke or TIA, treatment with a thiazide diuretic, ACE inhibitor, or ARB, or combination treatment consisting of a thiazide diuretic plus ACE inhibitor, is useful.</s><s xml:id="_DRZqX9T"><ref type="bibr">S9.4.3-1,S9.4.3-3-S9.4.3-5</ref></s><s xml:id="_M4HwnRC">I B-R</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_p5yPkkJ">3.</head><p xml:id="_qRFRWnj"><s xml:id="_NzHzTcU">Adults not previously treated for hypertension who experience a stroke or TIA and have an established BP of 140/90 mm Hg or higher should be prescribed antihypertensive treatment a few days after the index event to reduce the risk of recurrent stroke and other vascular events.</s><s xml:id="_kamEHRX">S9.4.3-1-S9.4.3-3</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_fAdwYrP">I B-NR</head><p xml:id="_JVr94pG"><s xml:id="_FdA5Wb9">4. For adults who experience a stroke or TIA, selection of specific drugs should be individualized on the basis of patient comorbidities and agent pharmacological class.</s><s xml:id="_KC29WS2"><ref type="bibr">S9.4.3-6</ref></s><s xml:id="_uuMAZhk">IIb B-R</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_AStDV5x">5.</head><p xml:id="_Q8Vaatv"><s xml:id="_aXhScKr">For adults who experience a stroke or TIA, a BP goal of less than 130/80 mm Hg may be reasonable.</s><s xml:id="_wQTpYAn"><ref type="bibr">S9.4.3-6,S9.4.3-7</ref></s><s xml:id="_5DcN7Sn">IIb B-R 6.</s><s xml:id="_8y8PqcT">For adults with a lacunar stroke, a target SBP goal of less than 130 mm Hg may be reasonable.</s><s xml:id="_cABHcss">S9.</s></p><p xml:id="_dnkPbGD"><s xml:id="_YqXHgKh">4.3-8 Figure 8. Management of hypertension in patients with acute ischemic stroke.</s><s xml:id="_2dY6SUG">Colors correspond to Class of Recommendation in Table 1.</s><s xml:id="_RwJrESY">BP indicates blood pressure; DBP, diastolic blood pressure; IV, intravenous; and SBP, systolic blood pressure.</s></p><p xml:id="_h6CzMCN"><s xml:id="_4JRBYHp">Recommendations for Treatment of Hypertension for Secondary Stroke Prevention (Continued) COR LOE Recommendations Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025 2. In adults with DM and hypertension, all first-line classes of antihypertensive agents (ie, diuretics, ACE inhibitors, ARBs, and CCBs) are useful and effective.</s><s xml:id="_EsDH8Fb">S9.6-1,S9.6-9,S9.6-10</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_b4cWmzU">IIb B-NR</head><p xml:id="_EXGzCs5"><s xml:id="_FZAKsGn">3. In adults with DM and hypertension, ACE inhibitors or ARBs may be considered in the presence of albuminuria.</s><s xml:id="_pGZGZT2"><ref type="bibr">S9.6-11,S9.6-12</ref></s><s xml:id="_jXFJ67z">SR indicates systematic review.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.7." xml:id="_gTM2tMh">Metabolic Syndrome</head><p xml:id="_pfhUxG2"><s xml:id="_Mbquex2">Metabolic syndrome is a state of metabolic dysregulation characterized by visceral fat accumulation, insulin resistance, hyperinsulinemia, and hyperlipidemia, as well as predisposition to type 2 DM, hypertension, and atherosclerotic CVD.</s><s xml:id="_gnbreqr"><ref type="bibr">S9.7-1-S9.7-3</ref></s><s xml:id="_zjY2raK">According to data from the NHANES <ref type="bibr">III and</ref><ref type="bibr">NHANES 1999-2006, S9.7-1,S9.7-4</ref> the prevalence of metabolic syndrome in the United States was 34.2% in 2006 and has likely increased substantially since that time.</s><s xml:id="_GNm72Cx">The metabolic syndrome is linked to several other disorders, including nonalcoholic steatohepatitis, polycystic ovary syndrome, certain cancers, CKD, Alzheimer's disease, Cushing's syndrome, lipodystrophy, and hyperalimentation.</s><s xml:id="_3WtqAgp"><ref type="bibr">S9.7-5,S9.7-6</ref></s><s xml:id="_uyBQNwP">Lifestyle modification, with an emphasis on improving insulin sensitivity by means of dietary modification, weight reduction, and exercise, is the foundation of treatment of the metabolic syndrome.</s><s xml:id="_KWxPBGP">The optimal antihypertensive drug therapy for patients with hypertension in the setting of the metabolic syndrome has not been clearly defined.</s><s xml:id="_7nhBXtz">S9.7-1</s><s xml:id="_t8Z8bZV">Although caution exists with regard to the use of thiazide diuretics in this population because of their ability to increase insulin resistance, dyslipidemia, and hyperuricemia and to accelerate conversion to overt DM, no data are currently available demonstrating deterioration in cardiovascular or renal outcomes in patients treated with these agents.</s><s xml:id="_zH9bPuY">S9.7-1 Indeed, as shown in follow-up of ALLHAT, chlorthalidone use was associated with only a small increase in fasting glucose levels (1.5-4.0 mg/dL), and this increase did not translate into increased CVD risk at a later date.</s><s xml:id="_QT8AWzd"><ref type="bibr">S9.7-7-S9.7-10</ref></s><s xml:id="_wzpUqPk">In addition, in post hoc analysis of the nearly two thirds of participants in ALLHAT that met criteria for the metabolic syndrome, chlorthalidone was unsurpassed in reducing CVD and renal outcomes compared with lisinopril, amlodipine, or doxazosin.</s><s xml:id="_SXGG4mD"><ref type="bibr">S9.7-9,S9.7-11</ref></s><s xml:id="_J2Pq5ev">Similarly, highdose ARB therapy reduces arterial stiffness in patients with hypertension with the metabolic syndrome, but no outcomes data are available from patients in which this form of treatment was used.</s><s xml:id="_7trbCaW"><ref type="bibr">S9.7-12</ref> Use of traditional beta blockers may lead to dyslipidemia or deterioration of glucose tolerance, and ability to lose weight.</s><s xml:id="_kZJMZym"><ref type="bibr">S9.7-2</ref></s><s xml:id="_YJPHMJX">In several large clinical trials, the risk of developing DM as a result of traditional beta-blocker therapy was 15% to 29%.</s><s xml:id="_QaakzVz">S9.7-2</s><s xml:id="_x5yBrg5">However, the newer vasodilating beta blockers (eg, labetalol, carvedilol, nebivolol) have shown neutral or favorable effects on metabolic profiles compared with the traditional beta blockers.</s><s xml:id="_nsFrjdT">S9.7-13 Trials using vasodilator beta blockers have not been performed to demonstrate effects on CVD outcomes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.8." xml:id="_RSDMHNR">Atrial Fibrillation</head><p xml:id="_X9W94Gz"><s xml:id="_FUYGXP7">Recommendation for Treatment of Hypertension in Patients With AF References that support the recommendation are summarized in Online Data Supplement 48.</s><s xml:id="_MkwSGfQ">COR LOE Recommendation IIa B-R 1. Treatment of hypertension with an ARB can be useful for prevention of recurrence of AF.</s><s xml:id="_zNtQEBN">S9.8-1,S9.8-2</s><s xml:id="_f9ekv3g">9.9.</s><s xml:id="_AHdS6tR">Valvular Heart Disease Recommendations for Treatment of Hypertension in Patients With Valvular Heart Disease References that support recommendations are summarized in Online Data Supplements 49 and 50.</s><s xml:id="_ZgeUMkJ">COR LOE Recommendations I B-NR 1.</s><s xml:id="_dRT9Hrv">In adults with asymptomatic aortic stenosis, hypertension should be treated with pharmacotherapy, starting at a low dose and gradually titrating upward as needed.</s><s xml:id="_BMpXubX">S9.9-1-S9.9-4</s><s xml:id="_WzVQ9qk">IIa C-LD 2. In patients with chronic aortic insufficiency, treatment of systolic hypertension with agents that do not slow the heart rate (ie, avoid beta blockers) is reasonable.</s><s xml:id="_qNnAzga">S9.9-5,S9.9-6</s><s xml:id="_DwPAVmM">9.10.</s><s xml:id="_qV3AhxZ">Aortic Disease Recommendation for Management of Hypertension in Patients With Aortic Disease COR LOE Recommendation I C-EO 1. Beta blockers are recommended as the preferred antihypertensive agents in patients with hypertension and thoracic aortic disease.</s><s xml:id="_W4JbAda">S9.10-1,S9.10-2</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="10." xml:id="_aqRSVSw">Special Patient Groups</head><p xml:id="_B6x6hFc"><s xml:id="_QM5JQ5p">Special attention is needed for specific patient subgroups.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="10.2." xml:id="_JBNDrkb">Sex-Related Issues</head><p xml:id="_qVgfqgK"><s xml:id="_SJnnQp3">The prevalence of hypertension is lower in women than in men until about the fifth decade but is higher later in life .</s><s xml:id="_5pT4C8h"><ref type="bibr">S10.2-1</ref> Other than special recommendations for management of hypertension during pregnancy, there is no evidence that the BP threshold for initiating drug treatment, the treatment target, the choice of initial antihypertensive medication, or the combination of medications for lowering BP differs for women versus men.</s><s xml:id="_nAJbM3N">S10.2-2,S10.2-3</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="10.2.1." xml:id="_fyfn6tk">Women</head><p xml:id="_Yc4SGu5"><s xml:id="_PfTYuQr">A potential limitation of RCTs, including SPRINT, is that they are not specifically powered to determine the value of intensive SBP reduction in subgroups, including women in the case of SPRINT.</s><s xml:id="_FqEesnQ">However, in prespecified analyses, there was no evidence of an interaction between sex and treatment effect.</s><s xml:id="_QYJkDA2">Furthermore, no significant differences in CVD outcomes were observed between men and women in a large meta-analysis that included 31 RCTs with about 100 000 men and 90 000 women with hypertension (1 Some have called for conduct of a SPRINT-like trial with sufficient power to assess the effects of intensive SBP reduction in women {Wenger, 2016 #9131).</s><s xml:id="_FNZxQsN">Some have called for a SPRINT-like trial with sufficient power to assess the effects of intensive SBP reduction in women.</s><s xml:id="_daErnHx"><ref type="bibr">S10.2.1-2</ref></s><s xml:id="_7NpqQy3">In meta-analyses, there was no convincing evidence that different antihypertensive drug classes exerted sex-related differences in BP lowering or provided distinct CVD protection.</s><s xml:id="_xRts49c">S10.2.1-1 Calcium antagonists offered slightly greater benefits for stroke prevention than did ACE inhibitors for women than for men, whereas calcium antagonists reduced all-cause deaths compared with placebo in men but not in women.</s><s xml:id="_hRsejnW">However, these sex-related differences might have been due to chance because of the large number of statistical comparisons that were performed.</s><s xml:id="_NqeGyfz">The Heart Attack Trial and Hypertension Care Computing Project reported that beta blockers were associated with reduced mortality in men but not in women, but this finding was likely due to the low event rates in women.</s><s xml:id="_qH5fvZ9"><ref type="bibr">S10.2.1-3</ref></s><s xml:id="_yQGhHQd">Similarly, in the open-label Second Australian National BP study, a significant reduction in CVD events was demonstrated in men but not in women with ACE inhibitors versus diuretics.</s><s xml:id="_AnaGGQH"><ref type="bibr">S10.2.1-4</ref> Adverse effects of antihypertensive therapy were noted twice as often in women as in men in the TOMHS study.</s><s xml:id="_9zYc6yD">S10.2.1-5</s><s xml:id="_qNK4ayw">A higher incidence of ACE inhibitor-induced cough and of edema with calcium antagonists was observed in women than in men.</s><s xml:id="_gXyfB6F"><ref type="bibr">S10.2.1-6</ref> Women were more likely to experience hypokalemia and hyponatremia and less likely to experience gout with diuretics.</s><s xml:id="_yBKDrz3"><ref type="bibr">S10.2.1-7</ref> Hypertension in pregnancy has special requirements (see Section 10.2.2).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="10.2.2." xml:id="_rkZukk2">Pregnancy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dKQbSPP">Recommendations for Treatment of Hypertension in Pregnancy</head><p xml:id="_rxNdzhB"><s xml:id="_vxdHYQg">References that support recommendations are summarized in Online Data Supplement 53.</s></p><p xml:id="_wcZSeEu"><s xml:id="_x5Yd6FF">COR LOE Recommendations I C-LD 1. Women with hypertension who become pregnant, or are planning to become pregnant, should be transitioned to methyldopa, nifedipine, and/or labetalol S10.2.2-1 during pregnancy.</s><s xml:id="_TYCv5ep">S10.2.2-2-S10.2.2-6 III: Harm C-LD 2. Women with hypertension who become pregnant should not be treated with ACE inhibitors, ARBs, or direct renin inhibitors.</s><s xml:id="_ANhMGk2">S10.2.2-4-S10.2.2-6 10.3.</s><s xml:id="_6zKwHp7">Age-Related Issues 10.3.1.</s><s xml:id="_Y3XZDzU">Older Persons Recommendations for Treatment of Hypertension in Older Persons References that support recommendations are summarized in Online Data Supplement 54.</s><s xml:id="_Bs2HTcr">COR LOE Recommendations I A 1. Treatment of hypertension with a SBP treatment goal of less than 130 mm Hg is recommended for noninstitutionalized ambulatory community-dwelling adults (≥65 years of age) with an average SBP of 130 mm Hg or higher.</s><s xml:id="_fs6tted">S10.3.1-1</s><s xml:id="_Gnupbqj">IIa C-EO 2. For older adults (≥65 years of age) with hypertension and a high burden of comorbidity and limited life expectancy, clinical judgment, patient preference, and a team-based approach to assess risk/benefit is reasonable for decisions regarding intensity of BP lowering and choice of antihypertensive drugs.</s><s xml:id="_Sksw2R7">Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025 11.2.</s><s xml:id="_JgYPF2H">Hypertensive Crises-Emergencies and Urgencies Recommendations for Hypertensive Crises and Emergencies References that support recommendations are summarized in Online Data Supplement 55.</s><s xml:id="_bJeenPk">COR LOE Recommendations I B-NR 1.</s><s xml:id="_zYxQHyU">In adults with a hypertensive emergency, admission to an intensive care unit is recommended for continuous monitoring of BP and target organ damage and for parenteral administration of an appropriate agent (Tables <ref type="table">19</ref> and <ref type="table">20</ref>).</s><s xml:id="_DUQPyvg">S11.</s></p><p xml:id="_Xx7g9hV"><s xml:id="_BVSDyj6">2-1,S11.2-2</s><s xml:id="_d3NfBzS">I C-EO 2. For adults with a compelling condition (ie, aortic dissection, severe preeclampsia or eclampsia, or pheochromocytoma crisis), SBP should be reduced to less than 140 mm Hg during the first hour and to less than 120 mm Hg in aortic dissection.</s><s xml:id="_qrt99dg">I C-EO 3.</s><s xml:id="_xAAZcnG">For adults without a compelling condition, SBP should be reduced by no more than 25% within the first hour; then, if stable, to 160/100 mm Hg within the next 2 to 6 hours; and then cautiously to normal during the following 24 to 48 hours.</s><s xml:id="_FjMte5C">Recommendations for Hypertensive Crises and Emergencies (Continued) COR LOE Recommendations Figure 10.</s><s xml:id="_cEj72Pp">Resistant hypertension: diagnosis, evaluation, and treatment.</s><s xml:id="_3KByBZr">*See additional details in Section 6, Nonpharmacological Intervention.</s><s xml:id="_j6aSwKF">†See Section 5.4.1 and Table 14 for complete list of drugs that elevate BP. ‡See Section 5.4 and Table 13 for secondary hypertension.</s><s xml:id="_kQRDnec">BP indicates blood pressure; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; NSAIDs, nonsteroidal antiinflammatory drugs; and SBP, systolic blood pressure.</s><s xml:id="_B4wPeyE">Adapted with permission from Calhoun et al S11.1-1 (American Heart Association, Inc.).</s><s xml:id="_4Ksx6DB">11.</s><s xml:id="_mj7vcfE">Other Considerations 11.1.</s><s xml:id="_kUpKCXM">Resistant Hypertension Table 19.</s><s xml:id="_HMVSMjX">Intravenous Antihypertensive Drugs for Treatment of Hypertensive Emergencies Class Drug(s) Usual Dose Range Comments CCBdihydropyridines Nicardipine Initial 5 mg/h, increasing every 5 min by 2.5 mg/h to maximum 15 mg/h.</s><s xml:id="_QTkrqKC">Contraindicated in advanced aortic stenosis; no dose adjustment needed for elderly.</s><s xml:id="_B5c9PbF">Clevidipine Initial 1-2 mg/h, doubling every 90 s until BP approaches target, then increasing by less than double every 5-10 min; maximum dose 32 mg/h; maximum duration 72 h.</s><s xml:id="_FJPpM4Y">Contraindicated in patients with soybean, soy product, egg, and egg product allergy and in patients with defective lipid metabolism (eg, pathological hyperlipidemia, lipoid nephrosis or acute pancreatitis).</s><s xml:id="_Jxt5mF3">Use low-end dose range for elderly patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_3tCAZWc">Vasodilators-Nitric-oxide dependent</head><p xml:id="_XshdcuW"><s xml:id="_S5mxW5N">Sodium nitroprusside Initial 0.3-0.5 mcg/kg/min; increase in increments of 0.5 mcg/kg/min to achieve BP target; maximum dose 10 mcg/ kg/min; duration of treatment as short as possible.</s><s xml:id="_2PhBHA2">For infusion rates ≥4-10 mcg/kg/min or duration &gt;30 min, thiosulfate can be coadministered to prevent cyanide toxicity.</s></p><p xml:id="_3355wMk"><s xml:id="_Qy7p4Kb">Intra-arterial BP monitoring recommended to prevent "overshoot."</s><s xml:id="_eDfuJ3r">Lower dosing adjustment required for elderly.</s><s xml:id="_2nmxjhv">Tachyphylaxis common with extended use.</s></p><p xml:id="_HWrqvNc"><s xml:id="_bjdwArd">Cyanide toxicity with prolonged use can result in irreversible neurological changes and cardiac arrest.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RZE5egN">Nitroglycerin</head><p xml:id="_zT3huWJ"><s xml:id="_Y5aHBCq">Initial 5 mcg/min; increase in increments of 5 mcg/min every 3-5 min to a maximum of 20 mcg/min.</s></p><p xml:id="_Fg2gWBn"><s xml:id="_xVG9ByA">Use only in patients with acute coronary syndrome and/or acute pulmonary edema.</s><s xml:id="_at88YrR">Do not use in volume-depleted patients.</s></p><p xml:id="_MYngm2a"><s xml:id="_29mGsd7">Vasodilators-direct Hydralazine Initial 10 mg via slow IV infusion (maximum initial dose 20 mg); repeat every 4-6 h as needed.</s></p><p xml:id="_43dUmwy"><s xml:id="_3MQMNWN">BP begins to decrease within 10-30 min, and the fall lasts 2-4 h.</s><s xml:id="_EDxvrfh">Unpredictability of response and prolonged duration of action do not make hydralazine a desirable first-line agent for acute treatment in most patients.</s><s xml:id="_jG5PekZ">Table 1.</s><s xml:id="_UpcqW7S">*Use drug(s) specified in Table 19.</s><s xml:id="_wExdBCw">†If other comorbidities are present, select a drug specified in Table 20.</s><s xml:id="_3fVgCtC">BP indicates blood pressure; DBP, diastolic blood pressure; ICU, intensive care unit; and SBP, systolic blood pressure.</s><s xml:id="_jUve3Ds">(Continued ) Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025</s></p><p xml:id="_Apk7tgw"><s xml:id="_s5AuxeM">Table 20.</s><s xml:id="_E6Jr68s">Intravenous Antihypertensive Drugs for Treatment of Hypertensive Emergencies in Patients With Selected Comorbidities Comorbidity Preferred Drug(s)* Comments Acute aortic dissection Esmolol, labetalol Requires rapid lowering of SBP to ≤120 mm Hg.</s><s xml:id="_Zz7cGK6">Beta blockade should precede vasodilator (eg, nicardipine or nitroprusside) administration, if needed for BP control or to prevent reflex tachycardia or inotropic effect; SBP ≤120 mm Hg should be achieved within 20 min.</s><s xml:id="_DExEjeG">Acute pulmonary edema Clevidipine, nitroglycerin, nitroprusside Beta blockers contraindicated.</s><s xml:id="_hEX2V9G">Acute coronary syndromes Esmolol, † labetalol, nicardipine, nitroglycerin † Nitrates given in the presence of PDE-5 inhibitors may induce profound hypotension.</s><s xml:id="_gVTXJ7v">Contraindications to beta blockers include moderateto-severe LV failure with pulmonary edema, bradycardia (&lt;60 bpm), hypotension (SBP &lt;100 mm Hg), poor peripheral perfusion, second-or third-degree heart block, and reactive airways disease.</s><s xml:id="_we4pV6J">Acute renal failure Clevidipine, fenoldopam, nicardipine N/A Eclampsia or preeclampsia Hydralazine, labetalol, nicardipine Requires rapid BP lowering.</s><s xml:id="_3mG8FC8">ACE inhibitors, ARBs, renin inhibitors, and nitroprusside contraindicated.</s><s xml:id="_QKGMYRx">Perioperative hypertension (BP ≥160/90 mm Hg or SBP elevation ≥20% of the preoperative value that persists for &gt;15 min) Clevidipine, esmolol, nicardipine, nitroglycerin Intraoperative hypertension is most frequently seen during anesthesia induction and airway manipulation.</s><s xml:id="_hENbJyY">Acute sympathetic discharge or catecholamine excess states (eg, pheochromocytoma, postcarotid endarterectomy status) Clevidipine, nicardipine, phentolamine Requires rapid lowering of BP.</s><s xml:id="_qFZnuQ4">Acute ICH Section 9.4.1 Section 9.4.1 Acute ischemic stroke Section 9.4.2</s><s xml:id="_Tk5s4sT">Section 9.4.2 *Agents are listed in alphabetical order, not in order of preference.</s><s xml:id="_htCNaHB">†Agent of choice for acute coronary syndromes.</s><s xml:id="_p9mcwVp">ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; bpm, beats per minute; ICH, intracerebral hemorrhage; LV, left ventricular; PDE-5, phosphodiesterase type-5; and SBP, systolic blood pressure.</s><s xml:id="_QUhAucf">Adrenergic blockers-beta 1 receptor selective antagonist Esmolol Loading dose 500-1000 mcg/kg/min over 1 min followed by a 50-mcg/kg/min infusion.</s><s xml:id="_WWfmK7b">For additional dosing, the bolus dose is repeated and the infusion increased in 50-mcg/kg/min increments as needed to a maximum of 200 mcg/kg/min.</s><s xml:id="_GjZrcFQ">Contraindicated in patients with concurrent beta-blocker therapy, bradycardia, or decompensated HF.</s><s xml:id="_M8V5wm6">Monitor for bradycardia.</s><s xml:id="_KcBVaGF">May worsen HF.</s><s xml:id="_UtqptyP">Higher doses may block beta 2 receptors and impact lung function in reactive airway disease.</s><s xml:id="_sD6UcMN">Adrenergic blockerscombined alpha 1 and nonselective beta receptor antagonist Labetalol Initial 0.3-1.0-mg/kg</s><s xml:id="_WSEqUYV">dose (maximum 20 mg) slow IV injection every 10 min or 0.4-1.0-mg/kg/h</s><s xml:id="_cp595s4">IV infusion up to 3 mg/kg/h.</s><s xml:id="_MKBNpu7">Adjust rate up to total cumulative dose of 300 mg.</s><s xml:id="_UqVM6Ch">This dose can be repeated every 4-6 h.</s><s xml:id="_AYAKv5w">Contraindicated in reactive airways disease or chronic obstructive pulmonary disease.</s><s xml:id="_BfpYzJV">Especially useful in hyperadrenergic syndromes.</s><s xml:id="_uqEMgGX">May worsen HF and should not be given in patients with second-or third-degree heart block or bradycardia.</s><s xml:id="_Zh8n2vT">Adrenergic blockersnonselective alpha receptor antagonist Phentolamine IV bolus dose 5 mg.</s><s xml:id="_Rk9Tu2u">Additional bolus doses every 10 min as needed to lower BP to target.</s><s xml:id="_zXSA7b9">Used in hypertensive emergencies induced by catecholamine excess (pheochromocytoma, interactions between monamine oxidase inhibitors and other drugs or food, cocaine toxicity, amphetamine overdose, or clonidine withdrawal).</s><s xml:id="_D2AKSSV">Dopamine 1 -receptor selective agonist Fenoldopam Initial 0.1-0.3</s><s xml:id="_8Z2ke2Y">mcg/kg/min; may be increased in increments of 0.05-0.1 mcg/kg/min every 15 min until target BP is reached.</s><s xml:id="_8Qce43H">Maximum infusion rate 1.6 mcg/kg/min.</s><s xml:id="_yqc2KAT">Contraindicated in patients at risk of increased intraocular pressure (glaucoma) or intracranial pressure and those with sulfite allergy.</s><s xml:id="_46qVXZu">ACE inhibitor Enalaprilat Initial 1.25 mg over a 5-min period.</s><s xml:id="_Anp9p4Z">Doses can be increased up to 5 mg every 6 h as needed to achieve BP target.</s><s xml:id="_5VWrhfq">Contraindicated in pregnancy and should not be used in acute MI or bilateral renal artery stenosis.</s><s xml:id="_BqkJWzT">Mainly useful in hypertensive emergencies associated with high plasma renin activity.</s><s xml:id="_fphkZ2x">Dose not easily adjusted.</s><s xml:id="_DKr6Ud8">Relatively slow onset of action (15 min) and unpredictability of BP response.</s><s xml:id="_APkr2Pa">BP indicates blood pressure; CCB, calcium channel blocker; HF, heart failure; IV, intravenous; and MI, myocardial infarction.</s></p><p xml:id="_JX48xPc"><s xml:id="_ZfwEGPY">Table 19.</s><s xml:id="_PsdDMTF">Continued Class Drug(s) Usual Dose Range Comments Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025 11.3.</s><s xml:id="_gDKs8s3">Cognitive Decline and Dementia Recommendation for Prevention of Cognitive Decline and Dementia References that support the recommendation are summarized in Online Data Supplement 56.</s><s xml:id="_xWaeE7N">COR LOE Recommendation IIa B-R 1.</s><s xml:id="_pbasebm">In adults with hypertension, BP lowering is reasonable to prevent cognitive decline and dementia.</s><s xml:id="_hBzM9wv">S11.3-1-S11.3-6</s><s xml:id="_ZVmguFE">11.4.</s><s xml:id="_hk4dsJg">Patients Undergoing Surgical Procedures Recommendations for Treatment of Hypertension in Patients Undergoing Surgical Procedures References that support recommendations are summarized in Online Data Supplements 57 and 58.</s><s xml:id="_nYWEfds">COR LOE Recommendations Preoperative I B-NR 1.</s><s xml:id="_TcNDbar">In patients with hypertension undergoing major surgery who have been on beta blockers chronically, beta blockers should be continued.</s><s xml:id="_ZzcEpRd">S11.4-1-S11.4-7</s><s xml:id="_jH6zGBb">IIa C-EO 2. In patients with hypertension undergoing planned elective major surgery, it is reasonable to continue medical therapy for hypertension until surgery.</s><s xml:id="_Hd2VPkC">IIb B-NR 3. In patients with hypertension undergoing major surgery, discontinuation of ACE inhibitors or ARBs perioperatively may be considered.</s><s xml:id="_dwFdZp3">S11.4-8-S11.4-10</s><s xml:id="_UYfDSdb">IIb C-LD 4. In patients with planned elective major surgery and SBP of 180 mm Hg or higher or DBP of 110 mm Hg or higher, deferring surgery may be considered.</s><s xml:id="_B5STrFD">S11.4-11,S11.4-12</s><s xml:id="_bv44JQX">III: Harm B-NR 5.</s><s xml:id="_qNb3qhQ">For patients undergoing surgery, abrupt preoperative discontinuation of beta blockers or clonidine is potentially harmful.</s><s xml:id="_y2cG6Qs">S11.4-2,S11.4-13</s><s xml:id="_B44xaqa">III: Harm B-NR 6. Beta blockers should not be started on the day of surgery in beta blocker-naïve patients.</s><s xml:id="_sDcWaqZ">S11.4-14 Intraoperative I C-EO 7. Patients with intraoperative hypertension should be managed with intravenous medications (Table 19) until such time as oral medications can be resumed.</s><s xml:id="_aJQQGqk">12. Strategies to Improve Hypertension Treatment and Control 12.1.</s><s xml:id="_2gRgsgH">Adherence Strategies for Treatment of Hypertension 12.1.1.</s><s xml:id="_6PVuass">Antihypertensive Medication Adherence Strategies Recommendations for Antihypertensive Medication Adherence Strategies References that support recommendations are summarized in Online Data Supplements 59 and 60.</s><s xml:id="_DCm9Nbj">COR LOE Recommendations I B-R</s></p><p xml:id="_vyQJmpM"><s xml:id="_Kn2RTP4">1.</s><s xml:id="_HfpRtgb">In adults with hypertension, dosing of antihypertensive medication once daily rather than multiple times daily is beneficial to improve adherence.</s><s xml:id="_6Qgr3pF">S12.1.1-1-S12.1.1-3</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ngBhqnT">IIa B-NR</head><p xml:id="_7CX9tX9"><s xml:id="_EaK2Z9C">2. Use of combination pills rather than free individual components can be useful to improve adherence to antihypertensive therapy.</s><s xml:id="_K3VbdN8"><ref type="bibr">S12.1.1-4-S12.1.1-7</ref></s><s xml:id="_NZgmvCw">Available fixed-dose combination drug therapy is listed in Online Data Supplement D.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="12.1.2." xml:id="_JaePRKp">Strategies to Promote Lifestyle Modification</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Sv9JzBs">Recommendation for Strategies to Promote Lifestyle Modification</head><p xml:id="_hKCAEYK"><s xml:id="_KVxdMs6">References that support the recommendation are summarized in Online Data Supplement 61.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_YNrHVyV">COR LOE Recommendation</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_8uKgdZq">I C-EO</head><p xml:id="_MpmqgBD"><s xml:id="_BvUQdRt">1. Effective behavioral and motivational strategies to achieve a healthy lifestyle (ie, tobacco cessation, weight loss, moderation in alcohol intake, increased physical activity, reduced sodium intake, and consumption of a healthy diet) are recommended for adults with hypertension.</s><s xml:id="_KqU3Q6f">S12.1.</s></p><p xml:id="_ePEyME6"><s xml:id="_AsW27Zr">2-1,S12.1.2-2</s><s xml:id="_8Gaq5tz">12.2.</s><s xml:id="_NZjQGXu">Structured, Team-Based Care Interventions for Hypertension Control Recommendation for Structured, Team-Based Care Interventions for Hypertension Control References that support the recommendation are summarized in Online Data Supplement 62. COR LOE Recommendation I A 1. A team-based care approach is recommended for adults with hypertension.</s><s xml:id="_wMSUyA6">S12.2-1-S12.2-7</s><s xml:id="_NQGWwk6">June 2018 12.3.</s><s xml:id="_qcrYEAW">Health Information Technology-Based Strategies to Promote Hypertension Control 12.3.1.</s><s xml:id="_chH56xV">EHR and Patient Registries Recommendations for EHR and Patient Registries References that support recommendations are summarized in Online Data Supplement 63.</s><s xml:id="_m5qw2XM">COR LOE Recommendations I B-NR 1. Use of the EHR and patient registries is beneficial for identification of patients with undiagnosed or undertreated hypertension.</s><s xml:id="_Xjj692W">S12.3.1-1-S12.3.1-3</s><s xml:id="_PnQ7aUH">I B-NR 2. Use of the EHR and patient registries is beneficial for guiding quality improvement efforts designed to improve hypertension control.</s><s xml:id="_ZSf7JPk">S12.3.1-1-S12.3.1-3</s><s xml:id="_dEnwEzY">12.3.2.</s><s xml:id="_tF6UWqF">Telehealth Interventions to Improve Hypertension Control Recommendation for Telehealth Interventions to Improve Hypertension Control References that support the recommendation are summarized in Online Data Supplement 64.</s><s xml:id="_H9rsA5j">COR LOE Recommendation IIa A 1. Telehealth strategies can be useful adjuncts to interventions shown to reduce BP for adults with hypertension.</s><s xml:id="_FahtZEt">S12.3.2-1-S12.3.2-5</s><s xml:id="_XwvxsUY">12.4.</s><s xml:id="_ppMKZmC">Improving Quality of Care for Patients With Hypertension 12.4.1.</s><s xml:id="_FvQg5ya">Performance Measures Recommendation for Performance Measures References that support the recommendation are summarized in Online Data Supplement 65.</s><s xml:id="_sb6sXUS">COR LOE Recommendation IIa B-NR 1. Use of performance measures in combination with other quality improvement strategies at patient-, provider-, and system-based levels is reasonable to facilitate optimal hypertension control.</s><s xml:id="_BfxUsuB">S12.4.1-1-S12.4.1-3 12.4.2.</s><s xml:id="_xsygPjB">Quality Improvement Strategies Recommendation for Quality Improvement Strategies References that support the recommendation are summarized in Online Data Supplements 66 and 67.</s><s xml:id="_4jYc26H">COR LOE Recommendation IIa B-R 1. Use of quality improvement strategies at the health system, provider, and patient levels to improve identification and control of hypertension can be effective.</s><s xml:id="_fcK44Ef">S12.4.2-1-S12.4.2-8 12.5.</s><s xml:id="_6TQzNnM">Financial Incentives Recommendations for Financial Incentives References that support recommendations are summarized in Online Data Supplement 68.</s><s xml:id="_WaD9pyf">COR LOE Recommendations IIa B-R 1. Financial incentives paid to providers can be useful in achieving improvements in treatment and management of patient populations with hypertension.</s><s xml:id="_jVZu685">S12.5-1-S12.5-3</s><s xml:id="_duqjwfa">IIa B-NR 2. Health system financing strategies (eg, insurance coverage and copayment benefit design) can be useful in facilitating improved medication adherence and BP control in patients with hypertension.</s><s xml:id="_8dUcm2Z">S12.5-4 13.</s><s xml:id="_cwq2CBp">The Plan of Care for Hypertension Recommendation for the Plan of Care for Hypertension COR LOE Recommendation I C-EO 1.</s><s xml:id="_ZRsjwQp">Every adult with hypertension should have a clear, detailed, and current evidence-based plan of care that ensures the achievement of treatment and self-management goals, encourages effective management of comorbid conditions, prompts timely followup with the healthcare team, and adheres to CVD GDMT (Table 22).</s></p><p xml:id="_53CKPNU"><s xml:id="_aNjCWB8">Table 21.</s><s xml:id="_rzCZUnK">Clinician's Sequential Flow Chart for the Management of Hypertension Clinician's Sequential Flow Chart for the Management of Hypertension Measure office BP accurately Section 4 Detect white coat hypertension or masked hypertension by using ABPM and HBPM Section 4 Evaluate for secondary hypertension Section 5 Identify target organ damage Sections 5 and 7 Introduce lifestyle interventions Section 6 Identify and discuss treatment goals Sections 7 and 8 Use ASCVD risk estimation to guide BP threshold for drug therapy Section 8.1.2</s><s xml:id="_C5G6HHX">Align treatment options with comorbidities Section 9 Account for age, race, ethnicity, sex, and special circumstances in antihypertensive treatment Sections 10 and 11 Initiate antihypertensive pharmacological therapy Section 8 Insure appropriate follow-up Section 8 Use team-based care Section 12 Connect patient to clinician via telehealth Section 12 Detect and reverse nonadherence Section 12 Detect white coat effect or masked uncontrolled hypertension Section 4 Use health information technology for remote monitoring and self-monitoring of BP Section 12</s></p><p xml:id="_fHP9DNZ"><s xml:id="_AXvCxV3">ABPM indicates ambulatory blood pressure monitoring; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; and HBPM, home blood pressure monitoring.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.1." xml:id="_fjvAEC4">Health Literacy</head><p xml:id="_Jc9eZhd"><s xml:id="_j3ZC9rU">Communicating alternative behaviors that support selfmanagement of healthy BP in addition to medication adherence is important.</s><s xml:id="_Fx8Dx9g">This should be done both verbally and in writing.</s><s xml:id="_ZrPJWzZ">Today, mobile phones have a recording option.</s><s xml:id="_99Suafk">For patients with mobile phones, the phone can be used to inform patients and family members of medical instructions after the doctor's visit as an additional level of communication.</s><s xml:id="_xZkGnx6">Inclusion of a family member or friend that can help interpret and encourage self-management treatment goals is suggested when appropriate.</s><s xml:id="_Y3PJCbc">Examples of needed communication for alternative behaviors include a specific regimen relating to physical activity; a specific sodium-reduced meal plan indicating selections for breakfast, lunch, and dinner; lifestyle recommendations relating to sleep, rest, and relaxation; and finally, suggestions and alternatives to environmental barriers, such as barriers that prevent healthy food shopping or limit reliable transportation to and from appointments with health providers and pharmacy visits.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.2." xml:id="_j3bhqZ7">Access to Health Insurance and Medication Assistance Plans</head><p xml:id="_eWjbqks"><s xml:id="_VshXxKv">Health insurance and medication plan assistance for patients is especially important to improving access to and affordability of medical care and BP medications.</s><s xml:id="_kjy8jRc">Learning how the patient financially supports and budgets for his or her medical care and medications offers the opportunity to share additional insight relating to cost reductions, including restructured payment plans.</s><s xml:id="_WqBrQgE">Ideally, this would improve the patient's compliance with medication adherence and treatment goals.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.3." xml:id="_HpyxG9c">Social and Community Services</head><p xml:id="_FxCqgZg"><s xml:id="_YVBVzwn">Health care can be strengthened through local partnerships.</s><s xml:id="_sAZXQKm">Hypertensive patients, particularly patients with lower incomes, have more opportunity to achieve treatment goals with the assistance of strong local partnerships.</s><s xml:id="_947UQ5t">In patients with low socioeconomic status or patients who are challenged by social situations, integration of social and community services offers complementary reinforcement of clinically identified treatment goals.</s><s xml:id="_hv4xgPX">Social and community services are helpful when explicitly related to medical care.</s></p><p xml:id="_ujmweg6"><s xml:id="_bkdRXsV">Electronic health record Section 12.3.1 Health information technology tools for remote and self-monitoring Section 12.3.2</s><s xml:id="_utyFpsx">Socioeconomic and cultural factors Health literacy Section 13.1.3</s><s xml:id="_7QkGVRe">Access to health insurance and medication assistance plans Section 13.1.3</s><s xml:id="_kxwgky6">Social services Section 13.1.3</s><s xml:id="_nMEESQK">Community services Section 13.1.3</s><s xml:id="_k4JfZDf">BP indicates blood pressure.</s></p><p xml:id="_K7X3GsZ"><s xml:id="_gaf2a6y">Table 22.</s><s xml:id="_S7jVt6u">Continued Plan of Care Associated Section(s) of Guideline and Other Reference(s)  13.</s><s xml:id="_sebJ4WK">The Plan of Care for Hypertension S13-1.</s><s xml:id="_DbSW34g">Smith SC Jr, Benjamin EJ, Bonow RO, et al.</s><s xml:id="_ufGWhEe">AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.</s><s xml:id="_7SXAb6h">Circulation.</s><s xml:id="_S6mB9s7">2011;124:2458-73.</s><s xml:id="_r7F96zy">S13-2.</s><s xml:id="_BVSq4ab">Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/ AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.</s><s xml:id="_F59ksN7">Circulation.</s><s xml:id="_dnsxQFW">2014;130:1749-67.</s><s xml:id="_vtpzWZr">S13-3.</s><s xml:id="_wQ2aTqj">Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/ AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on February 15, 2025</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><figDesc><div><p xml:id="_XSRP5Z3"><s xml:id="_ccJEZuz">for specific form(s) of secondary hypertension is recommended when the clinical indications and physical examination findings listed in Table</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3 .</head><label>3</label><figDesc><div><p xml:id="_GUd9wqB"><s xml:id="_JUCTMMe">Figure 3. Screening for secondary hypertension.</s><s xml:id="_XYqxe2C">Colors correspond to Class of Recommendation in Table1.</s><s xml:id="_7rm9nJX">TOD indicates target organ damage (eg, cerebrovascular disease, hypertensive retinopathy, left ventricular hypertrophy, left ventricular dysfunction, heart failure, coronary artery disease, chronic kidney disease, albuminuria, peripheral artery disease).</s></p></div></figDesc><graphic coords="13,54.90,94.23,217.21,313.29" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 .</head><label>4</label><figDesc><div><p xml:id="_KswE92C"><s xml:id="_JazQqMb">Figure 4. Blood Pressure (BP) thresholds and recommendations for treatment and follow-up.</s><s xml:id="_M4GMHc5">Colors correspond to Class of Recommendation in Table1.</s><s xml:id="_C2Gemfs">*Using the ACC/AHA Pooled Cohort Equations.S8.1.2-14,S8.1.2-15</s><s xml:id="_xwEx9a8">Note that patients with DM or CKD are automatically placed in the high-risk category.</s><s xml:id="_yShsecB">For initiation of RAS inhibitor or diuretic therapy, assess blood tests for electrolytes and renal function 2 to 4 weeks after initiating therapy.</s><s xml:id="_rUY6atH">†Consider initiation of pharmacological therapy for stage 2 hypertension with 2 antihypertensive agents of different classes.</s><s xml:id="_Y7GReD2">Patients with stage 2 hypertension and BP ≥160/100 mm Hg should be promptly treated, carefully monitored, and subject to upward medication dose adjustment as necessary to control BP.</s><s xml:id="_EDjXFkv">Reassessment includes BP measurement, detection of orthostatic hypotension in selected patients (eg, older or with postural symptoms), identification of white coat hypertension or a white coat effect, documentation of adherence, monitoring of the response to therapy, reinforcement of the importance of adherence, reinforcement of the importance of treatment, and assistance with treatment to achieve BP target.</s><s xml:id="_kF5xSBE">ACC indicates American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CKD, chronic kidney disease; DM, diabetes mellitus; and RAS, renin-angiotensin system.</s></p></div></figDesc><graphic coords="19,113.16,72.73,358.68,314.46" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><figDesc><div><p xml:id="_2kQfpJE"><s xml:id="_QZBAuxP">in combination with ACE inhibitors or direct renin inhibitor.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>2 . 10 DBP 4 . 5 .</head><label>21045</label><figDesc><div><p xml:id="_R2hTrW8"><s xml:id="_T4efMv9">adults with SIHD and hypertension, a BP target of less than 130/80 mm Hg is recommended.</s><s xml:id="_9ftnbcH">S9.1-1-S9.1-5</s><s xml:id="_eDS8sEX">DBP:Adults with SIHD and hypertension (BP ≥130/80 mm Hg) should be treated with medications (eg, GDMT S9.1-6 beta blockers, ACE inhibitors, or ARBs) for compelling indications (eg, previous MI, stable angina) as first-line therapy, with the addition of other drugs (eg, dihydropyridine CCBs, thiazide diuretics, and/or mineralocorticoid receptor antagonists) as needed to further control hypertension.</s><s xml:id="_ZkFnS8t">S9.1-7-S9.1-In</s><s xml:id="_Qd4466c">adults who have had a MI or acute coronary syndrome, it is reasonable to continue GDMT S9.1-6 beta blockers beyond 3 years as long-term therapy for hypertension.S9.1-13,S9.1Beta</s><s xml:id="_ypQ86kK">blockers and/or CCBs might be considered to control hypertension in patients with CAD (without HFrEF) who had an MI more than 3 years ago and have angina.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 5 .</head><label>5</label><figDesc><div><p xml:id="_cPahPgZ"><s xml:id="_9H9HuNV">Figure 5. Management of hypertension in patients with SIHD.</s><s xml:id="_X8B4stX">Colors correspond to Class of Recommendation in Table1.</s><s xml:id="_54A82eg">*GDMT beta blockers for BP control or relief of angina include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol, propranolol, and timolol.</s><s xml:id="_MDUsMgy">Avoid beta blockers with intrinsic sympathomimetic activity.</s><s xml:id="_UNwYq3s">The beta blocker atenolol should not be used because it is less effective than placebo in reducing cardiovascular events.</s><s xml:id="_Y5qQQJv">†If needed for BP control.</s><s xml:id="_wuCfGE9">ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; GDMT, guideline-directed management and therapy; and SIHD, stable ischemic heart disease.</s></p></div></figDesc><graphic coords="23,325.72,405.02,191.56,201.96" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>2 .</head><label>2</label><figDesc><div><p xml:id="_zfHkMzd"><s xml:id="_gU3b3hv">with HFrEF and hypertension should be prescribed GDMT (2) titrated to attain a BP of less than 130/80 mm Hg.Nondihydropyridine CCBs are not recommended in the treatment of hypertension in adults with HFrEF.S9.2.1-1</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head>2 . 6 9</head><label>26</label><figDesc><div><p xml:id="_v3sgkzj"><s xml:id="_7ufgbax">adults with HFpEF who present with symptoms of volume overload, diuretics should be prescribed to control hypertension.Adults with HFpEF and persistent hypertension after management of volume overload should be prescribed ACE inhibitors or ARBs and beta blockers titrated to attain SBP of less than 130 mm Hg.</s><s xml:id="_V4EQhZD">S9.2.2-1-S9.2.2-1.</s><s xml:id="_GHYRKup">Adults with hypertension and CKD should be treated to a BP goal of less than 130/80 mm Hg.</s><s xml:id="_989pRFz">S9.3-1-S9.3-6</s><s xml:id="_K3Rw9Uk">DBP:</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head>2 . 3 . 4 . 5 .</head><label>2345</label><figDesc><div><p xml:id="_YVMGmqn"><s xml:id="_FEjeCXq">In adults with an acute ischemic stroke, BP should be less than 185/110 mm Hg before administration of intravenous tissue plasminogen activator and should be maintained below 180/105 mm Hg for at least the first 24 hours after initiating drug therapy.S9.4.2Starting or restarting antihypertensive therapy during hospitalization in patients with BP greater than 140/90 mm Hg who are neurologically stable is safe and reasonable to improve long-term BP control, unless contraindicated.In patients with BP of 220/120 mm Hg or higher who did not receive intravenous alteplase or endovascular treatment and have no comorbid conditions requiring acute antihypertensive treatment, the benefit of initiating or reinitiating treatment of hypertension within the first 48 to 72 hours is uncertain.</s><s xml:id="_K5SMawD">It might be reasonable to lower BP by 15% during the first 24 hours after onset of stroke.In patients with BP less than 220/120 mm Hg who did not receive intravenous thrombolysis or endovascular treatment and do not have a comorbid condition requiring acute antihypertensive treatment, initiating or reinitiating treatment of hypertension within the first 48 to 72 hours after an acute ischemic stroke is not effective to prevent death or dependency.S9.4.2-4-S9.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_10"><head>4 9</head><label>4</label><figDesc><div><p xml:id="_GeDYynb"><s xml:id="_VDdNEWd">adults previously untreated for hypertension who experience an ischemic stroke or TIA and have a SBP less than 140 mm Hg and a DBP less than 90 mm Hg, the usefulness of initiating antihypertensive treatment is not well established.with</s><s xml:id="_dYCumCx">hypertension and PAD should be treated similarly to patients with hypertension without PAD.</s><s xml:id="_xux3RvZ">S9.5-1-S9.5-1.</s><s xml:id="_TmX7tyS">In adults with DM and hypertension, antihypertensive drug treatment should be initiated at a BP of 130/80 mm Hg or higher with a treatment goal of less than 130</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_11"><head>Figure 9 .</head><label>9</label><figDesc><div><p xml:id="_U5vGR3R"><s xml:id="_ZNk2w8q">Figure 9. Management of hypertension in patients with a previous history of stroke (secondary stroke prevention).</s><s xml:id="_sx4PqPx">Colors correspond to Class of Recommendation in Table 1.</s><s xml:id="_n7fsvg9">DBP indicates diastolic blood pressure; SBP, systolic blood pressure; and TIA, transient ischemic attack.</s></p></div></figDesc><graphic coords="27,132.83,72.73,319.34,296.35" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_12"><head>2 .</head><label>2</label><figDesc><div><p xml:id="_KJen8jB"><s xml:id="_HG9uMqN">black adults with hypertension but without HF or CKD, including those with DM, initial antihypertensive treatment should include a thiazide-type diuretic or CCB.Two or more antihypertensive medications are recommended to achieve a BP target of less than 130/80 mm Hg in most adults with hypertension, especially in black adults with hypertension.S10.1.1-5-S10.1.1-7</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_13"><head>Figure 11 .</head><label>11</label><figDesc><div><p xml:id="_43J2q4Z"><s xml:id="_frjfbzz">Figure 11.</s><s xml:id="_Gp5eJvR">Diagnosis and management of a hypertensive crisis.</s><s xml:id="_cv82apz">Colors correspond to Class of Recommendation in Table1.</s><s xml:id="_fyXQfke">*Use drug(s) specified in Table19.</s><s xml:id="_JwGd98G">†If other comorbidities are present, select a drug specified in Table20.</s><s xml:id="_XUSkZGM">BP indicates blood pressure; DBP, diastolic blood pressure; ICU, intensive care unit; and SBP, systolic blood pressure.</s></p></div></figDesc><graphic coords="31,113.11,72.73,358.79,359.03" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="11,111.89,442.35,361.21,138.55" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="12,53.23,72.73,358.67,338.10" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_15"><head>Table 8 . Continued</head><label>8</label><figDesc><div><p xml:id="_jRgqrGt"><s xml:id="_FZSHxRx">Verify use of automated validated devices.</s><s xml:id="_r3ssJtK">Use of auscultatory devices (mercury, aneroid, or other) is not generally useful for HBPM because patients rarely master the technique required for measurement of BP with auscultatory devices.</s></p></div></figDesc><table><row><cell>Key Steps for Proper</cell><cell>Devices:</cell></row><row><cell>BP Measurements</cell><cell>Specific Instructions</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_26"><head>Table 14 . Frequently Used Medications and Other Substances That May Cause Elevated BP*</head><label>14</label><figDesc><div><p xml:id="_vcQ3TWw"><s xml:id="_PVGvzTB">NSAIDs, nonsteroidal anti-inflammatory drugs; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; and TCA, tricyclic antidepressant.</s><s xml:id="_aEbJMrz">Downloaded from http://ahajournals.org by on February 15, 2025</s></p></div></figDesc><table><row><cell>Agent</cell><cell>Possible Management Strategy</cell></row><row><cell>Alcohol</cell><cell>Limit alcohol to ≤1 drink daily for women and ≤2 drinks for men S5.1.1-1</cell></row><row><cell>Amphetamines (eg, amphetamine, methylphenidate</cell><cell>Discontinue or decrease dose S5.1.1-2</cell></row><row><cell>dexmethylphenidate, dextroamphetamine)</cell><cell>Consider behavioral therapies for ADHD S5.1.1-3</cell></row><row><cell>Antidepressants (eg, MAOIs, SNRIs, TCAs)</cell><cell>Consider alternative agents (eg, SSRIs) depending on indication</cell></row><row><cell></cell><cell>Avoid tyramine-containing foods with MAOIs</cell></row><row><cell>Atypical antipsychotics (eg, clozapine, olanzapine)</cell><cell>Discontinue or limit use when possible</cell></row><row><cell></cell><cell>Consider behavior therapy where appropriate</cell></row><row><cell></cell><cell>Recommend lifestyle modification (see Section 6.2)</cell></row><row><cell></cell><cell>Consider alternative agents associated with lower risk of weight gain, diabetes mellitus, and dyslipidemia</cell></row><row><cell></cell><cell>(eg, aripiprazole, ziprasidone) S5.1.1-4,S5.1.1-5</cell></row><row><cell>Caffeine</cell><cell>Generally limit caffeine intake to &lt;300 mg/d</cell></row><row><cell></cell><cell>Avoid use in patients with uncontrolled hypertension</cell></row><row><cell></cell><cell>Coffee use in patients with hypertension is associated with acute increases in BP; long-term use is not</cell></row><row><cell></cell><cell>associated with increased BP or CVD S5.1.1-6</cell></row><row><cell>Decongestants (eg, phenylephrine,</cell><cell></cell></row><row><cell>pseudoephedrine)</cell><cell></cell></row><row><cell></cell><cell>Discontinue or avoid use</cell></row><row><cell>Systemic corticosteroids (eg, dexamethasone,</cell><cell>Avoid or limit use when possible</cell></row><row><cell>fludrocortisone, methylprednisolone, prednisone,</cell><cell>Consider alternative modes of administration (eg, inhaled, topical) when feasible</cell></row><row><cell>prednisolone)</cell><cell></cell></row><row><cell>Angiogenesis inhibitor (eg, bevacizumab) and</cell><cell>Initiate or intensify antihypertensive therapy</cell></row><row><cell>tyrosine kinase inhibitors (eg, sunitinib, sorafenib)</cell><cell></cell></row></table><note xml:id="_yPdgqqh"><p>Use for shortest duration possible, and avoid in severe or uncontrolled hypertension Consider alternative therapies (eg, nasal saline, intranasal corticosteroids, antihistamines) as appropriate Herbal supplements (eg, Ma Huang [ephedra], St. John's wort [with MAO inhibitors, yohimbine]) Avoid use Immunosuppressants (eg, cyclosporine)</p><p>Consider converting to tacrolimus, which may be associated with fewer effects on BP S5.1.1-7-S5.1.1-9</p><p>Oral contraceptives Use low-dose (eg, 20-30 mcg ethinyl estradiol) agents S5.1.1-10 or a progestin-only form of contraception, or consider alternative forms of birth control where appropriate (eg, barrier, abstinence, IUD)</p><p><s xml:id="_WzUFeNQ">Avoid use in women with uncontrolled hypertension S5.1.1-10</s><s xml:id="_fQ3raF2">NSAIDs Avoid systemic NSAIDs when possible Consider alternative analgesics (eg, acetaminophen, tramadol, topical NSAIDs), depending on indication and risk Recreational drugs (eg, "bath salts" [MDPV], cocaine, methamphetamine, etc.) *List is not all inclusive.</s><s xml:id="_bpjkwAT">ADHD indicates attention-deficit/hyperactivity disorder; BP, blood pressure; CVD, cardiovascular disease; IUD, intra-uterine device; MAOI, monoamine-oxidase inhibitors; MDPV, methylenedioxypyrovalerone;</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_67"><head>Table 22 . Evidence-Based Elements of the Plan of Care for Patients With Hypertension</head><label>22</label><figDesc><div><p xml:id="_RbSM3jG"><s xml:id="_aeRbCBU">Downloaded from http://ahajournals.org by on February 15, 2025</s></p></div></figDesc><table><row><cell></cell><cell>Associated Section(s)</cell></row><row><cell></cell><cell>of Guideline and Other</cell></row><row><cell>Plan of Care</cell><cell>Reference(s)</cell></row><row><cell cols="2">Pharmacological and nonpharmacological treatments</cell></row><row><cell>Medication selection (initial and ongoing)</cell><cell>Section 8.1</cell></row><row><cell>Monitoring for adverse effects and adherence</cell><cell>Sections 8.3.1,</cell></row><row><cell></cell><cell>8.3.2, 12.1.1</cell></row><row><cell>Nonpharmacological interventions</cell><cell>Sections 6, 12.1.2 S13-1</cell></row><row><cell>Diet</cell><cell></cell></row><row><cell>Exercise</cell><cell></cell></row><row><cell>Weight loss if overweight</cell><cell></cell></row><row><cell>Moderate alcohol consumption</cell><cell></cell></row><row><cell cols="2">Management of common comorbidities and conditions</cell></row><row><cell>Ischemic heart disease</cell><cell>Section 9.1 S13-2,S13-3</cell></row><row><cell>Heart failure</cell><cell>Section 9.2 S13-4</cell></row><row><cell>Reduced ejection fraction</cell><cell></cell></row><row><cell>Preserved ejection fraction</cell><cell></cell></row><row><cell>Diabetes mellitus</cell><cell>Section 9.6 S13-5</cell></row><row><cell>Chronic kidney disease</cell><cell>Section 9.3</cell></row><row><cell>Cerebrovascular disease</cell><cell>Section 9.4</cell></row><row><cell>Peripheral artery disease</cell><cell>Section 9.5</cell></row><row><cell>Atrial fibrillation</cell><cell>Section 9.8</cell></row><row><cell>Valvular heart disease</cell><cell>Section 9.9</cell></row><row><cell>Left ventricular hypertrophy</cell><cell>Section 7.3</cell></row><row><cell>Thoracic aortic disease</cell><cell>Section 9.10</cell></row><row><cell>Patient and family education</cell><cell></cell></row><row><cell>Achieving BP control and self-monitoring</cell><cell>Sections 4.2, 8.2</cell></row><row><cell>Risk assessment and prognosis</cell><cell>Section 8.1.2</cell></row><row><cell>Sexual activity and dysfunction</cell><cell>Section 11.4</cell></row><row><cell>Special patient groups</cell><cell></cell></row><row><cell>Pregnancy</cell><cell>Section 10.2.2</cell></row><row><cell>Older persons</cell><cell>Section 10.3.1</cell></row><row><cell>Children and adolescents</cell><cell>Section 10.3.2</cell></row><row><cell>Metabolic syndrome</cell><cell>Section 9.7</cell></row><row><cell>Possible secondary causes of hypertension</cell><cell>Section 5.4</cell></row><row><cell>Resistant hypertension</cell><cell>Section 11.1</cell></row><row><cell>Patients with hypertension undergoing surgery</cell><cell>Section 11.5</cell></row><row><cell>Renal transplantation</cell><cell>Section 9.3.1</cell></row><row><cell>Psychosocial factors</cell><cell></cell></row><row><cell>Sex-specific issues</cell><cell>Section 10.2</cell></row><row><cell>Culturally sensitive issues (race and ethnicity)</cell><cell>Section 10.1</cell></row><row><cell>Resource constraints</cell><cell>Section 12.5</cell></row><row><cell cols="2">Clinician follow-up, monitoring, and care coordination</cell></row><row><cell>Follow-up visits</cell><cell>Sections 8.1.3,</cell></row><row><cell></cell><cell>8.3.1, 8.3.2</cell></row><row><cell>Team-based care</cell><cell>Section 12.2</cell></row><row><cell></cell><cell>(Continued )</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_68"><head>Table 23 . BP Thresholds for and Goals of Pharmacological Therapy in Patients With Hypertension According to Clinical Conditions</head><label>23</label><figDesc><div><p xml:id="_wdgB6bs"><s xml:id="_jYx4y2x">CVD, cardiovascular disease; and SBP, systolic blood pressure.</s><s xml:id="_ec3MmV4">Downloaded from http://ahajournals.org by on February 15, 2025</s></p></div></figDesc><table><row><cell></cell><cell>BP</cell><cell></cell></row><row><cell></cell><cell>Threshold,</cell><cell>BP Goal,</cell></row><row><cell>Clinical Condition(s)</cell><cell>mm Hg</cell><cell>mm Hg</cell></row><row><cell>General</cell><cell></cell><cell></cell></row><row><cell>Clinical CVD or 10-year ASCVD risk ≥10%</cell><cell>≥130/80</cell><cell>&lt;130/80</cell></row><row><cell>No clinical CVD and 10-year ASCVD risk &lt;10%</cell><cell>≥140/90</cell><cell>&lt;130/80</cell></row><row><cell>Older persons (≥65 years of age; noninstitu-</cell><cell cols="2">≥130 (SBP) &lt;130 (SBP)</cell></row><row><cell>tionalized, ambulatory, community-living adults)</cell><cell></cell><cell></cell></row><row><cell>Specific comorbidities</cell><cell></cell><cell></cell></row><row><cell>Diabetes mellitus</cell><cell>≥130/80</cell><cell>&lt;130/80</cell></row><row><cell>Chronic kidney disease</cell><cell>≥130/80</cell><cell>&lt;130/80</cell></row><row><cell cols="2">Chronic kidney disease after renal transplantation ≥130/80</cell><cell>&lt;130/80</cell></row><row><cell>Heart failure</cell><cell>≥130/80</cell><cell>&lt;130/80</cell></row><row><cell>Stable ischemic heart disease</cell><cell>≥130/80</cell><cell>&lt;130/80</cell></row><row><cell>Secondary stroke prevention</cell><cell>≥140/90</cell><cell>&lt;130/80</cell></row><row><cell>Peripheral artery disease</cell><cell>≥130/80</cell><cell>&lt;130/80</cell></row><row><cell cols="3">ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure;</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_YFs4dc2"><s xml:id="_mE2jXXg">Downloaded from http://ahajournals.org by on February 15, 2025</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="2017" xml:id="foot_1"><p xml:id="_kAWjZrv"><s xml:id="_aVUtY96">High Blood Pressure Clinical Practice Guideline: Executive Summary</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="4" xml:id="foot_2"><p xml:id="_X8PKqjR"><s xml:id="_2vPKFqg">For auscultatory readings, deflate the cuff pressure 2 mm Hg per second, and listen for Korotkoff sounds.(Continued ) Downloaded from http://ahajournals.org by on February 15, 2025</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_3"><p xml:id="_UCkvFPK"><s xml:id="_gt4pd7c">June 2018</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div xml:id="_gPxThBt"><p xml:id="_4urUZtv"><s xml:id="_s3aWJc7">Westchester <rs type="institution">Medical Center and New York Medical College</rs>-Professor of Medicine None None None None None None None <rs type="person">Donald E. Casey</rs>, <rs type="person">Jr Thomas Jefferson</rs> College of Population Health-Adjunct Faculty; <rs type="person">Alvarez</rs> &amp; Marsal Ipo4health-Principal and Founder None None None None None None None <rs type="person">Karen J. Collins Collins</rs> Collaboration-President None None None None None None None <rs type="person">Cheryl Dennison Himmelfarb John Hopkins</rs> University-Professor of Nursing and Medicine, <rs type="affiliation">Institute for Clinical</rs> and Translational Research None None None None None None None <rs type="person">Sondra M. DePalma PinnacleHealth</rs> CardioVascular Institute-Physician Assistant; <rs type="affiliation">American Academy of PAs</rs>-Director, Regulatory and Professional Practice None None None None None None None <rs type="person">Samuel Gidding Alfred I</rs>. Dupont Hospital for Children-Chief, Division of Pediatric Cardiology, <rs type="affiliation">Nemours Cardiac Center</rs> None None None None None None None <rs type="person">David C. Goff</rs>, Jr* <rs type="affiliation">Colorado School of Public Health-Professor</rs> and Dean, <rs type="affiliation">Department of Epidemiology</rs> None None None None None None None <rs type="person">Kenneth A. Jamerson</rs> <rs type="affiliation">University of Michigan Health System-Professor of Internal Medicine</rs> and Frederick G.L. Huetwell Collegiate Professor of <rs type="affiliation">Cardiovascular Medicine None</rs> None None None None None None <rs type="person">Daniel W. Jones</rs> <rs type="affiliation">University of Mississippi Medical Center-Professor of Medicine and Physiology; Metabolic Diseases and Nutrition-University Sanderson Chair in Obesity Mississippi Center for Obesity Research-</rs>Director, Clinical and Population Science None None None None None None None <rs type="person">Eric J. MacLaughlin</rs> Texas <rs type="affiliation">Tech University Health Sciences Center-Professor and Chair, Department of Pharmacy Practice, School of Pharmacy None</rs> None None None None None None <rs type="person">Paul Muntner</rs> <rs type="affiliation">University of Alabama at Birmingham-Professor, Department of Epidemiology</rs> None None None None None None None (Continued ) June 2018 <rs type="person">Bruce Ovbiagele</rs> <rs type="affiliation">Medical University of South Carolina-Pihl</rs> Professor and Chairman of Neurology None • <rs type="affiliation">Boehringer Ingelheim Korea Ltd</rs> None None None None None <rs type="person">Sidney C. Smith</rs>, <rs type="affiliation">Jr University of North Carolina at Chapel Hill-Professor of Medicine; Center for Cardiovascular Science and Medicine</rs>-Director None None None None None None None Crystal <rs type="person">C. Spencer Spencer</rs> Law, PA-Attorney at Law None None None None None None None Randall S. Stafford Stanford Prevention Research <rs type="affiliation">Center-Professor of Medicine</rs>; Program on Prevention Outcomes-Director None None None None None None None <rs type="person">Sandra J. Taler Mayo Clinic</rs>-Professor of <rs type="affiliation">Medicine, College of Medicine</rs> None None None None None None None <rs type="person">Randal J. Thomas Mayo Clinic</rs>-Medical Director, Cardiac Rehabilitation Program None None None None None None None <rs type="person">Kim A. Williams</rs>, <rs type="person">Sr Rush</rs> <rs type="affiliation">University Medical Center-James B</rs>. Herrick Professor; Division of Cardiology-Chief None None None None None None None <rs type="person">Jeff D. Williamson</rs> Wake Forest <rs type="affiliation">Baptist Medical Center-Professor of Internal Medicine</rs>; Section on Gerontology and Geriatric Medicine-Chief None None None None None None None <rs type="person">Jackson T. Wright</rs>, Jr Case Western Reserve University-Professor of Medicine; William T. Dahms MD Clinical Research Unit-Program Director; University Hospitals Case Medical Center-Director, Clinical Hypertension Program None • Amgen † None None None None None</s></p><p xml:id="_M46wVxZ"><s xml:id="_tPc5hyQ">This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document.</s><s xml:id="_P9gEDRh">These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process.</s><s xml:id="_DSvm3pF">The table does not necessarily reflect relationships with industry at the time of publication.</s><s xml:id="_4cRPDPG">A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year.</s><s xml:id="_AeKSCZ4">Relationships that exist with no financial benefit are also included for the purpose of transparency.</s><s xml:id="_zmjS4ZM">Relationships in this table are modest unless otherwise noted.</s></p><p xml:id="_e7k98tg"><s xml:id="_FcEunDz">According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person's household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.</s></p><p xml:id="_NFDm4dm"><s xml:id="_CFH4DvB">We gratefully acknowledge the contributions of <rs type="person">Dr. Lawrence Appel</rs>, who served as a member of the Writing Committee from November 2014 to September 2015.</s><s xml:id="_t8vG9Gm">*<rs type="person">Dr.David C. Goff</rs> resigned from the writing committee in December 2016 because of a change in employment before the recommendations were balloted.</s><s xml:id="_vhwEUVC">The writing committee thanks him for his contributions, which were extremely beneficial to the development of the draft.</s><s xml:id="_BK254B8">†Significant relationship.</s><s xml:id="_yN4QJWU">AAPA indicates American Academy of Physician Assistants; <rs type="institution">ACC</rs>, <rs type="institution">American College of Cardiology</rs>; ACPM, <rs type="institution">American College of Preventive Medicine</rs>; AGS, <rs type="institution">American Geriatrics Society</rs>; <rs type="institution">AHA</rs>, <rs type="institution">American Heart Association</rs>; <rs type="institution">APhA</rs>, <rs type="institution">American Pharmacists Association</rs>; ASH, <rs type="institution">American Society of Hypertension</rs>; ASPC, American Society for Preventive Cardiology; ABC, Association of Black Cardiologists; NMA, <rs type="institution">National Medical Association</rs>; and PCNA, <rs type="institution">Preventive Cardiovascular Nurses Association</rs>.</s></p></div>
			</div>
			<div type="funding">
<div xml:id="_PuSJ5vQ"><p xml:id="_uSXrEzA"><s xml:id="_EhPcaeE">†ACC/AHA Representative.</s><s xml:id="_Jc39arR">‡Lay Volunteer/Patient Representative.</s><s xml:id="_Swb8EXE">§Preventive Cardiovascular Nurses Association Representative.</s><s xml:id="_yKafnVE">‖American Academy of Physician Assistants Representative.</s><s xml:id="_Z78jhKp">¶Task Force Liaison.</s><s xml:id="_2ry6tJC">#Association of Black Cardiologists Representative.</s><s xml:id="_pWa9Z6x">**American Pharmacists Association Representative.</s><s xml:id="_H3BH6CY">† †ACC/AHA Prevention Subcommittee Liaison.</s><s xml:id="_EtJTZ4x">‡ ‡American College of Preventive Medicine Representative.</s><s xml:id="_pyRAAuu">§ §American Society of Hypertension Representative.</s><s xml:id="_P6jumMP">‖‖Task Force on Performance Measures Liaison.</s><s xml:id="_tjUHQNP">¶ ¶American Geriatrics Society Representative.</s><s xml:id="_Uh2gtcS">##National Medical Association Representative.</s><s xml:id="_YacKfpd">***Former Task Force member; current member during the writing effort.</s><s xml:id="_fzGFx4t">This document was approved by the <rs type="funder">American College of Cardiology Clinical Policy Science Operations</rs>.</s><s xml:id="_9jDxY9e">For more on AHA statements and guidelines development, visit <ref type="url" target="http://professional.heart.org/statements">http://professional.heart.org/statements</ref>.</s></p><p xml:id="_d8PuYYB"><s xml:id="_6zSpc6K"><rs type="funder">National Heart, Lung, and Blood Institute (NHLBI) Advisory Council</rs> recommended that the <rs type="institution">NHLBI</rs> focus specifically on reviewing the highest-quality evidence and partner with other organizations to develop recommendations.</s><s xml:id="_B3M2Hxa">P-1,P-2 Accordingly, the ACC and AHA collaborated with the <rs type="institution">NHLBI</rs> and stakeholder and professional organizations to complete</s></p></div>
			</div>
			<listOrg type="funding">
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_7MgaseM"><p xml:id="_rTyA3ns"><s xml:id="_jJA4QEP">This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review, including those not deemed to be relevant to this document, at the time this document was under review.</s><s xml:id="_FSyqnAp">The table does not necessarily reflect relationships with industry at the time of publication.</s><s xml:id="_uw5KGZs">A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year.</s><s xml:id="_kgySVeX">Relationships that exist with no financial benefit are also included for the purpose of transparency.</s><s xml:id="_ex9ez8a">Relationships in this table are modest unless otherwise noted.</s><s xml:id="_X38RwF6">Names are listed in alphabetical order within each category of review.</s><s xml:id="_yQbfnrg">Please refer to <ref type="url" target="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy</ref> for definitions of disclosure categories or additional information about the ACC/AHA</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_Bt8ZN7y">9.4.2</title>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Veq9QMk">Acute Intracerebral Hemorrhage</title>
		<imprint>
			<biblScope unit="issue">3</biblScope>
			<publisher>Secondary Stroke Prevention</publisher>
		</imprint>
	</monogr>
	<note>Acute Ischemic Stroke</note>
	<note type="raw_reference">9.4.1. Acute Intracerebral Hemorrhage . . . 9.4.2. Acute Ischemic Stroke . . . . . . . . . . . 9.4.3. Secondary Stroke Prevention . . . . . .</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
		<idno type="DOI">10.5772/67180</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Mz5hfET">Peripheral Artery Disease</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">5. Peripheral Artery Disease . . . . . . . . . . . . . . .</note>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m" type="main" xml:id="_8xyEWKW">Metabolic Syndrome</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">7. Metabolic Syndrome. . . . . . . . . . . . . . . . . . .</note>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main" xml:id="_F4rAF4Y">Atrial Fibrillation</title>
		<idno type="DOI">10.1161/circulationaha.123.063672</idno>
		<imprint/>
	</monogr>
	<note type="raw_reference">8. Atrial Fibrillation . . . . . . . . . . . . . . . . . . . . .</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title/>
		<idno type="DOI">10.1201/b15782-19</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kC5M7fN">Valvular Heart Disease</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">9. Valvular Heart Disease . . . . . . . . . . . . . . . . .</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title/>
		<idno type="DOI">10.5772/55506</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RqJfK4e">Aortic Disease</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">10. Aortic Disease. . . . . . . . . . . . . . . . . . . . . . . .</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_TH9wph5">Racial and Ethnic Differences in Treatment</title>
		<idno type="DOI">10.31979/etd.uace-89tk</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8HANkJg">Special Patient Groups</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">Special Patient Groups . . . . . . . . . . . . . . . . . . . . . . . 10.1.1. Racial and Ethnic Differences in Treatment . . . . . . . . . . . . . . . . . . . .</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pqhsPNF">Other Considerations</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">Other Considerations . . . . . . . . . . . . . . . . . . . . . . . .</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_eEzmshG">Resistant Hypertension</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">1. Resistant Hypertension . . . . . . . . . . . . . . . . . .</note>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main" xml:id="_6zCrAxp">Hypertensive Crises-Emergencies and Urgencies</title>
		<idno type="DOI">10.1093/med/9780199204854.003.161705_update_002</idno>
		<imprint/>
	</monogr>
	<note type="raw_reference">2. Hypertensive Crises-Emergencies and Urgencies . . . . . . . . . . . . . . . . . . . . . . . . .</note>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<idno type="DOI">10.1016/b978-0-12-407824-6.00031-8</idno>
		<title level="m" xml:id="_K9Eymrd">Cognitive Decline and Dementia</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">3. Cognitive Decline and Dementia . . . . . . . . . .</note>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main" xml:id="_PS5mb3U">Patients Undergoing Surgical Procedures</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">4. Patients Undergoing Surgical Procedures. . . .</note>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main" xml:id="_47bXYr3">Strategies to Improve Hypertension Treatment and Control</title>
		<idno type="DOI">10.1097/hjh.0b013e32835d2c6c</idno>
		<imprint/>
	</monogr>
	<note type="raw_reference">Strategies to Improve Hypertension Treatment and Control . . . . . . . . . . . . . . . . . . . . . . .</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_4fSqpKr">Adherence Strategies for Treatment of Hypertension</title>
		<idno type="DOI">10.24124/2025/30537</idno>
	</analytic>
	<monogr>
		<title level="m" xml:id="_Sf8rdC6">Strategies to Promote Lifestyle Modification</title>
		<imprint/>
	</monogr>
	<note>Antihypertensive Medication Adherence Strategies</note>
	<note type="raw_reference">1. Adherence Strategies for Treatment of Hypertension . . . . . . . . . . . . . . . . . . . . . . . 12.1.1. Antihypertensive Medication Adherence Strategies . . . . . . . . . . . . . 12.1.2. Strategies to Promote Lifestyle Modification . . . . . . . . . . . .</note>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<idno type="DOI">10.1136/ebn1036</idno>
		<title level="m" xml:id="_beMRBaE">Structured, Team-Based Care Interventions for Hypertension Control</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">Structured, Team-Based Care Interventions for Hypertension Control . . . . .</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_9hbxHH7">The next steps in developing clinical practice guidelines for prevention</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Gibbons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Harold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jessup</surname></persName>
		</author>
		<idno type="DOI">10.1161/circulationaha.113.005548</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ctmYnNG">Circulation</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="1716" to="1717" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Health Information Technology</note>
	<note type="raw_reference">3. Health Information Technology-Based References Preamble P-1. Gibbons GH, Harold JG, Jessup M, et al. The next steps in devel- oping clinical practice guidelines for prevention. Circulation. 2013;128:1716-7.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_9MUkw47">Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute</title>
		<author>
			<persName><forename type="first">P-2</forename><surname>Gibbons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Shurin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Mensah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_s69EVAf">Circulation</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="1713" to="1715" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">P-2. Gibbons GH, Shurin SB, Mensah GA, et al. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. Circulation. 2013;128:1713-5.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m" xml:id="_8zwC6Xk">Committee on Standards for Developing Trustworthy Clinical Practice Guidelines</title>
		<meeting><address><addrLine>Washington, DC</addrLine></address></meeting>
		<imprint>
			<publisher>The National Academies Press</publisher>
			<date type="published" when="2011">2011</date>
		</imprint>
		<respStmt>
			<orgName>Institute of Medicine (US)</orgName>
		</respStmt>
	</monogr>
	<note>P-3 Clinical Practice Guidelines We Can Trust</note>
	<note type="raw_reference">P-3. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (US). Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press; 2011.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title level="m" xml:id="_5F6XvBd">Committee on Standards for Systematic Reviews of Comparative Effectiveness Research Institute of Medicine (US). Finding What Works in Health Care: Standards for Systematic Reviews</title>
		<meeting><address><addrLine>Washington, DC</addrLine></address></meeting>
		<imprint>
			<publisher>The National Academies Press</publisher>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>P-4</note>
	<note type="raw_reference">P-4. Committee on Standards for Systematic Reviews of Comparative Effectiveness Research Institute of Medicine (US). Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: The National Academies Press; 2011.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_7YzNXyS">ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">P-5</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Heidenreich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Barnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename></persName>
		</author>
		<idno type="DOI">10.1161/cir.0000000000000042</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Tr9GM74">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="2329" to="2345" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">P-5. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state- ment on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329-45.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<idno type="DOI">10.1213/ane.0b013e31825d02ef</idno>
		<ptr target="http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf" />
		<title level="m" xml:id="_xTJ6F8x">ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines</title>
		<imprint>
			<publisher>American College of Cardiology and American Heart Association</publisher>
			<date type="published" when="2010-09-15">2010. September 15, 2017</date>
		</imprint>
	</monogr>
	<note>P-6</note>
	<note type="raw_reference">P-6. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association, 2010. Available at: http://assets.cardiosource.com/ Methodology_Manual_for_ACC_AHA_Writing_Committees. pdf and http://professional.heart.org/idc/groups/ahamah-public/@ wcm/@sop/documents/downloadable/ucm_319826.pdf. Accessed September 15, 2017.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_pdNJgCc">Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines</title>
		<author>
			<persName><forename type="first">P-7</forename><surname>Halperin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Al-Khatib</forename><surname>Sm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kXu6YXh">Circulation</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="1426" to="1428" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">P-7. Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classi- fication system: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016;133:1426-28.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_nB9uN9k">ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">P-8</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Kushner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Ettinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename></persName>
		</author>
		<idno type="DOI">10.1213/ane.0b013e31825d02ef</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9wfRhXn">Circulation</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="1426" to="1428" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">P-8. Jacobs AK, Kushner FG, Ettinger SM. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2016;133:1426-28.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_vnPUeQQ">The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">P-9</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Halperin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gQdXxVq">Circulation</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="1208" to="1217" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">P-9. Jacobs AK, Anderson JL, Halperin JL. The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:1208-17.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_dfdcfQU">AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Arnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Goodman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Halperin</surname></persName>
		</author>
		<idno type="DOI">10.1161/cir.0000000000000128</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cR3DXzp">American College of Cardiology, and US Department of Health and Human Services</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="1208" to="1217" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Circulation</note>
	<note type="raw_reference">Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US Department of Health and Human Services. Circulation. 2014;130:1208-17.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_fJdqrVS">ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Whelton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Carey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Aronow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_eRgZJuJ">Hypertension</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="13" to="e115" />
			<date type="published" when="2017">2017. 2018</date>
		</imprint>
	</monogr>
	<note>Introduction S1-1</note>
	<note type="raw_reference">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guide- line for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-e115. 1. Introduction S1-1.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_aCFJM7b">Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Gibbons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Harold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jessup</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_K9Pe8Qn">Circulation</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="1713" to="1715" />
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
	<note>The next steps in developing clinical practice guidelines for prevention Circulation</note>
	<note type="raw_reference">Gibbons GH, Harold JG, Jessup M, et al. The next steps in devel- oping clinical practice guidelines for prevention. Circulation. 2013;128:1716-7. S1-2. Gibbons GH, Shurin SB, Mensah GA, et al. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. Circulation. 2013;128: 1713-5.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<idno type="DOI">10.4159/harvard.9780674492097</idno>
		<title level="m" xml:id="_eJDr7gH">The Framingham Study: The Epidemiology of Atherosclerotic Disease</title>
		<meeting><address><addrLine>Ann Arbor, MI; Cambridge, MA</addrLine></address></meeting>
		<imprint>
			<publisher>Harvard University Press</publisher>
			<date type="published" when="1959">1959. 1980</date>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="1" to="4" />
		</imprint>
		<respStmt>
			<orgName>The University of Michigan</orgName>
		</respStmt>
	</monogr>
	<note>S1-3 Society of Actuaries. Build and Blood Pressure Study</note>
	<note type="raw_reference">S1-3. Society of Actuaries. Build and Blood Pressure Study, Vol 1. Ann Arbor, MI: The University of Michigan; 1959. S1-4. Dawber TR. The Framingham Study: The Epidemiology of Atherosclerotic Disease. Cambridge, MA: Harvard University Press; 1980.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_knFx7mz">Effects of treatment on morbidity and mortality in hypertension. I. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg</title>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FTHZEjP">JAMA</title>
		<imprint>
			<biblScope unit="volume">202</biblScope>
			<biblScope unit="page" from="1028" to="1034" />
			<date type="published" when="1967">1967</date>
		</imprint>
	</monogr>
	<note>1-5</note>
	<note type="raw_reference">S1-5. Effects of treatment on morbidity and mortality in hypertension. I. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-34.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_hF7bsNk">Effects of treatment on morbidity and mortality in hypertension: II. results in patients with diastolic blood pressure averaging 90 through 114 mm Hg</title>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<idno type="DOI">10.1001/jama.1970.03170330025003</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_N6kbR8P">JAMA</title>
		<imprint>
			<biblScope unit="volume">213</biblScope>
			<biblScope unit="page" from="1143" to="1152" />
			<date type="published" when="1970">1970</date>
		</imprint>
	</monogr>
	<note>1-6</note>
	<note type="raw_reference">S1-6. Effects of treatment on morbidity and mortality in hypertension: II. results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143-52.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_X9aCKbX">Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Moser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Roccella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jknU8ry">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">237</biblScope>
			<biblScope unit="page" from="1" to="9" />
			<date type="published" when="1977">1977. 2013</date>
			<pubPlace>Greenwich)</pubPlace>
		</imprint>
	</monogr>
	<note>S1-7 The treatment of hypertension: a remarkable success story JAMA</note>
	<note type="raw_reference">S1-7. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA. 1977;237:255-61. S1-8. Moser M, Roccella EJ. The treatment of hypertension: a remarkable success story. J Clin Hypertens (Greenwich). 2013;15:88-91. S1-9.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_CZfr7MP">the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Chobanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Bakris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Black</surname></persName>
		</author>
		<idno type="DOI">10.1161/01.hyp.0000107251.49515.c2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3emeekr">Hypertension</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chobanian AV, Bakris GL, Black HR, et al. the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52. S1-10.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_JfQb4XA">Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Reboussin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Griswold</surname></persName>
		</author>
		<idno type="DOI">10.1161/hyp.0000000000000077</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_A4KTQwj">Hypertension</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e116-e135. S1-11.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_kavWmMg">ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Fihn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Gardin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Abrams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QnAKBbV">Circulation</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="2012">2012. 2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354-471. S1-12.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_cNr2Rrp">ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Yancy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jessup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bozkurt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Bv4Tr2U">Circulation</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="1" to="13" />
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-327. S1-13.</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_qg9NSCN">AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</title>
		<author>
			<persName><forename type="first">Gerhard-Herman Md</forename><surname>Gornik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RESQbHp">Circulation</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2016">2016. 2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gerhard-Herman MD, Gornik HL, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726-79. S1-14.</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_EJHkTN9">The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Funder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Carey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mantero</surname></persName>
		</author>
		<idno type="DOI">10.1210/jc.2015-4061</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pT8rzwN">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="1" to="15" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Funder JW, Carey RM, Mantero F, et al. The management of pri- mary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889-916. S1-15.</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_ejybxyr">ACC/AHA/ AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Fihn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Blankenship</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Alexander</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yPexNSW">Circulation</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="1" to="16" />
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/ AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749-67. S1-16.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_e7NgpKx">AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Lenders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">Y</forename><surname>Duh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Eisenhofer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Nc78Cqs">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="1" to="18" />
			<date type="published" when="2014-01">2014. January. 2014. 2014</date>
		</imprint>
	</monogr>
	<note>Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline Circulation</note>
	<note type="raw_reference">Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915-42. S1-17. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guide- line for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199-267. S1-18.</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_ucJSVe5">AHA/ACC focused update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Nishimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Otto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Bonow</surname></persName>
		</author>
		<idno type="DOI">10.1161/cir.0000000000000503</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_F6wWmQN">Circulation</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="1" to="19" />
			<date type="published" when="2017">2017. 2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC Guideline for the manage- ment of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e1159-95. S1-19.</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_P8kW4ya">ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">Lloyd</forename><forename type="middle">-</forename><surname>Goff Dc</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bennett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_N5mUwhA">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="issue">suppl 2</biblScope>
			<biblScope unit="page" from="49" to="73" />
			<date type="published" when="2013">2013. 2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guide- line on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49-73.</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_uvRmPU3">American College of Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&apos; Task Force on Hypertension in Pregnancy</title>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PpKnfBh">Obstet Gynecol</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="1" to="21" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>1-20</note>
	<note type="raw_reference">S1-20. American College of Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&apos; Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013; 122:1122-31. S1-21.</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_T7Mnd2f">ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America</title>
		<author>
			<persName><forename type="first">C</forename><surname>Yancy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jessup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bozkurt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EHBChP3">Circulation</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="1" to="22" />
			<date type="published" when="2017">2017. 2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yancy C, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137-61. S1-22.</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_acuBD5w">AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Eckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Jakicic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Ard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hvs4W7a">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="issue">suppl 2</biblScope>
			<biblScope unit="page" from="1" to="23" />
			<date type="published" when="2013">2013. 2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S76-99. S1-23.</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_xqNKzjH">ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mancia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fagard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Narkiewicz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_X37uVpA">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1" to="24" />
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guide- lines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219. S1-24.</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_9HrkXgy">AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Apovian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zUV66Cc">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="issue">suppl 2</biblScope>
			<biblScope unit="page" from="1" to="25" />
			<date type="published" when="2013">2013. 2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(suppl 2):S102-38. S1-25.</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_zGrpBG7">ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">O'</forename><surname>Gara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Kushner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Ascheim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hDYwFe7">Circulation</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="1" to="26" />
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">O&apos;Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guide- line for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362-425. S1-26.</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_R9fSEpj">ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Lichtenstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3dExKFQ">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="issue">suppl 2</biblScope>
			<biblScope unit="page" from="1" to="27" />
			<date type="published" when="2013">2013. 2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atheroscle- rotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1-45. S1-27.</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_gTmJMQk">ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)</title>
		<author>
			<persName><forename type="first">V</forename><surname>Regitz-Zagrosek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Blomstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Borghi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rYTVnjB">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="1" to="28" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Regitz-Zagrosek V, Blomstrom LC, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:3147-97. S1-28.</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_z66ERfY">Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association</title>
		<author>
			<persName><forename type="first">L</forename><surname>Mosca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Benjamin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Berra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sM6hESE">Circulation</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="1" to="29" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guide- lines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation. 2011;123:1243-62. S1-29.</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main" xml:id="_C7Zsk2g">AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation</title>
		<author>
			<persName><surname>Smith Sc</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Benjamin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Bonow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZwT97tN">Circulation</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="1" to="30" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458-73. S1-30.</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main" xml:id="_DXH4VeF">ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">P</forename><surname>Greenland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Alpert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Beller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fzAv7fv">Circulation</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="1" to="31" />
			<date type="published" when="2010">2010. 2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guide- line for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:e584-636. S1-31.</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main" xml:id="_Uu2vqXF">ACCF/AHA/AATS/ ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Hiratzka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Bakris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Beckman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wgGaVnG">Circulation</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="266" to="369" />
			<date type="published" when="2010">2010. 2010</date>
			<publisher>Society of Thoracic Surgeons, and Society for Vascular Medicine</publisher>
		</imprint>
		<respStmt>
			<orgName>American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagno- sis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010;121:e266-369.</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main" xml:id="_W7Zbywv">National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents</title>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_g7W4fWR">Pediatrics</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="1" to="33" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>1-32</note>
	<note type="raw_reference">S1-32. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555-76. S1-33.</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main" xml:id="_PAgk5X7">Salt sensitivity of blood pressure: a scientific statement from the American Heart Association</title>
		<author>
			<persName><forename type="first">F</forename><surname>Elijovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Weinberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cam</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_M6ne5wb">Hypertension</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1" to="34" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Elijovich F, Weinberger MH, Anderson CAM, et al. Salt sensitivity of blood pressure: a scientific statement from the American Heart Association. Hypertension. 2016;68:e7-46. S1-34.</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main" xml:id="_yaWfwm4">ACC health policy statement on cardiovascular team-based care and the role of advanced practice providers</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Brush</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Handberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Biga</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jacc.2015.03.550</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5TwHS2g">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="1" to="35" />
			<date type="published" when="2015">2015. 2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brush JE Jr, Handberg EM, Biga C, et al. 2015 ACC health policy statement on cardiovascular team-based care and the role of advanced practice providers. J Am Coll Cardiol. 2015;65:2118-36. S1-35.</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main" xml:id="_ZTMj9K2">Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association</title>
		<author>
			<persName><forename type="first">C</forename><surname>Rosendorff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Lackland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Allison</surname></persName>
		</author>
		<idno type="DOI">10.1161/cir.0000000000000459</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6WjMUtC">American College of Cardiology, and American Society of Hypertension</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="1" to="36" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Circulation</note>
	<note type="raw_reference">Rosendorff C, Lackland DT, Allison M, et al. Treatment of hyper- tension in patients with coronary artery disease: a scientific state- ment from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation. 2015;131:e435-70. S1-36.</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main" xml:id="_8tYuFcg">An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Flynn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Daniels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Hayman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KUUg399">Hypertension</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="1" to="38" />
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
	<note>Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association Hypertension</note>
	<note type="raw_reference">Flynn JT, Daniels SR, Hayman LL, et al. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. Hypertension. 2014;63:1116-35. S1-37. Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63:878-85. S1-38.</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main" xml:id="_RfsjhUB">European Society of Hypertension position paper on ambulatory blood pressure monitoring</title>
		<author>
			<persName><forename type="first">E</forename><surname>O'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Parati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stergiou</surname></persName>
		</author>
		<idno type="DOI">10.1097/hjh.0000000000000017</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KETxkX3">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1" to="39" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">O&apos;Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure moni- toring. J Hypertens. 2013;31:1731-68. S1-39.</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main" xml:id="_Ex2F2Nm">ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement</title>
		<author>
			<persName><forename type="first">J</forename><surname>Drozda</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Messer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Spertus</surname></persName>
		</author>
		<idno type="DOI">10.1161/cir.0b013e31821d9ef2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vVsWx9r">Circulation</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="1" to="40" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Drozda J Jr, Messer JV, Spertus J, et al. ACCF/AHA/AMA- PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association- Physician Consortium for Performance Improvement. Circulation. 2011;124:248-70. S1-40.</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main" xml:id="_TnmUKTU">Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">T</forename><surname>Artinian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Fletcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mozaffarian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6g9CRdS">Circulation</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="1" to="41" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for cardio- vascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation. 2010;122:406-41. S1-41.</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main" xml:id="_Q2brs87">Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Calhoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Textor</surname></persName>
		</author>
		<idno type="DOI">10.1161/hypertensionaha.108.189141</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rJ8uXbj">Hypertension</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="1403" to="1419" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-19.</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main" xml:id="_pJzzNER">2.1</title>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xeSWCB4">Observational Relationship S</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1" to="1" />
		</imprint>
	</monogr>
	<note>BP and CVD Risk</note>
	<note type="raw_reference">BP and CVD Risk 2.1. Observational Relationship S2.1-1.</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main" xml:id="_AUARE5z">Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lewington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Qizilbash</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3Nn9EdZ">Lancet</title>
		<imprint>
			<biblScope unit="volume">360</biblScope>
			<biblScope unit="page" from="1899" to="1911" />
			<date type="published" when="2002">2002. 2014</date>
		</imprint>
	</monogr>
	<note>Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet</note>
	<note type="raw_reference">Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of indi- vidual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13. S2.1-2. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899-911.</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title/>
		<idno type="DOI">10.7717/peerj.10336/supp-2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3GK8FEm">BP Components S</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="2" to="3" />
		</imprint>
	</monogr>
	<note type="raw_reference">2. BP Components S2.2-1.</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main" xml:id="_exUs7aK">Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lewington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Qizilbash</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RpJuUBR">Hypertension</title>
		<imprint>
			<biblScope unit="volume">360</biblScope>
			<biblScope unit="page" from="2" to="5" />
			<date type="published" when="1988">2002. 2014. 1988. 2000</date>
		</imprint>
	</monogr>
	<note>Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial Lancet Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in Men Circulation</note>
	<note type="raw_reference">Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of indi- vidual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13. S2.2-2. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899-911. S2.2-3. Rutan GH, Kuller LH, Neaton JD, et al. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation. 1988;77:504-14. S2.2-4. Sesso HD, Stampfer MJ, Rosner B, et al. Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in Men. Hypertension. 2000;36:801-7. S2.2-5.</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main" xml:id="_bJppZNS">Influence of systolic and diastolic blood pressure on stroke risk: a prospective observational study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Stamler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Stamler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jd ;</forename><surname>Neaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bean</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cMzw33z">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="2" to="8" />
			<date type="published" when="1993">1993. 2002. 1995</date>
		</imprint>
	</monogr>
	<note>Blood pressure, systolic and diastolic, and cardiovascular risks. US population data Arch Intern Med Prognostic value of systolic and diastolic blood pressure in treated hypertensive men Am J Epidemiol</note>
	<note type="raw_reference">Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and dia- stolic, and cardiovascular risks. US population data. Arch Intern Med. 1993;153:598-615. S2.2-6. Benetos A, Thomas F, Bean K, et al. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med. 2002;162:577-81. S2.2-7. Lindenstrom E, Boysen G, Nyboe J. Influence of systolic and dia- stolic blood pressure on stroke risk: a prospective observational study. Am J Epidemiol. 1995;142:1279-90. S2.2-8.</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main" xml:id="_UapYqqx">Brachial pulse pressure and cardiovascular or all-cause mortality in the general population: a metaanalysis of prospective observational studies</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JGpgwWX">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="2" to="9" />
			<date type="published" when="2014">2014</date>
			<pubPlace>Greenwich)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhao L, Song Y, Dong P, et al. Brachial pulse pressure and cardio- vascular or all-cause mortality in the general population: a meta- analysis of prospective observational studies. J Clin Hypertens (Greenwich). 2014;16:678-85. S2.2-9.</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main" xml:id="_KBEw8Sm">Predictive utility of pulse pressure and other blood pressure measures for cardiovascular outcomes</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Mosley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Greenland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Garside</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_awQjWpk">Hypertension</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="2" to="10" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mosley WJ, Greenland P, Garside DB, et al. Predictive utility of pulse pressure and other blood pressure measures for cardiovascular outcomes. Hypertension. 2007;49:1256-64. S2.2-10.</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main" xml:id="_yHjk6QK">Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Franklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Lopez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Wong</surname></persName>
		</author>
		<idno type="DOI">10.1161/circulationaha.108.797936</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YWh3fQB">Circulation</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="2" to="11" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:243-50. S2.2-11.</note>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main" xml:id="_QHCPjRq">Meta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kodama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Horikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fujihara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8jSxvAd">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="1058" to="1065" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kodama S, Horikawa C, Fujihara K, et al. Meta-analysis of the quantitative relation between pulse pressure and mean arterial pres- sure and cardiovascular risk in patients with diabetes mellitus. Am J Cardiol. 2014;113:1058-65.</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QbgAVsy">Population Risk S</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="3" to="4" />
		</imprint>
	</monogr>
	<note type="raw_reference">3. Population Risk S2.3-1.</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main" xml:id="_bSqzrs8">A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Flaxman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zsXAfCa">Lancet</title>
		<imprint>
			<biblScope unit="volume">380</biblScope>
			<biblScope unit="page" from="3" to="5" />
			<date type="published" when="2010">2010. 2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lim SS, Vos T, Flaxman AD, et al. A comparative risk assess- ment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-60. S2.3-2.</note>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main" xml:id="_4EMSqD7">The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Forouzanfar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Roth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_StP4EKy">Circulation</title>
		<imprint>
			<biblScope unit="volume">317</biblScope>
			<biblScope unit="page" from="3" to="6" />
			<date type="published" when="2009">2017. 2009. 2011. 2014</date>
		</imprint>
	</monogr>
	<note>Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015 JAMA Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States PLoS Med Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities Study Circulation</note>
	<note type="raw_reference">Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hyper- tension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317:165-82. S2.3-3. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009;6: e1000058. S2.3-4. Ford ES. Trends in mortality from all causes and cardiovascular dis- ease among hypertensive and nonhypertensive adults in the United States. Circulation. 2011;123:1737-44. S2.3-5. Cheng S, Claggett B, Correia AW, et al. Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities Study. Circulation. 2014;130: 820-8. S2.3-6.</note>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main" xml:id="_bWzDQAz">Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Z</forename><surname>Willey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Moon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kahn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uKqpH7E">J Am Heart Assoc</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="3" to="7" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Willey JZ, Moon YP, Kahn E, et al. Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study. J Am Heart Assoc. 2014;3:e001106. S2.3-7.</note>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main" xml:id="_6cxt5zp">US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States</title>
		<author>
			<persName><forename type="first">R</forename><surname>Saran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Robinson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JgECNAq">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1" to="305" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2015;66 Svii:S1-305.</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5ENCKF6">Coexistence of Hypertension and Related Chronic Conditions S</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="4" to="5" />
		</imprint>
	</monogr>
	<note type="raw_reference">4. Coexistence of Hypertension and Related Chronic Conditions S2.4-1.</note>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main" xml:id="_ukhRGnS">Clustering of metabolic factors and coronary heart disease</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Kannel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Silbershatz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7mmwauc">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="4" to="6" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wilson PW, Kannel WB, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:1104-9. S2.4-2.</note>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main" xml:id="_5M5EgyN">Lifetime risks of cardiovascular disease</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Berry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Cai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_eA6MsyS">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="page" from="4" to="7" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular dis- ease. N Engl J Med. 2012;366:321-9. S2.4-3.</note>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main" xml:id="_4v8eUCm">CPAP for prevention of cardiovascular events in obstructive sleep apnea</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Mcevoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Antic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Heeley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GjzCPaf">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="919" to="931" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375:919-31.</note>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main" xml:id="_drm4v7z">Classification of BP 3.1</title>
	</analytic>
	<monogr>
		<title level="m" xml:id="_y2ECVan">Definition of High BP S3</title>
		<imprint>
			<biblScope unit="page" from="1" to="1" />
		</imprint>
	</monogr>
	<note type="raw_reference">3. Classification of BP 3.1. Definition of High BP S3.1-1.</note>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main" xml:id="_N6KQbE9">Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1•25 million people</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lewington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Qizilbash</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(02)11911-8</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BfjrPNn">Lancet</title>
		<imprint>
			<biblScope unit="volume">360</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="4" />
			<date type="published" when="2002">2002. 2014. 2016</date>
		</imprint>
	</monogr>
	<note>Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis Lancet</note>
	<note type="raw_reference">Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of indi- vidual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13. S3.1-2. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1•25 million people. Lancet. 2014;383:1899-911. S3.1-3. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-67. S3.1-4.</note>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main" xml:id="_NerM3WR">Association between pre-hypertension and cardiovascular outcomes: a systematic review and metaanalysis of prospective studies</title>
		<author>
			<persName><forename type="first">X</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Guo</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11906-013-0403-y</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2NuJdXF">Curr Hypertens Rep</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Guo X, Zhang X, Guo L, et al. Association between pre-hyperten- sion and cardiovascular outcomes: a systematic review and meta- analysis of prospective studies. Curr Hypertens Rep. 2013;15: 703-16. S3.1-5.</note>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main" xml:id="_bXRDcfS">Prehypertension is not associated with all-cause mortality: a systematic review and meta-analysis of prospective studies</title>
		<author>
			<persName><forename type="first">X</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_M5m9sX5">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="6" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Guo X, Zhang X, Zheng L, et al. Prehypertension is not associated with all-cause mortality: a systematic review and meta-analysis of prospective studies. PLoS ONE. 2013;8:e61796. S3.1-6.</note>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main" xml:id="_sDfBvfv">Prehypertension and the risk of coronary heart disease in Asian and Western populations: a metaanalysis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1161/jaha.114.001519</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jsZM4vb">J Am Heart Assoc</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="1" to="8" />
			<date type="published" when="2014">2014. 2015</date>
		</imprint>
	</monogr>
	<note>Prehypertension and the risk of stroke: a meta-analysis Neurology</note>
	<note type="raw_reference">Huang Y, Cai X, Li Y, et al. Prehypertension and the risk of stroke: a meta-analysis. Neurology. 2014;82:1153-61. S3.1-7. Huang Y, Cai X, Liu C, et al. Prehypertension and the risk of coronary heart disease in Asian and Western populations: a meta- analysis. J Am Heart Assoc. 2015;4:e001519. S3.1-8.</note>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main" xml:id="_Wwjejdj">Prehypertension and Incidence of ESRD: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.ajkd.2013.07.024</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nHpKt6v">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="9" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Huang Y, Cai X, Zhang J, et al. Prehypertension and Incidence of ESRD: a systematic review and meta-analysis. Am J Kidney Dis. 2014;63:76-83. S3.1-9.</note>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main" xml:id="_ntStS75">Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Cai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_a7MbYNd">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Huang Y, Su L, Cai X, et al. Association of all-cause and cardiovas- cular mortality with prehypertension: a meta-analysis. Am Heart J. 2014;167:160-68.e1. S3.1-10.</note>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main" xml:id="_y68D97x">Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Cai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9NGYZEQ">BMC Med</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="2009">2013. 2009</date>
		</imprint>
	</monogr>
	<note>Prehypertension and incidence of cardiovascular disease: a meta-analysis BMJ</note>
	<note type="raw_reference">Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC Med. 2013;11:177. S3.1-11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospec- tive epidemiological studies. BMJ. 2009;338:b1665. S3.1-12.</note>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main" xml:id="_4mcpEgG">Presence of baseline prehypertension and risk of incident stroke: a meta-analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Saver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NkXexBp">Neurology</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="13" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lee M, Saver JL, Chang B, et al. Presence of baseline prehyper- tension and risk of incident stroke: a meta-analysis. Neurology. 2011;77:1330-7. S3.1-13.</note>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main" xml:id="_5EB7rcU">Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease</title>
		<author>
			<persName><forename type="first">L</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">X</forename><surname>Xiang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vJ7fZaZ">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shen L, Ma H, Xiang MX, et al. Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease. Am J Cardiol. 2013;112:266-71. S3.1-14.</note>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main" xml:id="_SFRjUU9">Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sundstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Arima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jackson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5dR4JhV">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="15" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sundstrom J, Arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-anal- ysis. Ann Intern Med. 2015;162:184-91. S3.1-15.</note>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main" xml:id="_FFYtRhC">Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels-overview and metaanalyses of randomized trials</title>
		<author>
			<persName><forename type="first">C</forename><surname>Thomopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Parati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zanchetti</surname></persName>
		</author>
		<idno type="DOI">10.1097/hjh.0000000000000379</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DpMzsds">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="16" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at differ- ent baseline and achieved blood pressure levels-overview and meta- analyses of randomized trials. J Hypertens. 2014;32:2296-304. S3.1-16.</note>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main" xml:id="_ygpWvYz">Impact of baseline prehypertension on cardiovascular events and all-cause mortality in the general population: a meta-analysis of prospective cohort studies</title>
		<author>
			<persName><forename type="first">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijcard.2013.07.063</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bARhymb">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="17" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang S, Wu H, Zhang Q, et al. Impact of baseline prehypertension on cardiovascular events and all-cause mortality in the general pop- ulation: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013;168:4857-60. S3.1-17.</note>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main" xml:id="_fCqbPYw">Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">X</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Atkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lv</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(15)00805-3</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_m9rtSbg">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="18" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2015;387:435-43. S3.1-18.</note>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main" xml:id="_Qz5nYZk">Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Cushman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Cutler</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1524-6175.2002.02045.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_J7ZPaXr">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="19" />
			<date type="published" when="2002">2002</date>
			<pubPlace>Greenwich)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4: 393-404. S3.1-19.</note>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main" xml:id="_AwmGdam">Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dahlof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Devereux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Kjeldsen</surname></persName>
		</author>
		<idno type="DOI">10.1016/s1062-1458(02)00777-8</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5NPHZ6R">Lancet</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="20" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular mor- bidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. S3.1-20.</note>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main" xml:id="_dKBV7Uy">Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Wald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Law</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Morris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_b2Pf9ub">Am J Med</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="290" to="300" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med. 2009;122:290-300.</note>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main" xml:id="_8t4rFh3">2</title>
		<idno type="DOI">10.1016/s0895-7061(99)00252-6</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zFvFwBw">Lifetime Risk of Hypertension S</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="2" to="3" />
		</imprint>
	</monogr>
	<note type="raw_reference">2. Lifetime Risk of Hypertension S3.2-1.</note>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main" xml:id="_xZbg7YG">Comparison of the Framingham Heart Study hypertension model with blood pressure alone in the prediction of risk of hypertension: the Multi-Ethnic Study of Atherosclerosis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Muntner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Mann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4yMDa58">Hypertension</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="2" to="2" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Muntner P, Woodward M, Mann DM, et al. Comparison of the Framingham Heart Study hypertension model with blood pressure alone in the prediction of risk of hypertension: the Multi-Ethnic Study of Atherosclerosis. Hypertension. 2010;55:1339-45. S3.2-2.</note>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main" xml:id="_9GusnFw">Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">I</forename><surname>Parikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Pencina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RZJbdn5">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="page" from="2983" to="2989" />
			<date type="published" when="2002">2008. 2011. 2002. 2012</date>
		</imprint>
	</monogr>
	<note>A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study Hypertension Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study JAMA Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study Circulation</note>
	<note type="raw_reference">Parikh NI, Pencina MJ, Wang TJ, et al. A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med. 2008;148:102-10. S3.2-3. Carson AP, Howard G, Burke GL, et al. Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension. 2011;57: 1101-7. S3.2-4. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003-10. S3.2-5. Shihab HM, Meoni LA, Chu AY, et al. Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study. Circulation. 2012;126:2983-9.</note>
</biblStruct>

<biblStruct xml:id="b100">
	<monogr>
		<title level="m" type="main" xml:id="_Eh5pzm7">Measurement of BP 4.1. Accurate Measurement of BP in the Office S4</title>
		<imprint>
			<biblScope unit="page" from="1" to="1" />
		</imprint>
	</monogr>
	<note type="raw_reference">Measurement of BP 4.1. Accurate Measurement of BP in the Office S4.1-1.</note>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main" xml:id="_HKErybC">ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mancia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fagard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Narkiewicz</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/eht151</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sHpzaMg">Blood Press Monit</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1" to="4" />
			<date type="published" when="2013">2013. 2013. 2014. 2016</date>
		</imprint>
	</monogr>
	<note>In the clinic: hypertension Eur Heart J Comparison of stethoscope bell and diaphragm, and of stethoscope tube length, for clinical blood pressure measurement Ann Intern Med</note>
	<note type="raw_reference">Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219. S4.1-2. Weir MR. In the clinic: hypertension. Ann Intern Med. 2014;161: ITC1-15. S4.1-3. Liu C, Griffiths C, Murray A, et al. Comparison of stethoscope bell and diaphragm, and of stethoscope tube length, for clinical blood pressure measurement. Blood Press Monit. 2016;21:178-83. S4.1-4.</note>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main" xml:id="_vvvDPSc">Bell or diaphragm in the measurement of blood pressure?</title>
		<author>
			<persName><forename type="first">I</forename><surname>Kantola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vesalainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kangassalo</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.hjh.0000160204.74028.95</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_r98r56K">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kantola I, Vesalainen R, Kangassalo K, et al. Bell or dia- phragm in the measurement of blood pressure? J Hypertens. 2005;23:499-503. S4.1-5.</note>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main" xml:id="_Nc5vqDu">Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Pickering</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Appel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_y9AHr3F">Circulation</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="697" to="716" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for profession- als from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697-716.</note>
</biblStruct>

<biblStruct xml:id="b104">
	<monogr>
		<title level="m" type="main" xml:id="_pYCcQrk">Out-of-Office and Self-Monitoring of BP S4</title>
		<imprint>
			<biblScope unit="page" from="2" to="3" />
		</imprint>
	</monogr>
	<note type="raw_reference">Out-of-Office and Self-Monitoring of BP S4.2-1.</note>
</biblStruct>

<biblStruct xml:id="b105">
	<monogr>
		<title level="m" type="main" xml:id="_CtqDCEt">Self-Measured Blood Pressure Monitoring: Comparative Effectiveness</title>
		<author>
			<persName><forename type="first">K</forename><surname>Uhlig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Balk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Patel</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012">2012</date>
			<publisher>Agency for Healthcare Research and Quality (US</publisher>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="2" to="2" />
			<pubPlace>Rockville, MD</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Uhlig K, Balk EM, Patel K, et al. Self-Measured Blood Pressure Monitoring: Comparative Effectiveness. Rockville, MD: Agency for Healthcare Research and Quality (US); 2012. S4.2-2.</note>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main" xml:id="_RaKrw6w">Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Margolis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Asche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Bergdall</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2013.6549</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gs4sRqY">JAMA</title>
		<imprint>
			<biblScope unit="volume">310</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="2" to="3" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310:46-56. S4.2-3.</note>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main" xml:id="_AUtebVJ">Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Mcmanus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Haque</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bcZF7mv">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">312</biblScope>
			<biblScope unit="page" from="2" to="5" />
			<date type="published" when="2014">2014. 2015</date>
		</imprint>
	</monogr>
	<note>Screening for high blood pressure in adults: US Preventive Services Task Force recommendation statement JAMA</note>
	<note type="raw_reference">McManus RJ, Mant J, Haque MS, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hyperten- sive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA. 2014;312:799-808. S4.2-4. Siu AL. Screening for high blood pressure in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163:778-86. S4.2-5.</note>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main" xml:id="_Kmmyff7">ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mancia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fagard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Narkiewicz</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/eht151</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kXwdQGR">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="2" to="6" />
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219. S4.2-6.</note>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main" xml:id="_W4gfxsK">Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Pickering</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ogedegbe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BBcuPxb">Hypertension</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="10" to="29" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pickering TG, Miller NH, Ogedegbe G, et al. Call to action on use and reimbursement for home blood pressure monitoring: a joint sci- entific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008;52:10-29.</note>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main" xml:id="_XkHwbXZ">Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34</title>
	</analytic>
	<monogr>
		<title level="m" xml:id="_xNkhkdP">S4.2-7</title>
		<meeting><address><addrLine>London, UK; UK</addrLine></address></meeting>
		<imprint>
			<publisher>Royal College of Physicians</publisher>
			<date type="published" when="2011">2011</date>
		</imprint>
		<respStmt>
			<orgName>National Clinical Guideline Centre (UK</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">S4.2-7. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. London, UK: Royal College of Physicians (UK); 2011.</note>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Dny8vJZ">Masked and White Coat Hypertension S</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="3" to="4" />
		</imprint>
	</monogr>
	<note type="raw_reference">3. Masked and White Coat Hypertension S4.3-1.</note>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main" xml:id="_yDum7ST">Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the US Preventive Services Task Force</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Pickering</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Boddie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AZPBeDq">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">259</biblScope>
			<biblScope unit="page" from="3" to="6" />
			<date type="published" when="1988">1988. 2015. 2005. 2007. 2011</date>
			<publisher>Royal College of Physicians (UK</publisher>
			<pubPlace>London, UK</pubPlace>
		</imprint>
		<respStmt>
			<orgName>National Clinical Guideline Centre (UK</orgName>
		</respStmt>
	</monogr>
	<note>How common is white coat hypertension? JAMA Prognosis of &quot;masked&quot; hypertension and &quot;white-coat&quot; hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study Ann Intern Med Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis J Hypertens Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34</note>
	<note type="raw_reference">Pickering TG, James GD, Boddie C, et al. How common is white coat hypertension? JAMA. 1988;259:225-28. S4.3-2. Piper MA, Evans CV, Burda BU, et al. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2015;162:192-204. S4.3-3. Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of &quot;masked&quot; hypertension and &quot;white-coat&quot; hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol. 2005;46:508-15. S4.3-4. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension ver- sus true normotension: a meta-analysis. J Hypertens. 2007;25: 2193-8. S4.3-5. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. London, UK: Royal College of Physicians (UK); 2011. S4.3-6.</note>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main" xml:id="_5CpJYJA">Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population</title>
		<author>
			<persName><forename type="first">K</forename><surname>Asayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Thijs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_v3ryNa2">Hypertension</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="3" to="7" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Asayama K, Thijs L, Li Y, et al. Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the popula- tion. Hypertension. 2014;64:935-42. S4.3-7.</note>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main" xml:id="_pEp4QT5">Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mancia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bombelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Brambilla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rQsswtb">Hypertension</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="3" to="8" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mancia G, Bombelli M, Brambilla G, et al. Long-term prognos- tic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension. 2013;62:168-74. S4.3-8.</note>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main" xml:id="_jq8fwjq">Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Pierdomenico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F ;</forename><surname>Cuccurullo</surname></persName>
		</author>
		<author>
			<persName><surname>Aj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Hinderliter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Kshirsagar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aVQYHWz">Am. J Hypertens</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="3" to="10" />
			<date type="published" when="2010">2011. June 2018 S4. 2010</date>
		</imprint>
	</monogr>
	<note>Reproducibility of masked hypertension in adults with untreated borderline office blood pressure: comparison of ambulatory and home monitoring Am. J Hypertens</note>
	<note type="raw_reference">Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am. J Hypertens. 2011;24:52-8. June 2018 S4.3-9. Viera AJ, Hinderliter AL, Kshirsagar AV, et al. Reproducibility of masked hypertension in adults with untreated borderline office blood pressure: comparison of ambulatory and home monitoring. Am. J Hypertens. 2010;23:1190-7. S4.3-10.</note>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main" xml:id="_GdJKV9S">Reproducibility of masked hypertension among adults 30 years or older</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Viera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Tuttle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_K9Xq4Bj">Blood Press Monit</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="3" to="11" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Viera AJ, Lin FC, Tuttle LA, et al. Reproducibility of masked hypertension among adults 30 years or older. Blood Press Monit. 2014;19:208-15. S4.3-11.</note>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main" xml:id="_CDrNWYs">Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Stergiou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Asayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Thijs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zTA8tmJ">Hypertension</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="3" to="12" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Stergiou GS, Asayama K, Thijs L, et al. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome. Hypertension. 2014;63:675-82. S4.3-12.</note>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main" xml:id="_gZDhwBu">Masked hypertension and target organ damage in treated hypertensive patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tomiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Horio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yoshii</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ssRXvjM">Am J Hypertens</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="880" to="886" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tomiyama M, Horio T, Yoshii M, et al. Masked hypertension and target organ damage in treated hypertensive patients. Am J Hypertens. 2006;19:880-6.</note>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main" xml:id="_GfPkUG8">Causes of Hypertension 5.1</title>
		<idno type="DOI">10.1093/med/9780198784906.003.0566</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_z58nVNX">Secondary Forms of Hypertension S</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="1" to="1" />
		</imprint>
	</monogr>
	<note type="raw_reference">5. Causes of Hypertension 5.1. Secondary Forms of Hypertension S5.1-1.</note>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main" xml:id="_s2KFuzx">A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Levey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Lewis</surname></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-130-6-199903160-00002</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VwmXauz">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="1" to="2" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-70. S5.1-2.</note>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main" xml:id="_Dn3wE7e">ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease)</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Calhoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Textor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JEQ6Tw7">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="1" to="9" />
			<date type="published" when="1991">2008. 2006. 2008. 2016. 2011. 1994. 1991</date>
		</imprint>
	</monogr>
	<note>Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Circulation Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline Hypertension The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline J Clin Endocrinol Metab Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension Hypertension Assessment of the validity and utility of a sleep-symptom questionnaire J Clin Endocrinol Metab A new method for measuring daytime sleepiness: the Epworth sleepiness scale Sleep</note>
	<note type="raw_reference">Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diag- nosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-19. S5.1-3. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation. 2006;113:e463-654. S5.1-4. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:3266-81. S5.1-5. Funder JW, Carey RM, Mantero F, et al. The management of pri- mary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:1889-916. S5.1-6. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58:811-7. S5.1-7. Kump K, Whalen C, Tishler PV, et al. Assessment of the validity and utility of a sleep-symptom questionnaire. Am J Respir Crit Care Med. 1994;150:735-41. S5.1-8. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540-5. S5.1-9.</note>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main" xml:id="_7UyG9yY">Drug-induced hypertension: an unappreciated cause of secondary hypertension</title>
		<author>
			<persName><forename type="first">E</forename><surname>Grossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Messerli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UBnFEw3">Am J Med</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Grossman E, Messerli FH. Drug-induced hypertension: an unappre- ciated cause of secondary hypertension. Am J Med. 2012;125:14-22. S5.1-10.</note>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main" xml:id="_TUueAhk">Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Lenders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">Y</forename><surname>Duh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Eisenhofer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rYUsyuG">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915-42. S5.1-11.</note>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main" xml:id="_RWUmeRR">The diagnosis of Cushing&apos;s syndrome: an Endocrine Society clinical practice guideline</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Nieman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Biller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Findling</surname></persName>
		</author>
		<idno type="DOI">10.1210/jc.2008-0125</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4X7BJUn">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing&apos;s syndrome: an Endocrine Society clinical practice guide- line. J Clin Endocrinol Metab. 2008;93:1526-40. S5.1-12.</note>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main" xml:id="_eUN7M62">Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension</title>
		<author>
			<persName><forename type="first">E</forename><surname>Lurbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cifkova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Cruickshank</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_g3PGD5E">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1" to="13" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommenda- tions of the European Society of Hypertension. J Hypertens. 2009;27:1719-42. S5.1-13.</note>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main" xml:id="_xu2d2n5">Prevalence of primary and secondary hypertension: studies in a random population sample</title>
		<author>
			<persName><forename type="first">G</forename><surname>Berglund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Andersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wilhelmsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fvqF2nn">Br Med J</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="1976">1976</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sam- ple. Br Med J. 1976;2:554-6. S5.1-14.</note>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main" xml:id="_UEYSA2g">Inherited forms of mineralocorticoid hypertension</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Hassan-Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Stewart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CtdeVRA">Curr Opin Endocrinol Diabetes Obes</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1" to="15" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hassan-Smith Z, Stewart PM. Inherited forms of mineralo- corticoid hypertension. Curr Opin Endocrinol Diabetes Obes. 2011;18:177-85. S5.1-15.</note>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main" xml:id="_JHtQe2H">Acromegaly: an Endocrine Society clinical practice guideline</title>
		<author>
			<persName><forename type="first">L</forename><surname>Katznelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Laws</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Melmed</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kgYnPf4">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="3933" to="3951" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933-51.</note>
</biblStruct>

<biblStruct xml:id="b129">
	<monogr>
		<title level="m" type="main" xml:id="_jEKWn5k">1.1. Drugs and Other Substances With Potential to Impair BP Control S5</title>
		<imprint>
			<biblScope unit="page" from="1" to="1" />
		</imprint>
	</monogr>
	<note type="raw_reference">1.1. Drugs and Other Substances With Potential to Impair BP Control S5.1.1-1.</note>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main" xml:id="_5jgzpZK">Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Goldstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Bushnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Adams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_a8PNzZX">Stroke</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1" to="2" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare profes- sionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:517-84. S5.1.1-2.</note>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main" xml:id="_78xF9zf">Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents</title>
		<author>
			<persName><forename type="first">S</forename><surname>Cortese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Holtmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Banaschewski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Rjq8tsk">J Child Psychol. Psychiatry</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1" to="3" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cortese S, Holtmann M, Banaschewski T, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol. Psychiatry. 2013;54:227-46. S5.1.1-3.</note>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main" xml:id="_NAnamqt">ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents</title>
		<author>
			<persName><forename type="first">M</forename><surname>Wolraich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Brown</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_T6Ny2Fp">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="issue">suppl 1</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2007">2011. 2007</date>
		</imprint>
	</monogr>
	<note>Metabolic considerations in the use of antipsychotic medications: a review of recent evidence Pediatrics</note>
	<note type="raw_reference">Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of atten- tion-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007-22. S5.1.1-4. Newcomer JW. Metabolic considerations in the use of antipsy- chotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(suppl 1):20-7. S5.1.1-5.</note>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main" xml:id="_G8EUunc">Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Z</forename><surname>Willey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Moon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kahn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bpm6W6M">J Am Heart Assoc</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="1" to="6" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Willey JZ, Moon YP, Kahn E, et al. Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study. J Am Heart Assoc. 2014;3:e001106. S5.1.1-6.</note>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main" xml:id="_6xeksdn">The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Mesas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Leon</forename><forename type="middle">-</forename><surname>Munoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Rodriguez-Artalejo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vNNyXHf">Am J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mesas AE, Leon-Munoz LM, Rodriguez-Artalejo F, et al. The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis. Am J Clin Nutr. 2011;94:1113-26. S5.1.1-7.</note>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main" xml:id="_7DdA36R">Immunosuppressant utilization and cardiovascular complications among Chinese patients after kidney transplantation: a systematic review and analysis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M-S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-Y</forename><surname>Yuan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mpFzxBK">Int Urol Nephrol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1" to="8" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Liu Y, Yang M-S, Yuan J-Y. Immunosuppressant utilization and cardiovascular complications among Chinese patients after kidney transplantation: a systematic review and analysis. Int Urol Nephrol. 2013;45:885-92. S5.1.1-8.</note>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main" xml:id="_mxPBCpV">Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients</title>
		<author>
			<persName><forename type="first">L</forename><surname>Penninga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Penninga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Moller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xTwvuS7">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="1" to="9" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Penninga L, Penninga EI, Moller CH, et al. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database Syst Rev. 2013;5:CD008817. S5.1.1-9.</note>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main" xml:id="_EyvX3Fb">Effects of tacrolimus and cyclosporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis</title>
		<author>
			<persName><forename type="first">W</forename><surname>Xue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WS6KWUT">Chin Med J</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Xue W, Zhang Q, Xu Y, et al. Effects of tacrolimus and cyclo- sporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis. Chin Med J. 2014;127:2376-81. S5.1.1-10.</note>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main" xml:id="_Vv4bHpk">ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mancia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fagard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Narkiewicz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2vQgPTA">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="2159" to="2219" />
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guide- lines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219.</note>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_H3M7kp8">Primary Aldosteronism S5</title>
		<imprint>
			<biblScope unit="page" from="2" to="3" />
		</imprint>
	</monogr>
	<note type="raw_reference">5.1.2. Primary Aldosteronism S5.1.2-1.</note>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main" xml:id="_e7Eqhq9">Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Montori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Young</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ENan9nJ">Endocrinol Metab Clin North Am</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="3" to="4" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>Renal Artery Stenosis S</note>
	<note type="raw_reference">Montori VM, Young WF Jr. Use of plasma aldosterone concentra- tion-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am. 2002;31:619-32; xi. 5.1.3. Renal Artery Stenosis S5.1.3-1.</note>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main" xml:id="_f9skBGf">Stenting and medical therapy for atherosclerotic renal-artery stenosis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Cutlip</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Bkz8RX8">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="3" to="5" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370:13-22. S5.1.3-2.</note>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main" xml:id="_X9aXPdN">Meta-analysis of revascularization versus medical therapy for atherosclerotic renal artery stenosis</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">B</forename><surname>Riaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Husnain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Riaz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_U7HfymN">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="1116" to="1123" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Obstructive Sleep Apnea S5.1.4-1</note>
	<note type="raw_reference">Riaz IB, Husnain M, Riaz H, et al. Meta-analysis of revasculariza- tion versus medical therapy for atherosclerotic renal artery stenosis. Am J Cardiol. 2014;114:1116-23. 5.1.4. Obstructive Sleep Apnea S5.1.4-1.</note>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main" xml:id="_s26U3Ee">Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea</title>
		<author>
			<persName><forename type="first">F</forename><surname>Barbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Duran-Cantolla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Capote</surname></persName>
		</author>
		<idno type="DOI">10.1164/rccm.200901-0050oc</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_T36S43X">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">181</biblScope>
			<biblScope unit="page" from="4" to="6" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Barbe F, Duran-Cantolla J, Capote F, et al. Long-term effect of con- tinuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med. 2010;181:718-26. S5.1.4-2.</note>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main" xml:id="_N6NBZNE">Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Martinez-Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Capote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Campos-Rodriguez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ycNz3y8">JAMA</title>
		<imprint>
			<biblScope unit="volume">310</biblScope>
			<biblScope unit="page" from="4" to="7" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Martinez-Garcia MA, Capote F, Campos-Rodriguez F, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA. 2013;310:2407-15. S5.1.4-3.</note>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main" xml:id="_HeUGhdb">Effects of continuous positive airway pressure treatment on clinic and ambulatory blood pressures in patients with obstructive sleep apnea and resistant hypertension: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">L</forename><surname>Lozano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Tovar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sampol</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MJx32W2">Hypertension. Hypertension</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="4" to="5" />
			<date type="published" when="2010">2010. 2015</date>
		</imprint>
	</monogr>
	<note>Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial J Hypertens</note>
	<note type="raw_reference">Lozano L, Tovar JL, Sampol G, et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hyperten- sion: a randomized, controlled trial. J Hypertens. 2010;28:2161-68. S5.1.4-4. Muxfeldt ES, Margallo V, Costa LM, et al. Effects of continu- ous positive airway pressure treatment on clinic and ambulatory blood pressures in patients with obstructive sleep apnea and resis- tant hypertension: a randomized controlled trial. Hypertension. Hypertension. 2015;65:736-42. S5.1.4-5.</note>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main" xml:id="_52pbKBN">Effects of OSA treatment on BP in patients with resistant hypertension: a randomized trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Pedrosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Drager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>De Paula</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zneKPNf">Chest</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page" from="1487" to="1494" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pedrosa RP, Drager LF, de Paula LK, et al. Effects of OSA treat- ment on BP in patients with resistant hypertension: a randomized trial. Chest. 2013;144:1487-94.</note>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6Uapyku">Nonpharmacological Interventions S</title>
		<imprint>
			<biblScope unit="page" from="6" to="7" />
		</imprint>
	</monogr>
	<note type="raw_reference">Nonpharmacological Interventions S6-1.</note>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<title level="a" type="main" xml:id="_mBuTDFE">Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. Trials of Hypertension Prevention Collaborative Research Group</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Neter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Stam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Kok</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_duWywaw">Am J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="652S" to="660S" />
			<date type="published" when="1997">2003. 1997</date>
		</imprint>
	</monogr>
	<note>Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials Hypertension</note>
	<note type="raw_reference">Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878-84. S6-2. Whelton PK, Kumanyika SK, Cook NR, et al. Efficacy of nonphar- macologic interventions in adults with high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. Trials of Hypertension Prevention Collaborative Research Group. Am J Clin Nutr. 1997;65:652S-60S.</note>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main" xml:id="_cA5fuD7">The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I</title>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HYSxcZy">JAMA</title>
		<imprint>
			<biblScope unit="volume">267</biblScope>
			<biblScope unit="page" from="1213" to="1220" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note>6-3</note>
	<note type="raw_reference">S6-3. The effects of nonpharmacologic interventions on blood pres- sure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA. 1992;267:1213-20.</note>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main" xml:id="_7R7rn3n">Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group</title>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fhBMRx5">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="page" from="6" to="11" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>6-4</note>
	<note type="raw_reference">S6-4. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med. 1997;157:657-67. S6-5.</note>
</biblStruct>

<biblStruct xml:id="b151">
	<analytic>
		<title level="a" type="main" xml:id="_dp5TSQx">Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Sacks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Svetkey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Vollmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Y5fsJzJ">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">344</biblScope>
			<biblScope unit="page" from="6" to="6" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pres- sure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3-10. S6-6.</note>
</biblStruct>

<biblStruct xml:id="b152">
	<analytic>
		<title level="a" type="main" xml:id="_NxM9kAs">Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Appel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Champagne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Harsha</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.289.16.2083</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3sE2Uyd">JAMA</title>
		<imprint>
			<biblScope unit="volume">289</biblScope>
			<biblScope unit="page" from="6" to="7" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Appel LJ, Champagne CM, Harsha DW, et al. Effects of com- prehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289: 2083-93. S6-7.</note>
</biblStruct>

<biblStruct xml:id="b153">
	<analytic>
		<title level="a" type="main" xml:id="_UAvzPNs">A clinical trial of the effects of dietary patterns on blood pressure</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Appel</surname></persName>
			<affiliation>
				<orgName type="collaboration">DASH Collaborative Research Group</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Moore</surname></persName>
			<affiliation>
				<orgName type="collaboration">DASH Collaborative Research Group</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Obarzanek</surname></persName>
			<affiliation>
				<orgName type="collaboration">DASH Collaborative Research Group</orgName>
			</affiliation>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Y7YJ9dV">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">336</biblScope>
			<biblScope unit="page" from="6" to="9" />
			<date type="published" when="1997">1997. 2014</date>
		</imprint>
	</monogr>
	<note>Global sodium consumption and death from cardiovascular causes N Engl J Med</note>
	<note type="raw_reference">Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117-24. S6-8. Mozaffarian D, Fahimi S, Singh GM, et al. Global sodium con- sumption and death from cardiovascular causes. N Engl J Med. 2014;371:624-34. S6-9.</note>
</biblStruct>

<biblStruct xml:id="b154">
	<analytic>
		<title level="a" type="main" xml:id="_pjwbCWt">Effect of lower sodium intake on health: systematic review and meta-analyses</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Aburto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ziolkovska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hooper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_avcCrqC">BMJ</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page" from="6" to="10" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aburto NJ, Ziolkovska A, Hooper L, et al. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ. 2013;346:f1326. S6-10.</note>
</biblStruct>

<biblStruct xml:id="b155">
	<analytic>
		<title level="a" type="main" xml:id="_6zKmUeK">Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and metaanalysis of randomised trials</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Macgregor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FfC4gG9">BMJ</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page" from="6" to="11" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">He FJ, Li J, MacGregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta- analysis of randomised trials. BMJ. 2013;346:f1325. S6-11.</note>
</biblStruct>

<biblStruct xml:id="b156">
	<analytic>
		<title level="a" type="main" xml:id="_v4ZFupz">Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review)</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Graudal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hubeck-Graudal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Jurgens</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.cd004022.pub3</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kuBJFYD">Am J Hypertens</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="6" to="12" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, cat- echolamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens. 2012;25:1-15. S6-12.</note>
</biblStruct>

<biblStruct xml:id="b157">
	<analytic>
		<title level="a" type="main" xml:id="_vynPke6">Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Whelton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Appel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Espeland</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.279.11.839</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HHtKAUE">JAMA</title>
		<imprint>
			<biblScope unit="volume">279</biblScope>
			<biblScope unit="page" from="6" to="13" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998;279:839-46. S6-13.</note>
</biblStruct>

<biblStruct xml:id="b158">
	<analytic>
		<title level="a" type="main" xml:id="_FJ9YRNr">Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Whelton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Cutler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m" xml:id="_xbnBjGq">Guideline: Potassium Intake for Adults and Children</title>
		<meeting><address><addrLine>Geneva, Switzerland</addrLine></address></meeting>
		<imprint>
			<publisher>World Health Organization</publisher>
			<date type="published" when="1997">1997. 2003. 2012</date>
			<biblScope unit="volume">277</biblScope>
			<biblScope unit="page" from="6" to="16" />
		</imprint>
	</monogr>
	<note>Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials JAMA</note>
	<note type="raw_reference">Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical tri- als. JAMA. 1997;277:1624-32. S6-14. Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens. 2003;17:471-80. S6-15. World Health Organization. Guideline: Potassium Intake for Adults and Children. Geneva, Switzerland: World Health Organization; 2012. S6-16.</note>
</biblStruct>

<biblStruct xml:id="b159">
	<analytic>
		<title level="a" type="main" xml:id="_khSe3ES">Health effects of sodium and potassium in humans</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Whelton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>He</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EhmepHF">Curr Opin Lipidol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="6" to="17" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Whelton PK, He J. Health effects of sodium and potassium in humans. Curr Opin Lipidol. 2014;25:75-9. S6-17.</note>
</biblStruct>

<biblStruct xml:id="b160">
	<analytic>
		<title level="a" type="main" xml:id="_GnEgRjN">Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Aburto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hanson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gutierrez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YGZrbz8">BMJ</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page" from="6" to="18" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aburto NJ, Hanson S, Gutierrez H, et al. Effect of increased potas- sium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ. 2013;346:f1378. S6-18.</note>
</biblStruct>

<biblStruct xml:id="b161">
	<analytic>
		<title level="a" type="main" xml:id="_ZhmMvME">Exercise training for blood pressure: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Cornelissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Smart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_v9XzguW">J Am Heart Assoc</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="6" to="19" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cornelissen VA, Smart NA. Exercise training for blood pres- sure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2:e004473. S6-19.</note>
</biblStruct>

<biblStruct xml:id="b162">
	<analytic>
		<title level="a" type="main" xml:id="_RM2E5Cn">Isometric exercise training for blood pressure management: a systematic review and metaanalysis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Carlson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dieberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Hess</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WGmSpCn">Mayo Clin Proc</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="6" to="20" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Carlson DJ, Dieberg G, Hess NC, et al. Isometric exercise train- ing for blood pressure management: a systematic review and meta- analysis. Mayo Clin Proc. 2014;89:327-34. S6-20.</note>
</biblStruct>

<biblStruct xml:id="b163">
	<analytic>
		<title level="a" type="main" xml:id="_Rmx2YY2">Effects of exercise on resting blood pressure in obese children: a meta-analysis of randomized controlled trials</title>
		<author>
			<persName><forename type="first">A</forename><surname>Garcia-Hermoso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Saavedra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Escalante</surname></persName>
		</author>
		<idno type="DOI">10.1111/obr.12054</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_26dmn8k">Obes Rev</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="6" to="21" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Garcia-Hermoso A, Saavedra JM, Escalante Y. Effects of exercise on resting blood pressure in obese children: a meta-analysis of ran- domized controlled trials. Obes Rev. 2013;14:919-28. S6-21.</note>
</biblStruct>

<biblStruct xml:id="b164">
	<analytic>
		<title level="a" type="main" xml:id="_CJ9vmDs">The evolution of a Canadian Hypertension Education Program recommendation: the impact of resistance training on resting blood pressure in adults as an example</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Moullec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Lavoie</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cjca.2013.02.010</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Cqb28UC">Can J Cardiol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="6" to="22" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rossi AM, Moullec G, Lavoie KL, et al. The evolution of a Canadian Hypertension Education Program recommendation: the impact of resistance training on resting blood pressure in adults as an example. Can J Cardiol. 2013;29:622-7. S6-22.</note>
</biblStruct>

<biblStruct xml:id="b165">
	<analytic>
		<title level="a" type="main" xml:id="_4rvfdkN">Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Whelton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_H5MekZx">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="6" to="23" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493-503. S6-23.</note>
</biblStruct>

<biblStruct xml:id="b166">
	<analytic>
		<title level="a" type="main" xml:id="_tudYpnx">Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials</title>
		<author>
			<persName><forename type="first">X</forename><surname>Xin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Frontini</surname></persName>
		</author>
		<idno type="DOI">10.1161/hy1101.093424</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_anUeT3P">Hypertension</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="6" to="24" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2001;38:1112-7. S6-24.</note>
</biblStruct>

<biblStruct xml:id="b167">
	<analytic>
		<title level="a" type="main" xml:id="_z5ucAWW">The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Roerecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kaczorowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Tobe</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2468-2667(17)30003-8</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zJntZqd">Lancet Public Health</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="6" to="25" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Roerecke M, Kaczorowski J, Tobe SW, et al. The effect of a reduc- tion in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health. 2017;2:e108-20. S6-25.</note>
</biblStruct>

<biblStruct xml:id="b168">
	<analytic>
		<title level="a" type="main" xml:id="_VvBSfUP">Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Latham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gnaZxWw">Addiction</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="6" to="26" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Stewart SH, Latham PK, Miller PM, et al. Blood pressure reduc- tion during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction. 2008;103:1622-8. S6-26.</note>
</biblStruct>

<biblStruct xml:id="b169">
	<analytic>
		<title level="a" type="main" xml:id="_Pj8S3wF">Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">O</forename><surname>Dickinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Mason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Nicolson</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.hjh.0000199800.72563.26</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8G2aJYH">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="6" to="27" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interven- tions to reduce raised blood pressure: a systematic review of ran- domized controlled trials. J Hypertens. 2006;24:215-33. S6-27.</note>
</biblStruct>

<biblStruct xml:id="b170">
	<analytic>
		<title level="a" type="main" xml:id="_UbpR6Uk">Randomised controlled trial of general practitioner intervention in patients with excessive alcohol consumption</title>
		<author>
			<persName><forename type="first">P</forename><surname>Wallace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cutler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Haines</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vYYYXjP">BMJ</title>
		<imprint>
			<biblScope unit="volume">297</biblScope>
			<biblScope unit="page" from="6" to="28" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wallace P, Cutler S, Haines A. Randomised controlled trial of gen- eral practitioner intervention in patients with excessive alcohol con- sumption. BMJ. 1988;297:663-8. S6-28.</note>
</biblStruct>

<biblStruct xml:id="b171">
	<analytic>
		<title level="a" type="main" xml:id="_rAkKyFW">Improving hypertension control among excessive alcohol drinkers: a randomised controlled trial in France. The WALPA Group</title>
		<author>
			<persName><forename type="first">T</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Nicaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Darne</surname></persName>
		</author>
		<ptr target="https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/what-standard-drink" />
	</analytic>
	<monogr>
		<title level="m" xml:id="_2zexh8t">What Is A Standard Drink?</title>
		<imprint>
			<date type="published" when="1995-08-16">1995. August 16, 2017</date>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="6" to="30" />
		</imprint>
		<respStmt>
			<orgName>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Lang T, Nicaud V, Darne B, et al. Improving hypertension control among excessive alcohol drinkers: a randomised controlled trial in France. The WALPA Group. J Epidemiol Community Health. 1995;49:610-6. S6-29. National Institute on Alcohol Abuse and Alcoholism (NIAAA). What Is A Standard Drink? Available at: https://www.niaaa.nih. gov/alcohol-health/overview-alcohol-consumption/what-standard- drink. Accessed: August 16, 2017. S6-30.</note>
</biblStruct>

<biblStruct xml:id="b172">
	<analytic>
		<title level="a" type="main" xml:id="_TpsSfxU">Isometric exercise training for blood pressure management: a systematic review and meta-analysis to optimize benefit</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Inder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Carlson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dieberg</surname></persName>
		</author>
		<idno type="DOI">10.1038/hr.2015.111</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7hZFysJ">Hypertension Res</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="6" to="31" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Inder JD, Carlson DJ, Dieberg G, et al. Isometric exercise train- ing for blood pressure management: a systematic review and meta-analysis to optimize benefit. Hypertension Res. 2016;39: 88-94. S6-31.</note>
</biblStruct>

<biblStruct xml:id="b173">
	<monogr>
		<ptr target="https://www.nhlbi.nih.gov/health/resources/heart/hbp-dash-how-to" />
		<title level="m" xml:id="_a6HDBYr">Your Guide to Lowering Your Blood Pressure With DASH-How Do I Make the DASH? Available at</title>
		<imprint>
			<date type="published" when="2017-09-18">September 18, 2017. Top 10</date>
			<biblScope unit="page" from="6" to="32" />
		</imprint>
		<respStmt>
			<orgName>National Heart, Lung, and Blood Institute</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">National Heart, Lung, and Blood Institute. Your Guide to Lowering Your Blood Pressure With DASH-How Do I Make the DASH? Available at: https://www.nhlbi.nih.gov/health/resources/heart/hbp- dash-how-to. Accessed September 18, 2017. S6-32. Top 10</note>
</biblStruct>

<biblStruct xml:id="b174">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Diet</forename><surname>Dash</surname></persName>
		</author>
		<author>
			<persName><surname>Tips</surname></persName>
		</author>
		<ptr target="http://dashdiet.org/dash_diet_tips.asp" />
		<imprint>
			<date type="published" when="2017-09-18">September 18, 2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">DASH Diet Tips. Available at: http://dashdiet.org/dash_ diet_tips.asp. Accessed September 18, 2017.</note>
</biblStruct>

<biblStruct xml:id="b175">
	<monogr>
		<title level="m" type="main" xml:id="_bjmkR8V">Treatment of High BP 8.1. Pharmacological Treatment 8.1.1. Initiation of Pharmacological BP Treatment in the Context of Overall CVD Risk S8</title>
		<idno type="DOI">10.1001/jama.2023.26082</idno>
		<imprint>
			<biblScope unit="page" from="1" to="1" />
		</imprint>
	</monogr>
	<note type="raw_reference">Treatment of High BP 8.1. Pharmacological Treatment 8.1.1. Initiation of Pharmacological BP Treatment in the Context of Overall CVD Risk S8.1.1-1.</note>
</biblStruct>

<biblStruct xml:id="b176">
	<analytic>
		<title level="a" type="main" xml:id="_pHSr8jV">Hypertension in adults across the age spectrum: current outcomes and control in the community</title>
		<author>
			<persName><forename type="first">Lloyd-Jones Dm</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4fh8tAP">JAMA</title>
		<imprint>
			<biblScope unit="volume">294</biblScope>
			<biblScope unit="page" from="1" to="2" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294:466-72. S8.1.1-2.</note>
</biblStruct>

<biblStruct xml:id="b177">
	<analytic>
		<title level="a" type="main" xml:id="_fzJAxuf">Comparison of the sexspecific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ozyilmaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Bakker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>De Zeeuw</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_P5E8Efb">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2013">2013. 2013. 2013</date>
		</imprint>
	</monogr>
	<note>Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events Stroke The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review Semin Arthritis Rheum</note>
	<note type="raw_reference">Ozyilmaz A, Bakker SJ, de Zeeuw D, et al. Screening for albumin- uria with subsequent screening for hypertension and hypercho- lesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events. Nephrol Dial Transplant. 2013;28:2805-15. S8.1.1-3. Peters SA, Huxley RR, Woodward M. Comparison of the sex- specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals. Stroke. 2013;44:2394-401. S8.1.1-4. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43:77-95. S8.1.1-5.</note>
</biblStruct>

<biblStruct xml:id="b178">
	<analytic>
		<title level="a" type="main" xml:id="_eNVkm4c">Blood pressure and coronary heart disease: a review of the evidence</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Lawes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lewington</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UfhTnRV">Semin Vasc Med</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1" to="6" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lawes CM, Bennett DA, Lewington S, et al. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med. 2002;2:355-68. S8.1.1-6.</note>
</biblStruct>

<biblStruct xml:id="b179">
	<analytic>
		<title level="a" type="main" xml:id="_yx34vWQ">Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lewington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Qizilbash</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_W7VhRxu">Lancet</title>
		<imprint>
			<biblScope unit="volume">360</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of indi- vidual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13. S8.1.1-7.</note>
</biblStruct>

<biblStruct xml:id="b180">
	<analytic>
		<title level="a" type="main" xml:id="_Upg6pkG">Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes</title>
		<author>
			<persName><forename type="first">N</forename><surname>Takashima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ohkubo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Miura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5zwUJsc">Diabetes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2012">2012. 2014. 2012</date>
		</imprint>
	</monogr>
	<note>Long-term risk of BP values above normal for cardiovascular mortality: a 24-year observation of Japanese aged 30 to 92 years J Epidemiol Meta-analyses using individual participant data from cardiovascular cohort studies in Japan: current status and future directions J Hypertens</note>
	<note type="raw_reference">Takashima N, Ohkubo T, Miura K, et al. Long-term risk of BP val- ues above normal for cardiovascular mortality: a 24-year obser- vation of Japanese aged 30 to 92 years. J Hypertens. 2012;30: 2299-306. S8.1.1-8. Murakami Y. Meta-analyses using individual participant data from cardiovascular cohort studies in Japan: current status and future directions. J Epidemiol. 2014;24:96-101. S8.1.1-9. van Dieren S, Kengne AP, Chalmers J, et al. Effects of blood pres- sure lowering on cardiovascular outcomes in different cardiovascu- lar risk groups among participants with type 2 diabetes. Diabetes Res Clin Pract. 2012;98:83-90. S8.1.1-10.</note>
</biblStruct>

<biblStruct xml:id="b181">
	<analytic>
		<title level="a" type="main" xml:id="_YJuE9bk">Blood Pressure Lowering Treatment Trialists&apos; Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sundstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Arima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodward</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(14)61212-5</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4vQhHJe">Lancet</title>
		<imprint>
			<biblScope unit="volume">384</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sundstrom J, Arima H, Woodward M, et al. Blood Pressure Lowering Treatment Trialists&apos; Collaboration. Blood pressure-low- ering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591-8. S8.1.1-11.</note>
</biblStruct>

<biblStruct xml:id="b182">
	<analytic>
		<title level="a" type="main" xml:id="_YN6BVuK">Effects of different blood pressurelowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials</title>
		<author>
			<persName><forename type="first">F</forename><surname>Turnbull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Algert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tuXCKjt">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure- lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed over- views of randomized trials. Arch Intern Med. 2005;165:1410-9. S8.1.1-12.</note>
</biblStruct>

<biblStruct xml:id="b183">
	<analytic>
		<title level="a" type="main" xml:id="_9SykCxa">Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Staessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Franklin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sBDUCPd">Hypertension</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1" to="13" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang JG, Staessen JA, Franklin SS, et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular out- come. Hypertension. 2005;45:907-13. S8.1.1-13.</note>
</biblStruct>

<biblStruct xml:id="b184">
	<analytic>
		<title level="a" type="main" xml:id="_KPbkKxW">Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials</title>
		<author>
			<persName><forename type="first">F</forename><surname>Turnbull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ugrFFjj">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Turnbull F, Woodward M, Neal B, et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29:2669-80. S8.1.1-14.</note>
</biblStruct>

<biblStruct xml:id="b185">
	<analytic>
		<title level="a" type="main" xml:id="_CWcAbN9">Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials</title>
		<author>
			<persName><forename type="first">F</forename><surname>Turnbull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ninomiya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gv3dDUT">BMJ</title>
		<imprint>
			<biblScope unit="volume">336</biblScope>
			<biblScope unit="page" from="1" to="15" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Turnbull F, Neal B, Ninomiya T, et al. Effects of different regi- mens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121-3. S8.1.1-15.</note>
</biblStruct>

<biblStruct xml:id="b186">
	<analytic>
		<title level="a" type="main" xml:id="_8Mxm5S2">Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study</title>
		<author>
			<persName><forename type="first">X</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ninomiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>De Galan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Ene456U">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1" to="16" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Du X, Ninomiya T, de Galan B, et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J. 2009;30:1128-35. S8.1.1-16.</note>
</biblStruct>

<biblStruct xml:id="b187">
	<analytic>
		<title level="a" type="main" xml:id="_AMMBsKx">Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Czernichow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ninomiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Huxley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SwYd3EF">Hypertension</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1" to="17" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Czernichow S, Ninomiya T, Huxley R, et al. Impact of blood pres- sure lowering on cardiovascular outcomes in normal weight, over- weight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial. Hypertension. 2010;55:1193-8. S8.1.1-17.</note>
</biblStruct>

<biblStruct xml:id="b188">
	<analytic>
		<title level="a" type="main" xml:id="_6nMFea8">Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Heerspink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ninomiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Perkovic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_t36kbgr">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1" to="18" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Heerspink HJ, Ninomiya T, Perkovic V, et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J. 2010;31:2888-96. S8.1.1-18.</note>
</biblStruct>

<biblStruct xml:id="b189">
	<analytic>
		<title level="a" type="main" xml:id="_GQRs3US">Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCEtrial</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ninomiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zoungas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jpPnwsb">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1" to="19" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ninomiya T, Zoungas S, Neal B, et al. Efficacy and safety of rou- tine blood pressure lowering in older patients with diabetes: results from the ADVANCEtrial. J Hypertens. 2010;28:1141-9. S8.1.1-19.</note>
</biblStruct>

<biblStruct xml:id="b190">
	<analytic>
		<title level="a" type="main" xml:id="_YyKxrEy">Impact of amlodipinebased therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Collier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Poulter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dahlof</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GRk3SY2">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1" to="20" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Collier DJ, Poulter NR, Dahlof B, et al. Impact of amlodipine- based therapy among older and younger patients in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). J Hypertens. 2011;29:583-91. S8.1.1-20.</note>
</biblStruct>

<biblStruct xml:id="b191">
	<analytic>
		<title level="a" type="main" xml:id="_7QddgD3">Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ninomiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Perkovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Turnbull</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_34nPdMT">BMJ</title>
		<imprint>
			<biblScope unit="volume">347</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1" to="21" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ninomiya T, Perkovic V, Turnbull F, et al. Blood pressure lower- ing and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled tri- als. BMJ. 2013;347:f5680. S8.1.1-21.</note>
</biblStruct>

<biblStruct xml:id="b192">
	<analytic>
		<title level="a" type="main" xml:id="_aBD7t4y">Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)</title>
		<author>
			<persName><forename type="first">J</forename><surname>Redon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mancia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sleight</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pSDFaPF">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="1" to="22" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Redon J, Mancia G, Sleight P, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in com- bination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74-83. S8.1.1-22.</note>
</biblStruct>

<biblStruct xml:id="b193">
	<analytic>
		<title level="a" type="main" xml:id="_S9kREWV">Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Ogden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lydick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RynAm4A">Hypertension</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1" to="23" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35:539-43. S8.1.1-23.</note>
</biblStruct>

<biblStruct xml:id="b194">
	<analytic>
		<title level="a" type="main" xml:id="_SkFUTpy">Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation</title>
		<author>
			<persName><forename type="first">J</forename><surname>Van Der Leeuw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Flj</forename><surname>Visseren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodward</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zgfY6YE">Hypertension</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="115" to="121" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">van der Leeuw J, Visseren FLJ, Woodward M, et al. Predicting the effects of blood pressure-lowering treatment on major car- diovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension. 2015;65:115-21.</note>
</biblStruct>

<biblStruct xml:id="b195">
	<analytic>
		<title level="a" type="main" xml:id="_Mh4WMek">Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies</title>
		<author>
			<persName><forename type="first">;</forename><surname>Bp Treatment</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Law</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Wald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AzJUKcM">BMJ</title>
		<imprint>
			<biblScope unit="volume">338</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="2" to="2" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>Threshold and the Use of CVD Risk Estimation to Guide Drug Treatment of Hypertension S8.1</note>
	<note type="raw_reference">BP Treatment Threshold and the Use of CVD Risk Estimation to Guide Drug Treatment of Hypertension S8.1.2-1. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospec- tive epidemiological studies. BMJ. 2009;338:b1665. S8.1.2-2.</note>
</biblStruct>

<biblStruct xml:id="b196">
	<analytic>
		<title level="a" type="main" xml:id="_rwzRXnx">Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Ettehad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Emdin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kiran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Hg5hMr5">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="2" to="3" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-67. S8.1.2-3.</note>
</biblStruct>

<biblStruct xml:id="b197">
	<analytic>
		<title level="a" type="main" xml:id="_Xxeg6j6">Blood Pressure Lowering Treatment Trialists&apos; Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sundstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Arima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodward</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FhupDvK">Lancet</title>
		<imprint>
			<biblScope unit="volume">384</biblScope>
			<biblScope unit="page" from="2" to="4" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sundstrom J, Arima H, Woodward M, et al. Blood Pressure Lowering Treatment Trialists&apos; Collaboration. Blood pressure-low- ering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591-8. S8.1.2-4.</note>
</biblStruct>

<biblStruct xml:id="b198">
	<analytic>
		<title level="a" type="main" xml:id="_jpqK2pt">Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levelsoverview and meta-analyses of randomized trials</title>
		<author>
			<persName><forename type="first">C</forename><surname>Thomopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Parati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zanchetti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7KUFZV4">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="2" to="5" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thomopoulos C, Parati G, Zanchetti A. Effects of blood pres- sure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels- overview and meta-analyses of randomized trials. J Hypertens. 2014;32:2296-304. S8.1.2-5.</note>
</biblStruct>

<biblStruct xml:id="b199">
	<analytic>
		<title level="a" type="main" xml:id="_jazbAXG">Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sundstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Arima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jackson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6wjsUev">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="page" from="2" to="6" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sundstrom J, Arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-anal- ysis. Ann Intern Med. 2015;162:184-91. S8.1.2-6.</note>
</biblStruct>

<biblStruct xml:id="b200">
	<analytic>
		<title level="a" type="main" xml:id="_7KB4xKm">Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Eshelbrenner</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2011.250</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GSMv8j2">JAMA</title>
		<imprint>
			<biblScope unit="volume">305</biblScope>
			<biblScope unit="page" from="2" to="7" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011;305:913-22. S8.1.2-7.</note>
</biblStruct>

<biblStruct xml:id="b201">
	<analytic>
		<title level="a" type="main" xml:id="_cTeb66Z">Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">X</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Atkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lv</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UbyTaCw">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="2" to="8" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2015;387:435-43. S8.1.2-8.</note>
</biblStruct>

<biblStruct xml:id="b202">
	<analytic>
		<title level="a" type="main" xml:id="_kWZN7Yt">A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wright</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Whelton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vDCQnva">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="2" to="9" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103-16. S8.1.2-9.</note>
</biblStruct>

<biblStruct xml:id="b203">
	<analytic>
		<title level="a" type="main" xml:id="_ftNMs3w">The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials</title>
		<author>
			<persName><forename type="first">S</forename><surname>Czernichow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zanchetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Turnbull</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_A4UUr3r">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="2" to="10" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Czernichow S, Zanchetti A, Turnbull F, et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011;29:4-16. S8.1.2-10.</note>
</biblStruct>

<biblStruct xml:id="b204">
	<analytic>
		<title level="a" type="main" xml:id="_UzDwfqU">Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lewington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Qizilbash</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WGa8btJ">Lancet</title>
		<imprint>
			<biblScope unit="volume">360</biblScope>
			<biblScope unit="page" from="2" to="11" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13. S8.1.2-11.</note>
</biblStruct>

<biblStruct xml:id="b205">
	<analytic>
		<title level="a" type="main" xml:id="_QNQ4SA2">Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes</title>
		<author>
			<persName><forename type="first">S</forename><surname>Van Dieren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Kengne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chalmers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UVC5pxe">Diabetes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="2" to="12" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">van Dieren S, Kengne AP, Chalmers J, et al. Effects of blood pres- sure lowering on cardiovascular outcomes in different cardiovascu- lar risk groups among participants with type 2 diabetes. Diabetes Res Clin Pract. 2012;98:83-90. S8.1.2-12.</note>
</biblStruct>

<biblStruct xml:id="b206">
	<analytic>
		<title level="a" type="main" xml:id="_9tbxmnb">The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Montgomery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fahey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ben-Shlomo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SDREaUE">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="2" to="13" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Montgomery AA, Fahey T, Ben-Shlomo Y, et al. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertens. 2003;21:1753-9. S8.1.2-13.</note>
</biblStruct>

<biblStruct xml:id="b207">
	<analytic>
		<title level="a" type="main" xml:id="_nTvUfnR">Treatment of high blood pressure and gain in event-free life expectancy</title>
		<author>
			<persName><forename type="first">B</forename><surname>Kassai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-P</forename><surname>Boissel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cucherat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SvdJRV7">Vasc Health Risk Manag</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="2" to="14" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kassai B, Boissel J-P, Cucherat M, et al. Treatment of high blood pressure and gain in event-free life expectancy. Vasc Health Risk Manag. 2005;1:163-9. S8.1.2-14.</note>
</biblStruct>

<biblStruct xml:id="b208">
	<analytic>
		<title level="a" type="main" xml:id="_Yz24wN9">ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">Lloyd</forename><forename type="middle">-</forename><surname>Goff Dc</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bennett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CqqqCQC">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="issue">suppl 2</biblScope>
			<biblScope unit="page" from="2" to="15" />
			<date type="published" when="2013">2013. 2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49-73. S8.1.2-15.</note>
</biblStruct>

<biblStruct xml:id="b209">
	<analytic>
		<title level="a" type="main" xml:id="_eCnXxAt">ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Lichtenstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WXpgXsa">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="issue">suppl 2</biblScope>
			<biblScope unit="page" from="1" to="45" />
			<date type="published" when="2013">2013. 2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce athero- sclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1-45.</note>
</biblStruct>

<biblStruct xml:id="b210">
	<monogr>
		<title level="m" type="main" xml:id="_w9QTK7T">Follow-Up After Initial BP Evaluation S8</title>
		<imprint>
			<biblScope unit="page" from="3" to="4" />
		</imprint>
	</monogr>
	<note type="raw_reference">Follow-Up After Initial BP Evaluation S8.1.3-1.</note>
</biblStruct>

<biblStruct xml:id="b211">
	<analytic>
		<title level="a" type="main" xml:id="_BEk8WVC">The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Ambrosius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Sink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Foy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FnTzQPN">Clin Trials</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="3" to="5" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11:532-46. S8.1.3-2.</note>
</biblStruct>

<biblStruct xml:id="b212">
	<analytic>
		<title level="a" type="main" xml:id="_Zp59Wr4">Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Cushman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Grimm</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Cutler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qP4U4yR">General Principles of Drug Therapy S</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="4" to="5" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>Am J Cardiol</note>
	<note type="raw_reference">Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:44i-55i. 8.1.4. General Principles of Drug Therapy S8.1.4-1.</note>
</biblStruct>

<biblStruct xml:id="b213">
	<analytic>
		<title level="a" type="main" xml:id="_s8ruhny">Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators</title>
		<author>
			<persName><forename type="first">S</forename><surname>Yusuf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Teo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pogue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZxCxjQw">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">358</biblScope>
			<biblScope unit="page" from="4" to="7" />
			<date type="published" when="2008">2008. 2012</date>
		</imprint>
	</monogr>
	<note>Cardiorenal end points in a trial of aliskiren for type 2 diabetes N Engl J Med</note>
	<note type="raw_reference">Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med. 2008;358:1547-59. S8.1.4-2. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204-13. S8.1.4-3.</note>
</biblStruct>

<biblStruct xml:id="b214">
	<analytic>
		<title level="a" type="main" xml:id="_DWXsWaq">Combined angiotensin inhibition for the treatment of diabetic nephropathy</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Fried</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Emanuele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vvjGRDk">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="4" to="4" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892-903. S8.1.4-4.</note>
</biblStruct>

<biblStruct xml:id="b215">
	<analytic>
		<title level="a" type="main" xml:id="_pQ7kq9q">the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Chobanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Bakris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Black</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GnVwEZ5">Hypertension</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1206" to="1252" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chobanian AV, Bakris GL, Black HR, et al. the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52.</note>
</biblStruct>

<biblStruct xml:id="b216">
	<monogr>
		<title level="m" type="main" xml:id="_RVcWR7M">BP Goal for Patients With Hypertension S8</title>
		<imprint>
			<biblScope unit="page" from="5" to="6" />
		</imprint>
	</monogr>
	<note type="raw_reference">1.5. BP Goal for Patients With Hypertension S8.1.5-1.</note>
</biblStruct>

<biblStruct xml:id="b217">
	<analytic>
		<title level="a" type="main" xml:id="_y2byUre">Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels -updated overview and meta-analyses of randomized trials</title>
		<author>
			<persName><forename type="first">C</forename><surname>Thomopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Parati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zanchetti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FB25vWM">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="5" to="7" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels -updated overview and meta-analyses of ran- domized trials. J Hypertens. 2016;34:613-22. S8.1.5-2.</note>
</biblStruct>

<biblStruct xml:id="b218">
	<analytic>
		<title level="a" type="main" xml:id="_Aea2Dx2">Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">X</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Atkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lv</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cCArBGD">Hypertension</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="5" to="5" />
			<date type="published" when="2015">2015. 2016. 2017</date>
		</imprint>
	</monogr>
	<note>More versus less intensive blood pressure-lowering strategy: cumulative evidence and trial sequential analysis Lancet Optimal systolic blood pressure target after SPRINT insights from a network meta-analysis of randomized trials Am J Med</note>
	<note type="raw_reference">Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2015;387:435-43. S8.1.5-3. Verdecchia P, Angeli F, Gentile G, et al. More versus less intensive blood pressure-lowering strategy: cumulative evidence and trial sequential analysis. Hypertension. 2016;68:642-53. S8.1.5-4. Bangalore S, Toklu B, Gianos E, et al. Optimal systolic blood pres- sure target after SPRINT insights from a network meta-analysis of randomized trials. Am J Med. 2017;30:707-19.e8. S8.1.5-5.</note>
</biblStruct>

<biblStruct xml:id="b219">
	<analytic>
		<title level="a" type="main" xml:id="_Ghh3fPT">Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Bundy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stuchlik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DbsFcZp">JAMA Cardiol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="5" to="6" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduc- tion and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775-81. S8.1.5-6.</note>
</biblStruct>

<biblStruct xml:id="b220">
	<analytic>
		<title level="a" type="main" xml:id="_58VKc7T">Feasibility of treating prehypertension with an angiotensin-receptor blocker</title>
		<author>
			<persName><forename type="first">S</forename><surname>Julius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Nesbitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Egan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HhqP8P8">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<biblScope unit="page" from="5" to="7" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating pre- hypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685-97. S8.1.5-7.</note>
</biblStruct>

<biblStruct xml:id="b221">
	<analytic>
		<title level="a" type="main" xml:id="_Y3RWvxy">Blood pressure and coronary heart disease: a review of the evidence</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Lawes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lewington</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5ES7paC">Semin Vasc Med</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="5" to="8" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lawes CM, Bennett DA, Lewington S, et al. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med. 2002;2:355-68. S8.1.5-8.</note>
</biblStruct>

<biblStruct xml:id="b222">
	<analytic>
		<title level="a" type="main" xml:id="_yHfgJaE">Blood-pressure lowering in intermediate-risk persons without cardiovascular disease</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Lonn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lopez-Jaramillo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_s4DsV6X">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="page" from="5" to="9" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-pressure low- ering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009-20. S8.1.5-9.</note>
</biblStruct>

<biblStruct xml:id="b223">
	<analytic>
		<title level="a" type="main" xml:id="_JxCMq76">Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Neaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grimm</forename><surname>Rhjr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Prineas</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.1993.03510060059034</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2P3cDFm">JAMA</title>
		<imprint>
			<biblScope unit="volume">270</biblScope>
			<biblScope unit="page" from="713" to="724" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Neaton JD, Grimm RHJr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270:713-24.</note>
</biblStruct>

<biblStruct xml:id="b224">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6c74M8z">Choice of Initial Medication S</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="6" to="7" />
		</imprint>
	</monogr>
	<note type="raw_reference">1.6. Choice of Initial Medication S8.1.6-1.</note>
</biblStruct>

<biblStruct xml:id="b225">
	<analytic>
		<title level="a" type="main" xml:id="_cdGt9Pp">Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Reboussin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Griswold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fhk8Mjt">Hypertension</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="2534" to="2544" />
			<date type="published" when="2003">2018. 2003</date>
		</imprint>
	</monogr>
	<note>Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis JAMA</note>
	<note type="raw_reference">Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e116-e135. S8.1.6-2. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes asso- ciated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534-44.</note>
</biblStruct>

<biblStruct xml:id="b226">
	<monogr>
		<title level="m" type="main" xml:id="_T4FB53Q">Follow-Up of BP During Antihypertensive Drug Therapy S</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="2" to="3" />
		</imprint>
	</monogr>
	<note type="raw_reference">2. Follow-Up of BP During Antihypertensive Drug Therapy S8.2-1.</note>
</biblStruct>

<biblStruct xml:id="b227">
	<analytic>
		<title level="a" type="main" xml:id="_b6uPVVj">The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Ambrosius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Sink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Foy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_eammswC">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="44" to="55" />
			<date type="published" when="2007">2014. 2007</date>
		</imprint>
	</monogr>
	<note>Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial Clin Trials</note>
	<note type="raw_reference">Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11:532-46. S8.2-2. Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:44i-55i.</note>
</biblStruct>

<biblStruct xml:id="b228">
	<monogr>
		<title level="m" type="main" xml:id="_NhwGW2S">Follow-Up After Initiating Antihypertensive Drug Therapy S</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1" to="1" />
		</imprint>
	</monogr>
	<note type="raw_reference">Follow-Up After Initiating Antihypertensive Drug Therapy S8.2.1-1.</note>
</biblStruct>

<biblStruct xml:id="b229">
	<analytic>
		<title level="a" type="main" xml:id="_kHM7nAP">The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Ambrosius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Sink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Foy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cvSU3v5">Clin Trials</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1" to="2" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11:532-46. S8.2.1-2.</note>
</biblStruct>

<biblStruct xml:id="b230">
	<analytic>
		<title level="a" type="main" xml:id="_ebu4EeN">Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Cushman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Grimm</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Cutler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fm2bxvb">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="1" to="3" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:44i-55i. S8.2.1-3.</note>
</biblStruct>

<biblStruct xml:id="b231">
	<analytic>
		<title level="a" type="main" xml:id="_CtNDbqN">Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study</title>
		<author>
			<persName><forename type="first">W</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Goldberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shubina</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NwkyuPf">BMJ</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page">158</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Xu W, Goldberg SI, Shubina M, et al. Optimal systolic blood pres- sure target, time to intensification, and time to follow-up in treat- ment of hypertension: population based retrospective cohort study. BMJ. 2015;350:h158.</note>
</biblStruct>

<biblStruct xml:id="b232">
	<monogr>
		<title level="m" type="main" xml:id="_8sRgDDR">Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP S8</title>
		<imprint>
			<biblScope unit="page" from="2" to="3" />
		</imprint>
	</monogr>
	<note type="raw_reference">2.2. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP S8.2.2-1.</note>
</biblStruct>

<biblStruct xml:id="b233">
	<analytic>
		<title level="a" type="main" xml:id="_NkzP8hB">Disease management to promote blood pressure control among African Americans</title>
		<author>
			<persName><forename type="first">T</forename><surname>Brennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Spettell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Villagra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sgmQTT5">Popul Health Manag</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="2" to="2" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brennan T, Spettell C, Villagra V, et al. Disease management to promote blood pressure control among African Americans. Popul Health Manag. 2010;13:65-72. S8.2.2-2.</note>
</biblStruct>

<biblStruct xml:id="b234">
	<analytic>
		<title level="a" type="main" xml:id="_QP6zYtM">Two self-management interventions to improve hypertension control: a randomized trial</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Bosworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Olsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Grubber</surname></persName>
		</author>
		<idno type="DOI">10.7326/0000605-200911170-00148</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_t4SqWje">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="page" from="2" to="3" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bosworth HB, Olsen MK, Grubber JM, et al. Two self-manage- ment interventions to improve hypertension control: a randomized trial. Ann Intern Med. 2009;151:687-95. S8.2.2-3.</note>
</biblStruct>

<biblStruct xml:id="b235">
	<analytic>
		<title level="a" type="main" xml:id="_q47G27q">Home blood pressure management and improved blood pressure control: results from a randomized controlled trial</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Bosworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Powers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Olsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_dXes6YG">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">171</biblScope>
			<biblScope unit="page" from="2" to="4" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bosworth HB, Powers BJ, Olsen MK, et al. Home blood pressure management and improved blood pressure control: results from a randomized controlled trial. Arch Intern Med. 2011;171:1173-80. S8.2.2-4.</note>
</biblStruct>

<biblStruct xml:id="b236">
	<analytic>
		<title level="a" type="main" xml:id="_8wHDqtd">Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Ralston</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_55zVZG4">JAMA</title>
		<imprint>
			<biblScope unit="volume">299</biblScope>
			<biblScope unit="page" from="2" to="5" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Green BB, Cook AJ, Ralston JD, et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA. 2008;299:2857-67. S8.2.2-5.</note>
</biblStruct>

<biblStruct xml:id="b237">
	<analytic>
		<title level="a" type="main" xml:id="_2VrXgZx">Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster randomized, controlled pragmatic trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Heisler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Hofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Schmittdiel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5aFCfG8">Circulation</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="2863" to="2872" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Heisler M, Hofer TP, Schmittdiel JA, et al. Improving blood pres- sure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster random- ized, controlled pragmatic trial. Circulation. 2012;125:2863-72.</note>
</biblStruct>

<biblStruct xml:id="b238">
	<analytic>
		<title/>
		<idno type="DOI">10.7717/peerj.3277/supp-15</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5djC6fu">S</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="2" to="6" />
		</imprint>
	</monogr>
	<note type="raw_reference">S8.2.2-6.</note>
</biblStruct>

<biblStruct xml:id="b239">
	<analytic>
		<title level="a" type="main" xml:id="_j7Fjysc">Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Margolis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Asche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Bergdall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RyjxEJ9">JAMA</title>
		<imprint>
			<biblScope unit="volume">310</biblScope>
			<biblScope unit="page" from="46" to="56" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pres- sure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310:46-56.</note>
</biblStruct>

<biblStruct xml:id="b240">
	<monogr>
		<title level="m" type="main" xml:id="_7Hzubug">Hypertension in Patients With Comorbidities S9-1</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">Hypertension in Patients With Comorbidities S9-1.</note>
</biblStruct>

<biblStruct xml:id="b241">
	<analytic>
		<title level="a" type="main" xml:id="_xqQMxN9">ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Aronow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Fleg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Pepine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RFaWUcd">American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="2434" to="2506" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>Circulation</note>
	<note type="raw_reference">Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. Circulation. 2011;123:2434-506.</note>
</biblStruct>

<biblStruct xml:id="b242">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<imprint>
			<biblScope unit="page" from="9" to="11" />
		</imprint>
	</monogr>
	<note type="raw_reference">S9-2.</note>
</biblStruct>

<biblStruct xml:id="b243">
	<analytic>
		<title level="a" type="main" xml:id="_p7dFG4q">ACC/AHA/ AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Yancy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jessup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bozkurt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rp2EeUT">Circulation</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="9" to="13" />
			<date type="published" when="2013">2013. 2013. 2014. 2014</date>
		</imprint>
	</monogr>
	<note>ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation</note>
	<note type="raw_reference">Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-327. S9-3. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/ AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749-67. S9-4.</note>
</biblStruct>

<biblStruct xml:id="b244">
	<analytic>
		<title level="a" type="main" xml:id="_c2S85xh">AHA/ ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</title>
		<author>
			<persName><forename type="first">Gerhard-Herman Md</forename><surname>Gornik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<idno type="DOI">10.1161/cir.0000000000000502</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VQMEMjx">Circulation</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="726" to="779" />
			<date type="published" when="2016">2016. 2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ ACC guideline on the management of patients with lower extrem- ity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726-79.</note>
</biblStruct>

<biblStruct xml:id="b245">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bVwPjQx">Stable Ischemic Heart Disease S</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="1" to="1" />
		</imprint>
	</monogr>
	<note type="raw_reference">1. Stable Ischemic Heart Disease S9.1-1.</note>
</biblStruct>

<biblStruct xml:id="b246">
	<analytic>
		<title level="a" type="main" xml:id="_CNwKATu">A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wright</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Whelton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4qfRAct">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="1" to="2" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103-16. S9.1-2.</note>
</biblStruct>

<biblStruct xml:id="b247">
	<analytic>
		<title level="a" type="main" xml:id="_6q6nbcF">Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Bundy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stuchlik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7HbVxz3">JAMA Cardiol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1" to="4" />
			<date type="published" when="2006">2017. 2006</date>
		</imprint>
	</monogr>
	<note>Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis Hypertension</note>
	<note type="raw_reference">Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduc- tion and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775-81. S9.1-3. Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48:374-84. S9.1-4.</note>
</biblStruct>

<biblStruct xml:id="b248">
	<analytic>
		<title level="a" type="main" xml:id="_7PKzpXE">Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alphablocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Zanchetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Julius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kjeldsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VsNBvnk">Hypertension</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1" to="6" />
			<date type="published" when="2003">2006. 2003</date>
		</imprint>
	</monogr>
	<note>Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial J Hypertens</note>
	<note type="raw_reference">Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163-8. S9.1-5. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha- blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239-46. S9.1-6.</note>
</biblStruct>

<biblStruct xml:id="b249">
	<analytic>
		<title level="a" type="main" xml:id="_WTKHAv9">ACC/AHA/AATS/ PCNA/SCAI/STS focused update of the Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Fihn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Blankenship</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Alexander</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yADbfub">Circulation</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1" to="9" />
			<date type="published" when="2003">2014. 2014. 2003. 2009</date>
		</imprint>
	</monogr>
	<note>EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of June 2018 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ</note>
	<note type="raw_reference">Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/ PCNA/SCAI/STS focused update of the Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749-67. S9.1-7. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-con- trolled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-8. S9.1-8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of June 2018 147 randomised trials in the context of expectations from prospec- tive epidemiological studies. BMJ. 2009;338:b1665. S9.1-9.</note>
</biblStruct>

<biblStruct xml:id="b250">
	<analytic>
		<title level="a" type="main" xml:id="_SuHkP9m">Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Pfeffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Braunwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Moye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PZVguU6">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">327</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunc- tion after myocardial infarction. Results of the survival and ven- tricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-77. S9.1-10.</note>
</biblStruct>

<biblStruct xml:id="b251">
	<analytic>
		<title level="a" type="main" xml:id="_7RZ9rxC">Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients. The Heart Outcomes Prevention Evaluation Study Investigators</title>
		<author>
			<persName><forename type="first">S</forename><surname>Yusuf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sleight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pogue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mw5VjFw">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">342</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-convert- ing-enzyme inhibitor, ramipril, on cardiovascular events in high- risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53. S9.1-11.</note>
</biblStruct>

<biblStruct xml:id="b252">
	<analytic>
		<title level="a" type="main" xml:id="_aAP5xNn">Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Leon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Rosing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Bonow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mXCMYbA">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Leon MB, Rosing DR, Bonow RO, et al. Clinical efficacy of verapamil alone and combined with propranolol in treat- ing patients with chronic stable angina pectoris. Am J Cardiol. 1981;48:131-9. S9.1-12.</note>
</biblStruct>

<biblStruct xml:id="b253">
	<analytic>
		<title level="a" type="main" xml:id="_wkPWjmr">Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Staessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fagard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Thijs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_K9BAuna">Lancet</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page" from="1" to="13" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757-64. S9.1-13.</note>
</biblStruct>

<biblStruct xml:id="b254">
	<analytic>
		<title level="a" type="main" xml:id="_85cGjbx">beta Blockade after myocardial infarction: systematic review and meta regression analysis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Freemantle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cleland</forename><forename type="middle">J</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zKvQ3pt">BMJ</title>
		<imprint>
			<biblScope unit="volume">318</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Freemantle N, Cleland J, Young P, et al. beta Blockade after myo- cardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-7. S9.1-14.</note>
</biblStruct>

<biblStruct xml:id="b255">
	<analytic>
		<title level="a" type="main" xml:id="_Mh472XA">Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels -updated overview and meta-analyses of randomized trials</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">R</forename><surname>De Peuter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lussana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rjg</forename><surname>Peters</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_F9ZHMr7">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="2" to="3" />
			<date type="published" when="2009">2009. 2013. 2016</date>
		</imprint>
	</monogr>
	<note>Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis CMAJ A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure Neth J Med</note>
	<note type="raw_reference">de Peuter OR, Lussana F, Peters RJG, et al. A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure. Neth J Med. 2009;67:284-94. 9.2. Heart Failure S9.2-1. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pres- sure lowering on the progression of chronic kidney disease: a sys- tematic review and meta-analysis. CMAJ. 2013;185:949-57. S9.2-2. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels -updated overview and meta-analyses of ran- domized trials. J Hypertens. 2016;34:613-22. S9.2-3.</note>
</biblStruct>

<biblStruct xml:id="b256">
	<analytic>
		<title level="a" type="main" xml:id="_5tFGdC4">Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">X</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Atkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lv</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MVNMtp2">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="435" to="443" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2015;387:435-43.</note>
</biblStruct>

<biblStruct xml:id="b257">
	<monogr>
		<title level="m" type="main" xml:id="_rDfybU7">Heart Failure With Reduced Ejection Fraction S9</title>
		<imprint>
			<biblScope unit="page" from="1" to="1" />
		</imprint>
	</monogr>
	<note>2.1</note>
	<note type="raw_reference">2.1. Heart Failure With Reduced Ejection Fraction S9.2.1-1.</note>
</biblStruct>

<biblStruct xml:id="b258">
	<analytic>
		<title level="a" type="main" xml:id="_krgWFZD">Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Goldstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Boccuzzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cruess</surname></persName>
		</author>
		<idno type="DOI">10.1161/01.cir.83.1.52</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FThPPyT">Circulation</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="52" to="60" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83:52-60.</note>
</biblStruct>

<biblStruct xml:id="b259">
	<monogr>
		<title level="m" type="main" xml:id="_p7uqfp8">Heart Failure With Preserved Ejection Fraction S9</title>
		<idno type="DOI">10.1093/med/9780198784906.003.0435_update_001</idno>
		<imprint>
			<biblScope unit="page" from="2" to="3" />
		</imprint>
	</monogr>
	<note>2.2</note>
	<note type="raw_reference">2.2. Heart Failure With Preserved Ejection Fraction S9.2.2-1.</note>
</biblStruct>

<biblStruct xml:id="b260">
	<analytic>
		<title level="a" type="main" xml:id="_SwwBNV4">Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Pfeffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Claggett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Assmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_54fnF66">Circulation</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="2" to="2" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation. 2015;131:34-42. S9.2.2-2.</note>
</biblStruct>

<biblStruct xml:id="b261">
	<analytic>
		<title level="a" type="main" xml:id="_ReaPuGM">Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Yancy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jessup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bozkurt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uTUmCG6">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="2" to="4" />
			<date type="published" when="1997">2013. 2013. 1997</date>
		</imprint>
	</monogr>
	<note>ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation</note>
	<note type="raw_reference">Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-327. S9.2.2-3. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol. 1997;80:207-9. S9.2.2-4.</note>
</biblStruct>

<biblStruct xml:id="b262">
	<analytic>
		<title level="a" type="main" xml:id="_gmXyZBj">Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure)</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Van Veldhuisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cohen-Solal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bohm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gRVKTZ9">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="2" to="5" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009;53:2150-8. S9.2.2-5.</note>
</biblStruct>

<biblStruct xml:id="b263">
	<analytic>
		<title level="a" type="main" xml:id="_eaj3FYy">Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Yusuf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Pfeffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Swedberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JfyFaqe">Lancet</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="page" from="2" to="6" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ven- tricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-81. S9.2.2-6.</note>
</biblStruct>

<biblStruct xml:id="b264">
	<analytic>
		<title level="a" type="main" xml:id="_TCetFx3">Irbesartan in patients with heart failure and preserved ejection fraction</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Massie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Carson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Mcmurray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gDqYJGj">Chronic Kidney Disease S</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="3" to="4" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>N Engl J Med</note>
	<note type="raw_reference">Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-67. 9.3. Chronic Kidney Disease S9.3-1.</note>
</biblStruct>

<biblStruct xml:id="b265">
	<analytic>
		<title level="a" type="main" xml:id="_a5MUMV3">The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group</title>
		<author>
			<persName><forename type="first">S</forename><surname>Klahr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Levey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Beck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wtMEYpQ">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">330</biblScope>
			<biblScope unit="page" from="3" to="5" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877-84. S9.3-2.</note>
</biblStruct>

<biblStruct xml:id="b266">
	<analytic>
		<title level="a" type="main" xml:id="_eBQMnGK">Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ruggenenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Perna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Loriga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Gn3S9hS">Lancet</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="page" from="3" to="3" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal dis- ease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939-46. S9.3-3.</note>
</biblStruct>

<biblStruct xml:id="b267">
	<analytic>
		<title level="a" type="main" xml:id="_eN2uAHC">Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wright</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bakris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Greene</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4GWpKac">JAMA</title>
		<imprint>
			<biblScope unit="volume">288</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="3" to="4" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pres- sure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-31. S9.3-4.</note>
</biblStruct>

<biblStruct xml:id="b268">
	<analytic>
		<title level="a" type="main" xml:id="_WAPcmsw">Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level metaanalysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Upadhyay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Earley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Haynes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VzdgxK6">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="page" from="3" to="9" />
			<date type="published" when="2003">2011. 2013. 2003. 2008. 2010</date>
		</imprint>
	</monogr>
	<note>Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier CMAJ Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis Ann Intern Med Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality Am J Epidemiol Comparison of different measures of urinary protein excretion for prediction of renal events Ann Intern Med</note>
	<note type="raw_reference">Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541-8. S9.3-5. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pres- sure lowering on the progression of chronic kidney disease: a sys- tematic review and meta-analysis. CMAJ. 2013;185:949-57. S9.3-6. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kid- ney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta- analysis. Ann Intern Med. 2003;139:244-52. S9.3-7. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, et al. Albuminuria assessed from first-morning-void urine samples ver- sus 24-hour urine collections as a predictor of cardiovascular mor- bidity and mortality. Am J Epidemiol. 2008;168:897-905. S9.3-8. Lambers Heerspink HJ, Gansevoort RT, Brenner BM, et al. Comparison of different measures of urinary protein excre- tion for prediction of renal events. J Am Soc Nephrol. 2010;21: 1355-60. S9.3-9.</note>
</biblStruct>

<biblStruct xml:id="b269">
	<analytic>
		<title level="a" type="main" xml:id="_J3UGQYk">Blood pressure control, drug therapy, and kidney disease</title>
		<author>
			<persName><forename type="first">G</forename><surname>Contreras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Greene</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Y</forename><surname>Agodoa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nWP5fCE">Hypertension</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="3" to="10" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Contreras G, Greene T, Agodoa LY, et al. Blood pressure control, drug therapy, and kidney disease. Hypertension. 2005;46:44-50. S9.3-10.</note>
</biblStruct>

<biblStruct xml:id="b270">
	<analytic>
		<title level="a" type="main" xml:id="_kEFMnNF">The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">L</forename><surname>Esnault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Apetrei</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.clinthera.2008.03.006</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7cuhbRG">Clin Ther</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="3" to="11" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Esnault VL, Brown EA, Apetrei E, et al. The effects of amlodip- ine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther. 2008;30: 482-98. S9.3-11.</note>
</biblStruct>

<biblStruct xml:id="b271">
	<analytic>
		<title level="a" type="main" xml:id="_TMb6N4x">A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease</title>
		<author>
			<persName><forename type="first">R</forename><surname>Marin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Ruilope</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Aljama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XC24G2w">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="3" to="12" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Marin R, Ruilope LM, Aljama P, et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal dis- ease. J Hypertens. 2001;19:1871-6. S9.3-12.</note>
</biblStruct>

<biblStruct xml:id="b272">
	<analytic>
		<title level="a" type="main" xml:id="_jHA3y8C">Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group</title>
		<author>
			<persName><forename type="first">I</forename><surname>Giatras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Levey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Mbzre7j">Hypertension After Renal Transplantation S</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="1" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>Ann Intern Med</note>
	<note type="raw_reference">Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting- Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med. 1997;127:337-45. 9.3.1. Hypertension After Renal Transplantation S9.3.1-1.</note>
</biblStruct>

<biblStruct xml:id="b273">
	<analytic>
		<title level="a" type="main" xml:id="_mYpqqUu">A randomized trial of intensive versus standard blood-pressure control</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wright</surname><genName>Jr</genName></persName>
			<affiliation>
				<orgName type="collaboration">SPRINT Research Group</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Williamson</surname></persName>
			<affiliation>
				<orgName type="collaboration">SPRINT Research Group</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Whelton</surname></persName>
			<affiliation>
				<orgName type="collaboration">SPRINT Research Group</orgName>
			</affiliation>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PfGsN6f">Acute Intracerebral Hemorrhage S9</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1" to="1" />
			<date type="published" when="2009">2015. 2009</date>
		</imprint>
	</monogr>
	<note>Antihypertensive treatment for kidney transplant recipients N Engl J Med Cerebrovascular Disease 9.4.1 Cochrane Database Syst Rev</note>
	<note type="raw_reference">Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103-16. S9.3.1-2. Cross NB, Webster AC, Masson P, et al. Antihypertensive treat- ment for kidney transplant recipients. Cochrane Database Syst Rev. 2009:CD003598. 9.4. Cerebrovascular Disease 9.4.1. Acute Intracerebral Hemorrhage S9.4.1-1.</note>
</biblStruct>

<biblStruct xml:id="b274">
	<analytic>
		<title level="a" type="main" xml:id="_xVfMFRp">Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Heeley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa1214609</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Bf5UKZe">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="1" to="2" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355-65. S9.4.1-2.</note>
</biblStruct>

<biblStruct xml:id="b275">
	<analytic>
		<title level="a" type="main" xml:id="_uSfZErn">rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Qureshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Y</forename><surname>Palesch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Barsan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sVWNRY4">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="2" to="2" />
			<date type="published" when="1995">2016. 1995</date>
		</imprint>
		<respStmt>
			<orgName>National Institute of Neurological Disorders and Stroke</orgName>
		</respStmt>
	</monogr>
	<note>Acute Ischemic Stroke S9.4.2-1 Intensive blood-pressure lowering in patients with acute cerebral hemorrhage N Engl J Med</note>
	<note type="raw_reference">Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pres- sure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375:1033-43. 9.4.2. Acute Ischemic Stroke S9.4.2-1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute isch- emic stroke. N Engl J Med. 1995;333:1581-7. S9.4.2-2.</note>
</biblStruct>

<biblStruct xml:id="b276">
	<analytic>
		<title level="a" type="main" xml:id="_FwQr3S4">Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke</title>
		<author>
			<persName><forename type="first">W</forename><surname>Hacke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kaste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bluhmki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rhaEc8q">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope unit="page" from="2" to="3" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-29. S9.4.2-3.</note>
</biblStruct>

<biblStruct xml:id="b277">
	<analytic>
		<title level="a" type="main" xml:id="_9FkVrS6">Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR)</title>
		<author>
			<persName><forename type="first">N</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Wahlgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brainin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gYXVXzA">Stroke</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="2" to="4" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ahmed N, Wahlgren N, Brainin M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke- International Stroke Thrombolysis Register (SITS-ISTR). Stroke. 2009;40:2442-9. S9.4.2-4.</note>
</biblStruct>

<biblStruct xml:id="b278">
	<analytic>
		<title level="a" type="main" xml:id="_6pB2GaT">Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Potter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Ford</surname></persName>
		</author>
		<idno type="DOI">10.1016/s1474-4422(10)70163-0</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_McuHvYe">Lancet Neurol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="2" to="5" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Robinson TG, Potter JF, Ford GA, et al. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospec- tive, randomised, open, blinded-endpoint trial. Lancet Neurol. 2010;9:767-75. S9.4.2-5.</note>
</biblStruct>

<biblStruct xml:id="b279">
	<analytic>
		<title level="a" type="main" xml:id="_4kCNmAY">Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xuXFvqz">JAMA</title>
		<imprint>
			<biblScope unit="volume">311</biblScope>
			<biblScope unit="page" from="2" to="6" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">He J, Zhang Y, Xu T, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014;311:479-89. S9.4.2-6.</note>
</biblStruct>

<biblStruct xml:id="b280">
	<analytic>
		<title level="a" type="main" xml:id="_zfF4D9A">Effects of early blood pressure lowering on early and long-term outcomes after acute stroke: an updated meta-analysis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Rong</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0097917</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Tu73FW7">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="2" to="7" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang H, Tang Y, Rong X, et al. Effects of early blood pressure lowering on early and long-term outcomes after acute stroke: an updated meta-analysis. PLoS ONE. 2014;9:e97917. S9.4.2-7.</note>
</biblStruct>

<biblStruct xml:id="b281">
	<analytic>
		<title level="a" type="main" xml:id="_yXp9gY2">Blood pressure reduction in the acute phase of an ischemic stroke does not improve short-or longterm dependency or mortality: a meta-analysis of current literature</title>
		<author>
			<persName><forename type="first">R</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F-D</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_akdqskc">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="741" to="750" />
			<date type="published" when="2011">2015. 2014. 2011</date>
			<pubPlace>Baltimore)</pubPlace>
		</imprint>
	</monogr>
	<note>Interventions for deliberately altering blood pressure in acute stroke Medicine The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial Lancet</note>
	<note type="raw_reference">Zhao R, Liu F-D, Wang S, et al. Blood pressure reduction in the acute phase of an ischemic stroke does not improve short-or long- term dependency or mortality: a meta-analysis of current literature. Medicine (Baltimore). 2015;94:e896. S9.4.2-8. Bath PM, Krishnan K. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev. 2014;10:CD000039. S9.4.2-9. Sandset EC, Bath PMW, Boysen G, et al. The angiotensin-recep- tor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011;377:741-50.</note>
</biblStruct>

<biblStruct xml:id="b282">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bH9fxG3">Secondary Stroke Prevention S9</title>
		<imprint>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="3" to="4" />
		</imprint>
	</monogr>
	<note type="raw_reference">9.4.3. Secondary Stroke Prevention S9.4.3-1.</note>
</biblStruct>

<biblStruct xml:id="b283">
	<analytic>
		<title level="a" type="main" xml:id="_M3GanxN">Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6 105 individuals with previous stroke or transient ischaemic attack</title>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_teWJrxT">Hypertens Res</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="3" to="5" />
			<date type="published" when="1995">2009. 2009. 2001. 1995</date>
		</imprint>
		<respStmt>
			<orgName>PROGRESS Collaborative Group ; PATS Collaborating Group</orgName>
		</respStmt>
	</monogr>
	<note>Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis Int Arch Med Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature Lancet . Post-stroke antihypertensive treatment study. A preliminary result Chin Med J</note>
	<note type="raw_reference">Liu L, Wang Z, Gong L, et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res. 2009;32:1032-40. S9.4.3-2. Lakhan SE, Sapko MT. Blood pressure lowering treatment for pre- venting stroke recurrence: a systematic review and meta-analysis. Int Arch Med. 2009;2:30. S9.4.3-3. PROGRESS Collaborative Group. Randomised trial of a perin- dopril-based blood-pressure-lowering regimen among 6 105 indi- viduals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41. S9.4.3-4. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J. 1995;108:710-7. S9.4.3-5.</note>
</biblStruct>

<biblStruct xml:id="b284">
	<analytic>
		<title level="a" type="main" xml:id="_j5uTWGy">Renin-angiotensin system modulators modestly reduce vascular risk in persons with prior stroke</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Saver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K-S</forename><surname>Hong</surname></persName>
		</author>
		<idno type="DOI">10.1161/strokeaha.111.632596</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_z4x79FG">Stroke</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="3" to="6" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lee M, Saver JL, Hong K-S, et al. Renin-angiotensin system modu- lators modestly reduce vascular risk in persons with prior stroke. Stroke. 2012;43:113-9. S9.4.3-6.</note>
</biblStruct>

<biblStruct xml:id="b285">
	<analytic>
		<title level="a" type="main" xml:id="_bTUgYzX">Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke: traditional and Bayesian network meta-analysis of randomized trials</title>
		<author>
			<persName><forename type="first">W-T</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L-K</forename><surname>You</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C-E</forename><surname>Chiang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xWRxh9G">Medicine</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="3" to="7" />
			<date type="published" when="2016">2016</date>
			<pubPlace>Baltimore)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang W-T, You L-K, Chiang C-E, et al. Comparative effectiveness of blood pressure-lowering drugs in patients who have already suf- fered from stroke: traditional and Bayesian network meta-analysis of randomized trials. Medicine (Baltimore). 2016;95:e3302. S9.4.3-7.</note>
</biblStruct>

<biblStruct xml:id="b286">
	<analytic>
		<title level="a" type="main" xml:id="_Zgg9TzX">Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Katsanos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Filippatou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Manios</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HCRhp4e">Hypertension</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="3" to="8" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Katsanos AH, Filippatou A, Manios E, et al. Blood pressure reduc- tion and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. Hypertension. 2017;69:171-9. S9.4.3-8.</note>
</biblStruct>

<biblStruct xml:id="b287">
	<analytic>
		<title level="a" type="main" xml:id="_eFDUaK9">Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">R</forename><surname>Benavente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Coffey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Conwit</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wQfvynj">Lancet</title>
		<imprint>
			<biblScope unit="volume">382</biblScope>
			<biblScope unit="page" from="3" to="9" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Benavente OR, Coffey CS, Conwit R, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507-15. S9.4.3-9.</note>
</biblStruct>

<biblStruct xml:id="b288">
	<analytic>
		<title level="a" type="main" xml:id="_YXgNSPB">Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial</title>
		<author>
			<persName><forename type="first">H</forename><surname>Arima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chalmers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodward</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wqETu2n">Peripheral Artery Disease S</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="5" to="6" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>J Hypertens</note>
	<note type="raw_reference">Arima H, Chalmers J, Woodward M, et al. Lower target blood pres- sures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:1201-8. 9.5. Peripheral Artery Disease S9.5-1.</note>
</biblStruct>

<biblStruct xml:id="b289">
	<analytic>
		<title level="a" type="main" xml:id="_k6hkCSA">Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ostergren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sleight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dagenais</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_W46rtcC">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="5" to="7" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25:17-24. S9.5-2.</note>
</biblStruct>

<biblStruct xml:id="b290">
	<analytic>
		<title level="a" type="main" xml:id="_YMP8JQR">Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Eshelbrenner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_k7ReAnk">Diabetes Mellitus S</title>
		<imprint>
			<biblScope unit="volume">305</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="6" to="7" />
			<date type="published" when="2006">2011. 2010. 2006</date>
		</imprint>
	</monogr>
	<note>Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis JAMA Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial J Hypertens Hypertension</note>
	<note type="raw_reference">Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011;305:913-22. S9.5-3. Bavry AA, Anderson RD, Gong Y, et al. Outcomes among hyperten- sive patients with concomitant peripheral and coronary artery dis- ease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55:48-53. S9.5-4. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163-8. 9.6. Diabetes Mellitus S9.6-1.</note>
</biblStruct>

<biblStruct xml:id="b291">
	<analytic>
		<title level="a" type="main" xml:id="_YhdyWeg">Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Emdin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rahimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yQYaGgd">JAMA</title>
		<imprint>
			<biblScope unit="volume">313</biblScope>
			<biblScope unit="page" from="6" to="8" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603-15. S9.6-2.</note>
</biblStruct>

<biblStruct xml:id="b292">
	<analytic>
		<title level="a" type="main" xml:id="_3K6aXAG">Blood pressure targets for hypertension in people with diabetes mellitus</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Arguedas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Leiva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Wright</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9H7uxGb">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="6" to="9" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev. 2013;10:CD008277. S9.6-3.</note>
</biblStruct>

<biblStruct xml:id="b293">
	<analytic>
		<title level="a" type="main" xml:id="_5rZ5FAa">Effects of intensive blood-pressure control in type 2 diabetes mellitus. ACCORD Study</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Cushman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Byington</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Gw8DaYx">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="page" from="6" to="10" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cushman WC, Evans GW, Byington RP, et al. Effects of inten- sive blood-pressure control in type 2 diabetes mellitus. ACCORD Study. N Engl J Med. 2010;362:1575-85. S9.6-4.</note>
</biblStruct>

<biblStruct xml:id="b294">
	<analytic>
		<title level="a" type="main" xml:id="_Fj78mDh">Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial</title>
		<author>
			<persName><forename type="first">X</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Atkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lv</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sNMHjyG">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="6" to="9" />
			<date type="published" when="2013">2015. 2014. 2015. 2013. 2017</date>
		</imprint>
	</monogr>
	<note>Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial Lancet Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis Hypertension Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis CMAJ Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial Diabetes Care</note>
	<note type="raw_reference">Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2015;387:435-43. S9.6-5. Margolis KL, O&apos;Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37:1721-8. S9.6-6. Soliman EZ, Byington RP, Bigger JT, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. Hypertension. 2015;66:1123-9. S9.6-7. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pres- sure lowering on the progression of chronic kidney disease: a sys- tematic review and meta-analysis. CMAJ. 2013;185:949-57. S9.6-8. Bress AP, King JB, Kreider KE, et al. Effect of intensive versus standard blood pressure treatment according to baseline prediabe- tes status: a post hoc analysis of a randomized trial. Diabetes Care. 2017;40:1401-8. S9.6-9.</note>
</biblStruct>

<biblStruct xml:id="b295">
	<analytic>
		<title level="a" type="main" xml:id="_ePbGsbX">Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials</title>
		<author>
			<persName><forename type="first">F</forename><surname>Turnbull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Algert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vyyFHnt">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="page" from="6" to="10" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospec- tively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-9. S9.6-10.</note>
</biblStruct>

<biblStruct xml:id="b296">
	<analytic>
		<title level="a" type="main" xml:id="_Dkvu3AT">Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Whelton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Barzilay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Cushman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XZyjQuY">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="page" from="6" to="11" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fast- ing glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:1401-9. S9.6-11.</note>
</biblStruct>

<biblStruct xml:id="b297">
	<analytic>
		<title level="a" type="main" xml:id="_NNcmFU8">Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mavridis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Navarese</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_We3DJyV">Lancet</title>
		<imprint>
			<biblScope unit="volume">385</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="6" to="12" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047-56. S9.6-12.</note>
</biblStruct>

<biblStruct xml:id="b298">
	<analytic>
		<title level="a" type="main" xml:id="_JKtwk6F">Renin-angiotensin system and cardiovascular risk</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Schmieder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">F</forename><surname>Hilgers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Schlaich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qck3du4">Lancet</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="1208" to="1219" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208-19.</note>
</biblStruct>

<biblStruct xml:id="b299">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RZg5k7Q">Metabolic Syndrome S</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="7" to="8" />
		</imprint>
	</monogr>
	<note type="raw_reference">7. Metabolic Syndrome S9.7-1.</note>
</biblStruct>

<biblStruct xml:id="b300">
	<analytic>
		<title level="a" type="main" xml:id="_FS9QmYW">Pharmacological treatment and therapeutic perspectives of metabolic syndrome</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Eckel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6kvUWv7">Rev Endocr Metab Disord</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="7" to="9" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lim S, Eckel RH. Pharmacological treatment and therapeutic perspectives of metabolic syndrome. Rev Endocr Metab Disord. 2014;15:329-41. S9.7-2.</note>
</biblStruct>

<biblStruct xml:id="b301">
	<analytic>
		<title level="a" type="main" xml:id="_nnHkXgD">Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Owen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E ;</forename><surname>Reisin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G ;</forename><surname>Liguori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Muntner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Hamm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m" xml:id="_aDS7h7e">Metabolic syndrome</title>
		<editor>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Jameson</surname></persName>
		</editor>
		<meeting><address><addrLine>Philadelphia, PA</addrLine></address></meeting>
		<imprint>
			<publisher>Elsevier Saunders</publisher>
			<date type="published" when="2004">2015. 2015. 2011. 2004</date>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="7" to="13" />
		</imprint>
	</monogr>
	<note>Persistent increase of prevalence of metabolic syndrome among US adults: NHANES III to NHANES 1999-2006 Diabetes Care The metabolic syndrome and chronic kidney disease in US adults Ann Intern Med</note>
	<note type="raw_reference">Owen JG, Reisin E. Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evi- dence, meta-analysis, post hoc and guidelines publications. Curr Hypertens Rep. 2015;17:558. S9.7-3. Ruderman NB, Shulman GI. Metabolic syndrome. Jameson JL. Endocrinology: Adult &amp; Pediatric. 2015. Elsevier Saunders: Philadelphia, PA:752-9. S9.7-4. Mozumdar A, Liguori G. Persistent increase of prevalence of meta- bolic syndrome among US adults: NHANES III to NHANES 1999- 2006. Diabetes Care. 2011;34:216-9. S9.7-5. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140:167-74. S9.7-6.</note>
</biblStruct>

<biblStruct xml:id="b302">
	<analytic>
		<title level="a" type="main" xml:id="_82f95Ey">Association between the metabolic syndrome and chronic kidney disease in Chinese adults</title>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C-S</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WrHqfAr">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="7" to="7" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chen J, Gu D, Chen C-S, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007;22:1100-6. S9.7-7.</note>
</biblStruct>

<biblStruct xml:id="b303">
	<analytic>
		<title level="a" type="main" xml:id="_2B7YQkw">The glycemic effects of antihypertensive medications</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Barzilay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Whelton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rVcRvkd">Curr Hypertens Rep</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="7" to="8" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Barzilay JI, Davis BR, Whelton PK. The glycemic effects of anti- hypertensive medications. Curr Hypertens Rep. 2014;16:410. S9.7-8.</note>
</biblStruct>

<biblStruct xml:id="b304">
	<analytic>
		<title level="a" type="main" xml:id="_vAJ4ZZ3">Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Kostis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Freudenberger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_APMq9Vg">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="7" to="9" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29-35. S9.7-9.</note>
</biblStruct>

<biblStruct xml:id="b305">
	<analytic>
		<title level="a" type="main" xml:id="_xweDJyh">Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wright</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harris-Haywood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pressel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_W5e7uKk">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="7" to="10" />
			<date type="published" when="2008-06">2008. June 2018 S9</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syn- drome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2008;168:207-17. June 2018 S9.7-10.</note>
</biblStruct>

<biblStruct xml:id="b306">
	<analytic>
		<title level="a" type="main" xml:id="_Kbzt5xH">ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wright</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Probstfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Cushman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WRfZrMe">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="7" to="11" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT find- ings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med. 2009;169:832-42. S9.7-11.</note>
</biblStruct>

<biblStruct xml:id="b307">
	<analytic>
		<title level="a" type="main" xml:id="_2yHbFPU">Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Black</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Barzilay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3MqEjrN">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="7" to="12" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Black HR, Davis B, Barzilay J, et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2008;31:353-60. S9.7-12.</note>
</biblStruct>

<biblStruct xml:id="b308">
	<analytic>
		<title level="a" type="main" xml:id="_aHdMmdf">Vascular Mechanism Collaboration. Dosedependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome</title>
		<author>
			<persName><forename type="first">S</forename><surname>Laurent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Boutouyrie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mNGbdFz">Hypertension</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="7" to="13" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Laurent S, Boutouyrie P. Vascular Mechanism Collaboration. Dose- dependent arterial destiffening and inward remodeling after olmes- artan in hypertensives with metabolic syndrome. Hypertension. 2014;64:709-16. S9.7-13.</note>
</biblStruct>

<biblStruct xml:id="b309">
	<analytic>
		<title level="a" type="main" xml:id="_DH8WWsw">Treatment: special conditions. Metabolic syndrome: obesity and the hypertension connection</title>
		<author>
			<persName><forename type="first">E</forename><surname>Reisin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Owen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jPvKGFB">Atrial Fibrillation S</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="8" to="9" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>J Am Soc Hypertens</note>
	<note type="raw_reference">Reisin E, Owen J. Treatment: special conditions. Metabolic syndrome: obesity and the hypertension connection. J Am Soc Hypertens. 2015;9:156-59. 9.8. Atrial Fibrillation S9.8-1.</note>
</biblStruct>

<biblStruct xml:id="b310">
	<analytic>
		<title level="a" type="main" xml:id="_gqbQFte">Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Healey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Baranchuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Crystal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DmWxcjB">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="8" to="10" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-9. S9.8-2.</note>
</biblStruct>

<biblStruct xml:id="b311">
	<analytic>
		<title level="a" type="main" xml:id="_9GrKjvD">Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials</title>
		<author>
			<persName><forename type="first">D</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z-M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L-S</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Eu2y8hY">J Biomed Res</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="475" to="485" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhao D, Wang Z-M, Wang L-S. Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials. J Biomed Res. 2015;29:475-85.</note>
</biblStruct>

<biblStruct xml:id="b312">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uwYgGvP">Valvular Heart Disease S</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="9" to="10" />
		</imprint>
	</monogr>
	<note type="raw_reference">9.9. Valvular Heart Disease S9.9-1.</note>
</biblStruct>

<biblStruct xml:id="b313">
	<analytic>
		<title level="a" type="main" xml:id="_3HY33k9">A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial)</title>
		<author>
			<persName><forename type="first">Å</forename><forename type="middle">E</forename><surname>Rieck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cramariuc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Boman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BUgEHwj">Eur Heart J Cardiovasc Imaging</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="9" to="13" />
			<date type="published" when="2012">2012. 2013. 2015</date>
		</imprint>
	</monogr>
	<note>Systemic hypertension in low-gradient severe aortic stenosis with preserved ejection fraction Circulation Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events Hypertension</note>
	<note type="raw_reference">Rieck ÅE, Cramariuc D, Boman K, et al. Hypertension in aortic stenosis: implications for left ventricular structure and cardiovas- cular events. Hypertension. 2012;60:90-7. S9.9-2. Eleid MF, Nishimura RA, Sorajja P, et al. Systemic hypertension in low-gradient severe aortic stenosis with preserved ejection fraction. Circulation. 2013;128:1349-53. S9.9-3. Bull S, Loudon M, Francis JM, et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur Heart J Cardiovasc Imaging. 2015;16:834-41. S9.9-4.</note>
</biblStruct>

<biblStruct xml:id="b314">
	<analytic>
		<title level="a" type="main" xml:id="_4Zz4dTQ">Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Chockalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Venkatesan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Subramaniam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9wKxw6j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="9" to="14" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chockalingam A, Venkatesan S, Subramaniam T, et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J. 2004;147:E19. S9.9-5.</note>
</biblStruct>

<biblStruct xml:id="b315">
	<analytic>
		<title level="a" type="main" xml:id="_sCjC6WB">Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function</title>
		<author>
			<persName><forename type="first">R</forename><surname>Scognamiglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Rahimtoola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fasoli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_apzEnRA">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">331</biblScope>
			<biblScope unit="page" from="9" to="15" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Scognamiglio R, Rahimtoola SH, Fasoli G, et al. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med. 1994;331:689-94. S9.9-6.</note>
</biblStruct>

<biblStruct xml:id="b316">
	<analytic>
		<title level="a" type="main" xml:id="_hFZAZbv">Long-term vasodilator therapy in patients with severe aortic regurgitation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Evangelista</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tornos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sambola</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jmJaXVd">Aortic Disease S</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page" from="10" to="11" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>N Engl J Med</note>
	<note type="raw_reference">Evangelista A, Tornos P, Sambola A, et al. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med. 2005;353:1342-9. 9.10. Aortic Disease S9.10-1.</note>
</biblStruct>

<biblStruct xml:id="b317">
	<analytic>
		<title level="a" type="main" xml:id="_nA2DeWq">Type-selective benefits of medications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection [IRAD])</title>
		<author>
			<persName><forename type="first">M</forename><surname>Genoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jenni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Sgumz9a">Eur J Cardiothorac Surg</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">10</biblScope>
			<date type="published" when="2001">2001. 2012</date>
		</imprint>
	</monogr>
	<note>Chronic beta-blocker therapy improves outcome and reduces treatment costs in chronic type B aortic dissection Am J Cardiol</note>
	<note type="raw_reference">Genoni M, Paul M, Jenni R, et al. Chronic beta-blocker therapy improves outcome and reduces treatment costs in chronic type B aortic dissection. Eur J Cardiothorac Surg. 2001;19:606-10. S9.10-2. Suzuki T, Isselbacher EM, Nienaber CA, et al. Type-selective ben- efits of medications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection [IRAD]). Am J Cardiol. 2012;109:122-7. 10</note>
</biblStruct>

<biblStruct xml:id="b318">
	<monogr>
		<title level="m" type="main" xml:id="_Y7r9KPY">Racial and Ethnic Differences in Treatment S10</title>
		<imprint>
			<biblScope unit="page" from="1" to="1" />
		</imprint>
	</monogr>
	<note>Special Patient Groups 10.1.1</note>
	<note type="raw_reference">Special Patient Groups 10.1.1. Racial and Ethnic Differences in Treatment S10.1.1-1.</note>
</biblStruct>

<biblStruct xml:id="b319">
	<analytic>
		<title level="a" type="main" xml:id="_38NwC6s">Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Leenen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Nwachuku</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Black</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RnmvfVp">Hypertension</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="2" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48:374-84. S10.1.1-2.</note>
</biblStruct>

<biblStruct xml:id="b320">
	<analytic>
		<title level="a" type="main" xml:id="_4KCGteN">ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wright</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Probstfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Cushman</surname></persName>
		</author>
		<idno type="DOI">10.1001/archinternmed.2009.60</idno>
		<idno>10.1.1-3</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uc97DAB">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="832" to="842" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT find- ings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med. 2009;169:832-42. S10.1.1-3.</note>
</biblStruct>

<biblStruct xml:id="b321">
	<analytic>
		<title level="a" type="main" xml:id="_rWtTQwc">Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wright</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Cutler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cq5Ym85">JAMA</title>
		<imprint>
			<biblScope unit="volume">293</biblScope>
			<biblScope unit="page" from="1" to="4" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodip- ine, and lisinopril. JAMA. 2005;293:1595-608. S10.1.1-4.</note>
</biblStruct>

<biblStruct xml:id="b322">
	<analytic>
		<title level="a" type="main" xml:id="_bHJX4qk">ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wright</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harris-Haywood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pressel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qCHZQwB">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="1" to="6" />
			<date type="published" when="2002">2008. 2002</date>
		</imprint>
	</monogr>
	<note>Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA</note>
	<note type="raw_reference">Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical out- comes by race in hypertensive patients with and without the meta- bolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2008;168:207-17. S10.1.1-5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97. S10.1.1-6.</note>
</biblStruct>

<biblStruct xml:id="b323">
	<analytic>
		<title level="a" type="main" xml:id="_a6Pm6kN">A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wright</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Whelton</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa1511939</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5Yn4BQZ">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103-16. S10.1.1-7.</note>
</biblStruct>

<biblStruct xml:id="b324">
	<analytic>
		<title level="a" type="main" xml:id="_feRZekw">Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wright</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bakris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Greene</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_k8E2eQf">JAMA</title>
		<imprint>
			<biblScope unit="volume">288</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="2" to="3" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pres- sure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-31. 10.2. Sex-Related Issues S10.2-1.</note>
</biblStruct>

<biblStruct xml:id="b325">
	<analytic>
		<title level="a" type="main" xml:id="_SVF7dV6">Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Benjamin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Blaha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Chiuve</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FK72P73">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="2" to="3" />
			<date type="published" when="1997">2017. 1997</date>
		</imprint>
	</monogr>
	<note>Heart disease and stroke statistics-2017 update: a report from the American Heart Association Circulation</note>
	<note type="raw_reference">Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146-603. S10.2-2. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihyperten- sive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med. 1997;126:761-7. S10.2-3.</note>
</biblStruct>

<biblStruct xml:id="b326">
	<analytic>
		<title level="a" type="main" xml:id="_Ck7zjPk">Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials</title>
		<author>
			<persName><forename type="first">F</forename><surname>Turnbull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neal</surname></persName>
		</author>
		<idno>Women S10.2.1-1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JYbApz3">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2669" to="2680" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Turnbull F, Woodward M, Neal B, et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29:2669-80. 10.2.1. Women S10.2.1-1.</note>
</biblStruct>

<biblStruct xml:id="b327">
	<analytic>
		<title level="a" type="main" xml:id="_UTmtYg8">Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials</title>
		<author>
			<persName><forename type="first">F</forename><surname>Turnbull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aqWgXKQ">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1" to="3" />
			<date type="published" when="2008">2008. 2016</date>
		</imprint>
	</monogr>
	<note>Women, hypertension, and the Systolic Blood Pressure Intervention Trial Am J Med</note>
	<note type="raw_reference">Turnbull F, Woodward M, Neal B, et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29:2669-80. S10.2.1-2. Wenger NK, Ferdinand KC, Bairey Merz CN, et al. Women, hyper- tension, and the Systolic Blood Pressure Intervention Trial. Am J Med. 2016;129:1030-6. S10.2.1-3.</note>
</biblStruct>

<biblStruct xml:id="b328">
	<analytic>
		<title level="a" type="main" xml:id="_hDGHA72">Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Fletcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Beevers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bulpitt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gvYFdkA">J Hum Hypertens</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1" to="4" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fletcher A, Beevers DG, Bulpitt C, et al. Beta adrenoceptor block- ade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens. 1988;2: 219-27. S10.2.1-4.</note>
</biblStruct>

<biblStruct xml:id="b329">
	<analytic>
		<title level="a" type="main" xml:id="_wznnWh6">General practitioners&apos; use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Jansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bonner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mckinn</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2014-004812</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZsJB6pH">BMJ OPEN</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jansen J, Bonner C, McKinn S, et al. General practitioners&apos; use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study. BMJ OPEN. 2014;4:e004812. S10.2.1-5.</note>
</biblStruct>

<biblStruct xml:id="b330">
	<analytic>
		<title level="a" type="main" xml:id="_CwfGJqA">Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Grandits</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Flack</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ubpSYg9">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="1" to="6" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lewis CE, Grandits A, Flack J, et al. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 dia- stolic hypertension. Results of the Treatment of Mild Hypertension Study. Arch Intern Med. 1996;156:377-85. S10.2.1-6.</note>
</biblStruct>

<biblStruct xml:id="b331">
	<analytic>
		<title level="a" type="main" xml:id="_cnzTFKP">Sex-and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Kloner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Sowers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Dibona</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JS4A8sH">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kloner RA, Sowers JR, DiBona GF, et al. Sex-and age-related anti- hypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol. 1996;77:713-22. S10.2.1-7.</note>
</biblStruct>

<biblStruct xml:id="b332">
	<analytic>
		<title level="a" type="main" xml:id="_b7H7GGv">Hypertension in women: part I</title>
		<author>
			<persName><forename type="first">Igho</forename><surname>Pemu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ofili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pwH55NZ">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="2" to="3" />
			<date type="published" when="2008">2008</date>
			<pubPlace>Greenwich)</pubPlace>
		</imprint>
	</monogr>
	<note>Pregnancy</note>
	<note type="raw_reference">Igho Pemu P, Ofili E. Hypertension in women: part I. J Clin Hypertens (Greenwich). 2008;10:406-10. 10.2.2. Pregnancy S10.2.2-1.</note>
</biblStruct>

<biblStruct xml:id="b333">
	<analytic>
		<title level="a" type="main" xml:id="_gRUcD34">S10.2.2-2. American College of Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&apos; Task Force on Hypertension in Pregnancy</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nelson</forename><forename type="middle">-</forename><surname>Piercy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<idno>10.2.2-3</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_afBm4j3">Obstet Gynecol</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="2" to="4" />
			<date type="published" when="2004">2004. 2013. 2011</date>
			<publisher>Royal College of Physicians</publisher>
			<pubPlace>London, UK; UK</pubPlace>
		</imprint>
		<respStmt>
			<orgName>National Clinical Guideline Centre (UK</orgName>
		</respStmt>
	</monogr>
	<note>Management of hypertension before, during, and after pregnancy Heart Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34</note>
	<note type="raw_reference">James PR, Nelson-Piercy C. Management of hypertension before, during, and after pregnancy. Heart. 2004;90:1499-504. S10.2.2-2. American College of Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&apos; Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122-31. S10.2.2-3. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. London, UK: Royal College of Physicians (UK); 2011. S10.2.2-4.</note>
</biblStruct>

<biblStruct xml:id="b334">
	<analytic>
		<title level="a" type="main" xml:id="_shmCyaJ">Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits</title>
		<author>
			<persName><forename type="first">M</forename><surname>Pucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sarween</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Knox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PevXfys">Expert Rev Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="2" to="5" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pucci M, Sarween N, Knox E, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits. Expert Rev Clin Pharmacol. 2015;8:221-31. S10.2.2-5.</note>
</biblStruct>

<biblStruct xml:id="b335">
	<analytic>
		<title level="a" type="main" xml:id="_Cu8eQHU">The fetal safety of angiotensin converting enzyme inhibitors and angiotensin ii receptor blockers</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Moretti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Caprara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Drehuta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4rtfhkk">Obstet Gynecol Int</title>
		<imprint>
			<biblScope unit="volume">2012</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2" to="6" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Moretti ME, Caprara D, Drehuta I, et al. The fetal safety of angio- tensin converting enzyme inhibitors and angiotensin ii receptor blockers. Obstet Gynecol Int. 2012;2012:658310. S10.2.2-6.</note>
</biblStruct>

<biblStruct xml:id="b336">
	<analytic>
		<title level="a" type="main" xml:id="_zjwTyrG">Management of mild chronic hypertension during pregnancy: a review</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Ferrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Sibai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Mulrow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_d2ZZxzs">Obstet Gynecol</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="1" to="1" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>Age-Related Issues 10</note>
	<note type="raw_reference">Ferrer RL, Sibai BM, Mulrow CD, et al. Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol. 2000;96:849-60. 10.3. Age-Related Issues 10.3.1. Older Persons S10.3.1-1.</note>
</biblStruct>

<biblStruct xml:id="b337">
	<analytic>
		<title level="a" type="main" xml:id="_2eyB5jV">Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Supiano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Applegate</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uWmH4Vq">Resistant Hypertension S</title>
		<imprint>
			<biblScope unit="volume">315</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="1" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>JAMA Other Considerations 11</note>
	<note type="raw_reference">Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease out- comes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016;315:2673-82. 11. Other Considerations 11.1. Resistant Hypertension S11.1-1.</note>
</biblStruct>

<biblStruct xml:id="b338">
	<analytic>
		<title level="a" type="main" xml:id="_c7pUXGS">Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Calhoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Textor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Pq7JWTW">Hypertension</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="1403" to="1419" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diag- nosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-19.</note>
</biblStruct>

<biblStruct xml:id="b339">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_s4y9D8T">Hypertensive Crises-Emergencies and Urgencies S</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="2" to="3" />
		</imprint>
	</monogr>
	<note type="raw_reference">2. Hypertensive Crises-Emergencies and Urgencies S11.2-1.</note>
</biblStruct>

<biblStruct xml:id="b340">
	<analytic>
		<title level="a" type="main" xml:id="_qMjHJSr">Impact of initial blood pressure on antihypertensive response in patients with acute hypertension</title>
		<author>
			<persName><forename type="first">S</forename><surname>Farias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Peacock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gonzalez</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ajem.2014.03.021</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ncrvwn5">Am J Emerg Med</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="2" to="2" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Farias S, Peacock WF, Gonzalez M, et al. Impact of initial blood pressure on antihypertensive response in patients with acute hyper- tension. Am J Emerg Med. 2014;32:833-6. S11.2-2.</note>
</biblStruct>

<biblStruct xml:id="b341">
	<analytic>
		<title level="a" type="main" xml:id="_yQPKghR">Clevidipine in acute heart failure: results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO)</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Peacock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chandra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Char</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fMPSf6X">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page" from="529" to="536" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure: results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO). Am Heart J. 2014;167:529-36.</note>
</biblStruct>

<biblStruct xml:id="b342">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_efZZRES">Cognitive Decline and Dementia S</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="3" to="4" />
		</imprint>
	</monogr>
	<note type="raw_reference">3. Cognitive Decline and Dementia S11.3-1.</note>
</biblStruct>

<biblStruct xml:id="b343">
	<analytic>
		<title level="a" type="main" xml:id="_yBvX4vk">Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Applegate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pressel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wittes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_58g6ZPw">Patients Undergoing Surgical Procedures S</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="page" from="4" to="5" />
			<date type="published" when="1994">1994. 1998. 2002. 2003. 2003. 2008</date>
		</imprint>
	</monogr>
	<note>Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial Lancet The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study Arch Intern Med The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial J Hypertens Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program Arch Intern Med Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease Arch Intern Med Lancet Neurology</note>
	<note type="raw_reference">Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med. 1994;154:2154-60. S11.3-2. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-51. S11.3-3. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162:2046-52. S11.3-4. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a random- ized double-blind intervention trial. J Hypertens. 2003;21:875-86. S11.3-5. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pres- sure lowering with perindopril and indapamide therapy on demen- tia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069-75. S11.3-6. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurology. 2008;7:683-9. 11.4. Patients Undergoing Surgical Procedures S11.4-1.</note>
</biblStruct>

<biblStruct xml:id="b344">
	<analytic>
		<title level="a" type="main" xml:id="_nQXJfum">Perioperative beta-blocker withdrawal and mortality in vascular surgical patients</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Lindenauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pekow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_dqDBs95">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page" from="4" to="7" />
			<date type="published" when="2001">2005. 2001</date>
		</imprint>
	</monogr>
	<note>Perioperative beta-blocker therapy and mortality after major noncardiac surgery Am Heart J</note>
	<note type="raw_reference">Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 2005;353:349-61. S11.4-2. Shammash JB, Trost JC, Gold JM, et al. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J. 2001;141:148-53. S11.4-3.</note>
</biblStruct>

<biblStruct xml:id="b345">
	<analytic>
		<title level="a" type="main" xml:id="_k7DQzus">Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Wallace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Au</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Cason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Andersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Merie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jorgensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Ph3Sd4T">JAMA Intern Med</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="4" to="5" />
			<date type="published" when="2010">2010. 2014</date>
		</imprint>
	</monogr>
	<note>Association of the pattern of use of perioperative β-blockade and postoperative mortality Anesthesiology</note>
	<note type="raw_reference">Wallace AW, Au S, Cason BA. Association of the pattern of use of perioperative β-blockade and postoperative mortality. Anesthesiology. 2010;113:794-805. S11.4-4. Andersson C, Merie C, Jorgensen M, et al. Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncar- diac surgery: a Danish nationwide cohort study. JAMA Intern Med. 2014;174:336-44. S11.4-5.</note>
</biblStruct>

<biblStruct xml:id="b346">
	<analytic>
		<title level="a" type="main" xml:id="_FDjnCAA">Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Hoeks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Scholte</forename><surname>Op Reimer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wjm</forename><surname>Van Urk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pvv5CqU">Eur J Vasc Endovasc Surg</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="4" to="6" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hoeks SE, Scholte Op Reimer WJM, van Urk H, et al. Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients. Eur J Vasc Endovasc Surg. 2007;33:13-9. S11.4-6.</note>
</biblStruct>

<biblStruct xml:id="b347">
	<analytic>
		<title level="a" type="main" xml:id="_2QYXqXd">Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Boer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D ;</forename><surname>London</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Hur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RSXtQ6n">Anesth Analg</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="4" to="9" />
			<date type="published" when="2007">2007. 2013. 2012</date>
		</imprint>
	</monogr>
	<note>Association of ambulatory use of statins and beta-blockers with long-term mortality after vascular surgery JAMA Association of perioperative β-blockade with mortality and cardiovascular morbidity following major noncardiac surgery J Hosp Med</note>
	<note type="raw_reference">Barrett TW, Mori M, De Boer D. Association of ambulatory use of statins and beta-blockers with long-term mortality after vascular surgery. J Hosp Med. 2007;2:241-52. S11.4-7. London MJ, Hur K, Schwartz GG, et al. Association of periopera- tive β-blockade with mortality and cardiovascular morbidity fol- lowing major noncardiac surgery. JAMA. 2013;309:1704-13. S11.4-8. Turan A, You J, Shiba A, et al. Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mor- tality after noncardiac surgery. Anesth Analg. 2012;114:552-60. S11.4-9.</note>
</biblStruct>

<biblStruct xml:id="b348">
	<analytic>
		<title level="a" type="main" xml:id="_EDaFcTh">Clinical consequences of withholding versus administering renin-angiotensinaldosterone system antagonists in the preoperative period</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Rosenman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Mcdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Ebbert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_y9SQ6FB">J Hosp Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="4" to="10" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rosenman DJ, McDonald FS, Ebbert JO, et al. Clinical conse- quences of withholding versus administering renin-angiotensin- aldosterone system antagonists in the preoperative period. J Hosp Med. 2008;3:319-25. S11.4-10.</note>
</biblStruct>

<biblStruct xml:id="b349">
	<analytic>
		<title level="a" type="main" xml:id="_6FHnTmc">Withholding versus continuing angiotensin-converting enzyme inhibitors or angiotensin ii receptor blockers before noncardiac surgery: an analysis of the vascular events in noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Roshanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rochwerg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Patel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Fz9ybMX">Anesthesiology</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="4" to="12" />
			<date type="published" when="2002">2017. 2002</date>
		</imprint>
	</monogr>
	<note>Preoperative evaluation of the patient with hypertension JAMA</note>
	<note type="raw_reference">Roshanov PS, Rochwerg B, Patel A, et al. Withholding versus con- tinuing angiotensin-converting enzyme inhibitors or angiotensin ii receptor blockers before noncardiac surgery: an analysis of the vascular events in noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort. Anesthesiology. 2017;126:16-27. S11.4-11. Fleisher LA. Preoperative evaluation of the patient with hyperten- sion. JAMA. 2002;287:2043-6. S11.4-12.</note>
</biblStruct>

<biblStruct xml:id="b350">
	<analytic>
		<title level="a" type="main" xml:id="_Fae9gMh">Hypertension, hypertensive heart disease and perioperative cardiac risk</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Howell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Sear</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Foex</surname></persName>
		</author>
		<idno type="DOI">10.1093/bja/aeh091</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_scgJyXc">Br J Anaesth</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="4" to="13" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Howell SJ, Sear JW, Foex P. Hypertension, hypertensive heart dis- ease and perioperative cardiac risk. Br J Anaesth. 2004;92:570-83. S11.4-13.</note>
</biblStruct>

<biblStruct xml:id="b351">
	<analytic>
		<title level="a" type="main" xml:id="_JmPXKxE">Withdrawal syndromes and the cessation of antihypertensive therapy</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Hart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jqQYV8w">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="4" to="14" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hart GR, Anderson RJ. Withdrawal syndromes and the cessa- tion of antihypertensive therapy. Arch Intern Med. 1981;141: 1125-27. S11.4-14.</note>
</biblStruct>

<biblStruct xml:id="b352">
	<analytic>
		<title level="a" type="main" xml:id="_sE6R8WG">Effects of extendedrelease metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Devereaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yusuf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_T2tc38R">Lancet</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="1839" to="1847" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended- release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371:1839-47.</note>
</biblStruct>

<biblStruct xml:id="b353">
	<analytic>
		<title level="a" type="main" xml:id="_Sw3eMYr">Strategies to Improve Hypertension Treatment and Control 12.1. Adherence Strategies for Treatment of Hypertension 12.1.1</title>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZXeEKX2">Antihypertensive Medication Adherence Strategies S</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="1" />
		</imprint>
	</monogr>
	<note type="raw_reference">Strategies to Improve Hypertension Treatment and Control 12.1. Adherence Strategies for Treatment of Hypertension 12.1.1. Antihypertensive Medication Adherence Strategies S12.1.1-1.</note>
</biblStruct>

<biblStruct xml:id="b354">
	<analytic>
		<title level="a" type="main" xml:id="_JjNH3t7">A systematic review of the associations between dose regimens and medication compliance</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Claxton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cramer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pierce</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0149-2918(01)80109-0</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SVnYCzw">Clin Ther</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1" to="2" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Claxton AJ, Cramer J, Pierce C. A systematic review of the asso- ciations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-310. S12.1.1-2.</note>
</biblStruct>

<biblStruct xml:id="b355">
	<analytic>
		<title level="a" type="main" xml:id="_55yQR8m">Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Iskedjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Einarson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Mackeigan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_n7dBqGq">Clin Ther</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1" to="3" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihyperten- sive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002;24:302-16. S12.1.1-3.</note>
</biblStruct>

<biblStruct xml:id="b356">
	<analytic>
		<title level="a" type="main" xml:id="_k6D8aH2">How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials</title>
		<author>
			<persName><forename type="first">K</forename><surname>Schroeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fahey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S ;</forename><surname>Ebrahim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bangalore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kamalakkannan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Parkar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EzPgbw8">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2004">2004. 2007</date>
		</imprint>
	</monogr>
	<note>Fixed-dose combinations improve medication compliance: a meta-analysis Am J Med</note>
	<note type="raw_reference">Schroeder K, Fahey T, Ebrahim S. How can we improve adher- ence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164:722-32. S12.1.1-4. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose com- binations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713-19. S12.1.1-5.</note>
</biblStruct>

<biblStruct xml:id="b357">
	<analytic>
		<title level="a" type="main" xml:id="_3K9nYAJ">Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Arshad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Poulter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YeC7RrZ">Hypertension</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1" to="6" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effec- tiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399-407. S12.1.1-6.</note>
</biblStruct>

<biblStruct xml:id="b358">
	<analytic>
		<title level="a" type="main" xml:id="_6hzCNz6">Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence</title>
		<author>
			<persName><forename type="first">B</forename><surname>Sherrill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Halpern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Khan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_63Bk4Gj">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="2011">2011</date>
			<pubPlace>Greenwich)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equiva- lent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13:898-909. S12.1.1-7.</note>
</biblStruct>

<biblStruct xml:id="b359">
	<analytic>
		<title level="a" type="main" xml:id="_6CzxaBA">Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives</title>
		<author>
			<persName><forename type="first">W</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Kahler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_twux7FH">Curr Med Res Opin</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2065" to="2076" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free com- bination antihypertensives. Curr Med Res Opin. 2010;26:2065-76.</note>
</biblStruct>

<biblStruct xml:id="b360">
	<analytic>
		<title level="a" type="main" xml:id="_6qjvQax">1.2</title>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gEVNUHq">Strategies to Promote Lifestyle Modification S</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="2" to="3" />
		</imprint>
	</monogr>
	<note type="raw_reference">1.2. Strategies to Promote Lifestyle Modification S12.1.2-1.</note>
</biblStruct>

<biblStruct xml:id="b361">
	<analytic>
		<title level="a" type="main" xml:id="_swFNXhw">Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">T</forename><surname>Artinian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Fletcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mozaffarian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bCCdh8p">Circulation</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="2" to="2" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for car- diovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation. 2010;122: 406-41. S12.1.2-2.</note>
</biblStruct>

<biblStruct xml:id="b362">
	<analytic>
		<title level="a" type="main" xml:id="_h5gpb9x">AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Eckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Jakicic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Ard</surname></persName>
		</author>
		<ptr target="http://ahajournals.org" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_WGgaGK9">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="issue">suppl 2</biblScope>
			<biblScope unit="page" from="76" to="99" />
			<date type="published" when="2013">2013. 2014. February 15, 2025 June 2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S76-99. Downloaded from http://ahajournals.org by on February 15, 2025 June 2018</note>
</biblStruct>

<biblStruct xml:id="b363">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_smXc4ab">Structured, Team-Based Care Interventions for Hypertension Control S</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="2" to="3" />
		</imprint>
	</monogr>
	<note type="raw_reference">Structured, Team-Based Care Interventions for Hypertension Control S12.2-1.</note>
</biblStruct>

<biblStruct xml:id="b364">
	<analytic>
		<title level="a" type="main" xml:id="_XrS5BSb">Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Daly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rUYPPJ8">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="2" to="3" />
			<date type="published" when="2009">2009. 2010</date>
		</imprint>
	</monogr>
	<note>The potency of team-based care interventions for hypertension: a meta-analysis BMJ</note>
	<note type="raw_reference">Carter BL, Rogers M, Daly J, et al. The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med. 2009;169:1748-55. S12.2-2. Clark CE, Smith LF, Taylor RS, et al. Nurse led interventions to improve control of blood pressure in people with hypertension: sys- tematic review and meta-analysis. BMJ. 2010;341:c3995. S12.2-3.</note>
</biblStruct>

<biblStruct xml:id="b365">
	<analytic>
		<title level="a" type="main" xml:id="_8zN3BdV">Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Proia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Thota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Njie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VkHX2hy">J Am Heart Assoc</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="2" to="5" />
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
	<note>Team-based care and improved blood pressure control: a community guide systematic review Am J Prev Med</note>
	<note type="raw_reference">Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014;47:86-99. S12.2-4. Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pres- sure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3:e000718. S12.2-5.</note>
</biblStruct>

<biblStruct xml:id="b366">
	<analytic>
		<title level="a" type="main" xml:id="_hs2zjfD">Effects of nurse-managed protocols in the outpatient management of adults with chronic conditions: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Shaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mcduffie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Hendrix</surname></persName>
		</author>
		<idno type="DOI">10.7326/m13-2567</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZqVM5tb">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="2" to="6" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shaw RJ, McDuffie JR, Hendrix CC, et al. Effects of nurse-man- aged protocols in the outpatient management of adults with chronic conditions: a systematic review and meta-analysis. Ann Intern Med. 2014;161:113-21. S12.2-6.</note>
</biblStruct>

<biblStruct xml:id="b367">
	<analytic>
		<title level="a" type="main" xml:id="_6xGkubc">Check it, change it: a community-based, multifaceted intervention to improve blood pressure control</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Elliot-Bynum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2rseEkK">Circ Cardiovasc Qual Outcomes</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="2" to="7" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thomas KL, Shah BR, Elliot-Bynum S, et al. Check it, change it: a community-based, multifaceted intervention to improve blood pressure control. Circ Cardiovasc Qual Outcomes. 2014;7:828-34. S12.2-7.</note>
</biblStruct>

<biblStruct xml:id="b368">
	<analytic>
		<title level="a" type="main" xml:id="_XbpFZrM">Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Coffey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ardery</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qdcbTjU">Circ Cardiovasc Qual Outcomes</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="235" to="243" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Carter BL, Coffey CS, Ardery G, et al. Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control. Circ Cardiovasc Qual Outcomes. 2015;8:235-43.</note>
</biblStruct>

<biblStruct xml:id="b369">
	<analytic>
		<title level="a" type="main" xml:id="_2J2gGcz">Health Information Technology-Based Strategies to Promote Hypertension Control 12.3.1</title>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gjruPra">EHR and Patient Registries S</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="1" />
		</imprint>
	</monogr>
	<note type="raw_reference">3. Health Information Technology-Based Strategies to Promote Hypertension Control 12.3.1. EHR and Patient Registries S12.3.1-1.</note>
</biblStruct>

<biblStruct xml:id="b370">
	<analytic>
		<title level="a" type="main" xml:id="_EcaxQnY">A technology-based quality innovation to identify undiagnosed hypertension among active primary care patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Rakotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Ewigman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sarav</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fupEuH6">Ann Fam Med</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1" to="2" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rakotz MK, Ewigman BG, Sarav M, et al. A technology-based quality innovation to identify undiagnosed hypertension among active primary care patients. Ann Fam Med. 2014;12:352-8. S12.3.1-2.</note>
</biblStruct>

<biblStruct xml:id="b371">
	<analytic>
		<title level="a" type="main" xml:id="_zfeN79v">Impact of the 2014 expert panel recommendations for management of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE registry</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Borden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Maddox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_f2ucx33">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="1" to="3" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Borden WB, Maddox TM, Tang F, et al. Impact of the 2014 expert panel recommendations for management of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014;64: 2196-203. S12.3.1-3.</note>
</biblStruct>

<biblStruct xml:id="b372">
	<analytic>
		<title level="a" type="main" xml:id="_yaGPnjR">Improved blood pressure control associated with a large-scale hypertension program</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Jaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Young</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2013.108769</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_F664Vz3">JAMA</title>
		<imprint>
			<biblScope unit="volume">310</biblScope>
			<biblScope unit="page" from="699" to="705" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure con- trol associated with a large-scale hypertension program. JAMA. 2013;310:699-705.</note>
</biblStruct>

<biblStruct xml:id="b373">
	<analytic>
		<title level="a" type="main" xml:id="_PpGxF5P">3.2</title>
		<idno type="DOI">10.1097/hjh.0b013e32835d2c6c</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2F4qWxr">Telehealth Interventions to Improve Hypertension Control S</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="2" to="3" />
		</imprint>
	</monogr>
	<note type="raw_reference">3.2. Telehealth Interventions to Improve Hypertension Control S12.3.2-1.</note>
</biblStruct>

<biblStruct xml:id="b374">
	<analytic>
		<title level="a" type="main" xml:id="_h33hxKr">Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies</title>
		<author>
			<persName><forename type="first">S</forename><surname>Omboni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gazzola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Carabelli</surname></persName>
		</author>
		<idno type="DOI">10.1097/hjh.0b013e32835ca8dd</idno>
		<idno>12.3.2-3</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8DwhCvK">Blood Press Monit</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="149" to="155" />
			<date type="published" when="2011">2013. 2011</date>
		</imprint>
	</monogr>
	<note>Telecare is a valuable tool for hypertension management, a systematic review and meta-analysis J Hypertens</note>
	<note type="raw_reference">Omboni S, Gazzola T, Carabelli G, et al. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013;31:455-67; discussion 467-8. S12.3.2-2. Verberk WJ, Kessels AGH, Thien T. Telecare is a valuable tool for hypertension management, a systematic review and meta-analysis. Blood Press Monit. 2011;16:149-155. S12.3.2-3.</note>
</biblStruct>

<biblStruct xml:id="b375">
	<analytic>
		<title level="a" type="main" xml:id="_QhqwRKq">Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Agarwal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Bills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tjw</forename><surname>Hecht</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_X5dxaNS">Hypertension</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="2" to="4" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Agarwal R, Bills JE, Hecht TJW, et al. Role of home blood pres- sure monitoring in overcoming therapeutic inertia and improv- ing hypertension control: a systematic review and meta-analysis. Hypertension. 2011;57:29-38. S12.3.2-4</note>
</biblStruct>

<biblStruct xml:id="b376">
	<analytic>
		<title level="a" type="main" xml:id="_pZmNKvU">Reducing blood pressure with Internet-based interventions: a meta-analysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Dunford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">W</forename><surname>Leung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TPauu7N">Can J Cardiol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="2" to="5" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Liu S, Dunford SD, Leung YW, et al. Reducing blood pressure with Internet-based interventions: a meta-analysis. Can J Cardiol. 2013;29:613-21. S12.3.2-5.</note>
</biblStruct>

<biblStruct xml:id="b377">
	<analytic>
		<title level="a" type="main" xml:id="_s2A3fX9">Current science on consumer use of mobile health for cardiovascular disease prevention: a scientific statement from the American Heart Association</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Burke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kmj</forename><surname>Azar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_39QU8c5">Circulation</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="1157" to="1213" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Burke LE, Ma J, Azar KMJ, et al. Current science on consumer use of mobile health for cardiovascular disease prevention: a scien- tific statement from the American Heart Association. Circulation. 2015;132:1157-213.</note>
</biblStruct>

<biblStruct xml:id="b378">
	<analytic>
		<title level="a" type="main" xml:id="_HHNxsFm">Improving Quality of Care for Patients With Hypertension 12</title>
	</analytic>
	<monogr>
		<title level="j" xml:id="_492Cb6y">Performance Measures S</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1" to="1" />
		</imprint>
	</monogr>
	<note type="raw_reference">4. Improving Quality of Care for Patients With Hypertension 12.4.1. Performance Measures S12.4.1-1.</note>
</biblStruct>

<biblStruct xml:id="b379">
	<analytic>
		<title level="a" type="main" xml:id="_cD2hTZ8">Hypertension improvement project: randomized trial of quality improvement for physicians and lifestyle modification for patients</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Svetkey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">I</forename><surname>Pollak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yancy</forename><forename type="middle">Ws</forename><surname>Jr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3NnFDDR">Hypertension</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1" to="2" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Svetkey LP, Pollak KI, Yancy WS Jr, et al. Hypertension improve- ment project: randomized trial of quality improvement for phy- sicians and lifestyle modification for patients. Hypertension. 2009;54:1226-33. S12.4.1-2.</note>
</biblStruct>

<biblStruct xml:id="b380">
	<analytic>
		<title level="a" type="main" xml:id="_wYf8tMy">Audit-based education lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results</title>
		<author>
			<persName><forename type="first">S</forename><surname>De Lusignan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gallagher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jones</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Fnxvy4v">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="1" to="3" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">de Lusignan S, Gallagher H, Jones S, et al. Audit-based educa- tion lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results. Kidney Int. 2013;84:609-20. S12.4.1-3.</note>
</biblStruct>

<biblStruct xml:id="b381">
	<analytic>
		<title level="a" type="main" xml:id="_tm95xyh">Improved blood pressure control associated with a large-scale hypertension program</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Jaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Young</surname></persName>
		</author>
		<idno>.4.2-1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ebD6C9H">JAMA</title>
		<imprint>
			<biblScope unit="volume">310</biblScope>
			<biblScope unit="page" from="699" to="705" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Quality Improvement Strategies S12</note>
	<note type="raw_reference">Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure con- trol associated with a large-scale hypertension program. JAMA. 2013;310:699-705. 12.4.2. Quality Improvement Strategies S12.4.2-1.</note>
</biblStruct>

<biblStruct xml:id="b382">
	<analytic>
		<title level="a" type="main" xml:id="_xwmFNsz">Quality improvement strategies for hypertension management: a systematic review</title>
		<author>
			<persName><forename type="first">Jme</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Mcdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Shojania</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.mlr.0000220260.30768.32</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nsVsvyp">Med Care</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="2" to="2" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Walsh JME, McDonald KM, Shojania KG, et al. Quality improve- ment strategies for hypertension management: a systematic review. Med Care. 2006;44:646-57. S12.4.2-2.</note>
</biblStruct>

<biblStruct xml:id="b383">
	<analytic>
		<title level="a" type="main" xml:id="_JTNgQbe">The potency of team-based care interventions for hypertension: a meta-analysis</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Daly</surname></persName>
		</author>
		<idno type="DOI">10.1001/archinternmed.2009.316</idno>
		<idno>12.4.2-3</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_F5MAD3x">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="1748" to="1755" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Carter BL, Rogers M, Daly J, et al. The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med. 2009;169:1748-55. S12.4.2-3.</note>
</biblStruct>

<biblStruct xml:id="b384">
	<analytic>
		<title level="a" type="main" xml:id="_xeVegcT">Interventions used to improve control of blood pressure in patients with hypertension</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Glynn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Smith</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.cd005182.pub4</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AzuZxRB">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2" to="4" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2010:CD005182. S12.4.2-4.</note>
</biblStruct>

<biblStruct xml:id="b385">
	<analytic>
		<title level="a" type="main" xml:id="_VcWBYHZ">Team-based care and improved blood pressure control: a community guide systematic review</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Proia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Thota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Njie</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amepre.2014.03.004</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_z3UdHuR">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="2" to="5" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014;47:86-99. S12.4.2-5.</note>
</biblStruct>

<biblStruct xml:id="b386">
	<analytic>
		<title level="a" type="main" xml:id="_fBUEazx">The role of Decision Support System (DSS) in prevention of cardiovascular disease: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Anchala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Pinto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shroufi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SjN8rnA">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="2" to="6" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Anchala R, Pinto MP, Shroufi A, et al. The role of Decision Support System (DSS) in prevention of cardiovascular disease: a systematic review and meta-analysis. PLoS ONE. 2012;7: e47064. S12.4.2-6.</note>
</biblStruct>

<biblStruct xml:id="b387">
	<analytic>
		<title level="a" type="main" xml:id="_nePhyE2">Check it, change it: a community-based, multifaceted intervention to improve blood pressure control</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Elliot-Bynum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zcrPW7n">Circ Cardiovasc Qual Outcomes</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="2" to="7" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thomas KL, Shah BR, Elliot-Bynum S, et al. Check it, change it: a community-based, multifaceted intervention to improve blood pressure control. Circ Cardiovasc Qual Outcomes. 2014;7: 828-34. S12.4.2-7.</note>
</biblStruct>

<biblStruct xml:id="b388">
	<analytic>
		<title level="a" type="main" xml:id="_egkNnuh">Improved blood pressure control associated with a large-scale hypertension program</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Jaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Young</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vMTw9Sz">JAMA</title>
		<imprint>
			<biblScope unit="volume">310</biblScope>
			<biblScope unit="page" from="2" to="8" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure con- trol associated with a large-scale hypertension program. JAMA. 2013;310:699-705. S12.4.2-8.</note>
</biblStruct>

<biblStruct xml:id="b389">
	<analytic>
		<title level="a" type="main" xml:id="_VcX5WGE">Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Agarwal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Bills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tjw</forename><surname>Hecht</surname></persName>
		</author>
		<idno>12.5-1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_q98aYxb">Financial Incentives S</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="29" to="38" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>Hypertension</note>
	<note type="raw_reference">Agarwal R, Bills JE, Hecht TJW, et al. Role of home blood pres- sure monitoring in overcoming therapeutic inertia and improv- ing hypertension control: a systematic review and meta-analysis. Hypertension. 2011;57:29-38. 12.5. Financial Incentives S12.5-1.</note>
</biblStruct>

<biblStruct xml:id="b390">
	<analytic>
		<title level="a" type="main" xml:id="_e84CnM5">Effects of individual physician-level and practice-level financial incentives on hypertension care: a randomized trial</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Hysong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Simpson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pietz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fYCJn4m">Am J Manag Care</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="5" to="8" />
			<date type="published" when="2012">2012. 2013</date>
		</imprint>
	</monogr>
	<note>Financial incentives and physician commitment to guideline-recommended hypertension management JAMA</note>
	<note type="raw_reference">Hysong SJ, Simpson K, Pietz K, et al. Financial incentives and physician commitment to guideline-recommended hypertension management. Am J Manag Care. 2012;18:e378-91. S12.5-2. Petersen LA, Simpson K, Pietz K, et al. Effects of individual phy- sician-level and practice-level financial incentives on hypertension care: a randomized trial. JAMA. 2013;310:1042-50. S12.5-3.</note>
</biblStruct>

<biblStruct xml:id="b391">
	<analytic>
		<title level="a" type="main" xml:id="_qGbsWkb">The impact of pay for performance on the control of blood pressure in people with chronic kidney disease stage 3-5</title>
		<author>
			<persName><forename type="first">K</forename><surname>Karunaratne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Irving</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bmqkrEt">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="13" to="14" />
			<date type="published" when="2012">2013. 2013. 2012</date>
			<publisher>Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</publisher>
		</imprint>
		<respStmt>
			<orgName>American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association</orgName>
		</respStmt>
	</monogr>
	<note>The influence of health systems on hypertension awareness, treatment, and control: a systematic literature review PLoS Med the Circulation</note>
	<note type="raw_reference">Karunaratne K, Stevens P, Irving J, et al. The impact of pay for per- formance on the control of blood pressure in people with chronic kidney disease stage 3-5. Nephrol Dial Transplant. 2013;28: 2107-16. S12.5-4. Maimaris W, Paty J, Perel P, et al. The influence of health systems on hypertension awareness, treatment, and control: a systematic lit- erature review. PLoS Med. 2013;10:e1001490. the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354-471. S13-4.</note>
</biblStruct>

<biblStruct xml:id="b392">
	<analytic>
		<title level="a" type="main" xml:id="_4R4hhJY">ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Yancy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jessup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bozkurt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Qe7wP7R">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="issue">suppl 1</biblScope>
			<biblScope unit="page" from="4" to="5" />
			<date type="published" when="2013">2013. 2013. 2016</date>
		</imprint>
	</monogr>
	<note>. S13-5 Standards of Medical Care in Diabetes-2016: Summary of Revisions Circulation</note>
	<note type="raw_reference">Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-327. S13-5. Standards of Medical Care in Diabetes-2016: Summary of Revisions. Diabetes Care. 2016;39(suppl 1):S4-5.</note>
</biblStruct>

<biblStruct xml:id="b393">
	<monogr>
		<title level="m" xml:id="_56A3BtA">Key Words: AHA Scientific Statements ◼ ambulatory care ◼ antihypertensive agents ◼ behavior modification ◼ blood pressure ◼ chronic kidney disease ◼ diabetes ◼ hypertension ◼ hypertension emergency ◼ lifestyle measures ◼ measurement ◼ nonpharmacologic treatment ◼ resistant hypertension ◼ risk reduction ◼ secondary hypertension ◼ systems of care ◼ treatment adherence ◼ treatment outcomes</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">Key Words: AHA Scientific Statements ◼ ambulatory care ◼ antihypertensive agents ◼ behavior modification ◼ blood pressure ◼ chronic kidney disease ◼ diabetes ◼ hypertension ◼ hypertension emergency ◼ lifestyle measures ◼ measurement ◼ nonpharmacologic treatment ◼ resistant hypertension ◼ risk reduction ◼ secondary hypertension ◼ systems of care ◼ treatment adherence ◼ treatment outcomes</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
